Elucidating the pathomechanism behind the neurocristopathy CHARGE syndrome by Freese, Luisa
  
Elucidating the pathomechanism behind 
the neurocristopathy CHARGE syndrome 
 
 
Doctoral Thesis 
 
 
In partial fulfillment of the requirements for the degree 
 
“Doctor rerum naturalium (Dr. rer. nat.)“ 
 
in the Molecular Medicine Study Program 
at the Georg-August University Göttingen 
 
 
submitted by 
Luisa Freese 
 
born in 
Halberstadt, Germany 
 
 
Göttingen, 2017 
 Members of the Thesis Committee 
 
Supervisor 
PD Dr. Silke Pauli 
Institute of Human Genetics 
University Medical Center Göttingen 
 
 
 
Second member of the Thesis Committee 
Prof. Steven A. Johnsen, PhD 
Department of General, Visceral and Pediatric Surgery 
University Medical Center Göttingen 
 
 
 
Third member of the Thesis Committee 
Prof. Dr. Ahmed Mansouri 
Department of Molecular Cell Biology/Molecular Cell Differentiation 
Max Planck Institute for Biophysical Chemistry, Göttingen 
 
 
 
 
 
 
 
 
 
 
 
Date of Disputation:  
 AFFIDAVIT 
 
Herewith I declare that my doctoral thesis entitled: “Elucidating the pathomechanism 
behind the neurocristopathy CHARGE syndrome” has been written independently with no 
other sources and aids than quoted. 
 
 
 
Göttingen, May 2017 
 
 
 
 
 
 
Luisa Freese 
 
 
 
 
  
 List of Publications 
 
 Schulz Y, Freese L, Manz J, Zoll B, Volter C, Brockmann K, Bogershausen N,  
Becker J, Wollnik B, Pauli S (2014). CHARGE and Kabuki syndromes: a phenotypic 
and molecular link. Human molecular genetics 23(16): 4396–4405. 
 
 
 A manuscript is in preparation that will contain parts of this doctoral thesis. 
 
 
 
 
Parts of this doctoral thesis were presented at the following meetings: 
 
 25th Annual Meeting of the German Society of Human Genetics together with the 
Austrian Society of Human Genetics and the Swiss Society of Medical Genetics 
March 19–21, 2014, Essen, Germany 
“CHARGE and Kabuki syndrome. Two related syndromes?” (poster presentation) 
 
 
 26th Annual Meeting of the German Society of Human Genetics together with the 
Austrian Society of Human Genetics and the Swiss Society of Medical Genetics 
April 15–17, 2015, Graz, Austria 
“Chd7, the protein affected in CHARGE syndrome, regulates the neural crest cell 
guidance molecule Sema3a.” (poster presentation) 
 
 
 
 
 
Table of contents  I 
Table of contents 
Table of contents ................................................................................... I 
List of figures ...................................................................................... VI 
List of tables ..................................................................................... VIII 
Abbreviations...................................................................................... IX 
 
1 Introduction........................................................................................... 1 
 
1.1 CHARGE Syndrome ..............................................................................1 
1.1.1 Chromodomain helicase DNA-binding protein 7 .....................................1 
1.1.2 Mutations in CHD7 lead to CHARGE syndrome .....................................2 
1.2 Neurocristopathies ...............................................................................2 
1.3 Neural crest cells – the fourth germ layer ...........................................3 
1.3.1 Migration of NCCs ..................................................................................4 
1.4 Semaphorins .........................................................................................6 
1.4.1 Class 3 semaphorins ..............................................................................8 
1.4.2 SEMA3A mutations contribute to the phenotype of  
Kallmann syndrome ................................................................................8 
1.5 Aim of the present study ......................................................................9 
 
2 Materials and Methods ....................................................................... 10 
 
2.1 Materials ..............................................................................................10 
2.1.1 Technical equipment.............................................................................10 
2.1.2 Consumable materials ..........................................................................12 
2.1.3 Chemicals, biochemicals and reagents .................................................13 
2.1.4 Ready-to-use reaction systems ............................................................16 
2.1.5 Sterilization ...........................................................................................16 
2.1.6 Buffers and solutions ............................................................................16 
2.1.7 Plasmids and vectors............................................................................20 
2.1.8 Bacterial strains ....................................................................................21 
2.1.8.1 Media and agar plates for bacterial culture ...........................................21 
Table of contents  II 
2.1.9 Eukaryotic cell lines ..............................................................................21 
2.1.9.1 Media for eukaryotic cell culture............................................................22 
2.1.9.2 Freezing media .....................................................................................22 
2.1.10 Yeast strains .........................................................................................22 
2.1.10.1 Media and agar plates for yeast culture ................................................23 
2.1.11 Antibodies .............................................................................................24 
2.1.11.1 Primary antibodies ................................................................................24 
2.1.11.2 Secondary antibodies ...........................................................................25 
2.1.12 Synthetic oligonucleotides ....................................................................25 
2.1.12.1 Synthetic oligonucleotides for genotyping PCR experiments ................25 
2.1.12.2 Synthetic oligonucleotides for In-Fusion® experiments ..........................25 
2.1.12.3 Synthetic oligonucleotides for mutagenesis experiments ......................26 
2.1.12.4 Synthetic oligonucleotides for mycoplasma contamination....................26 
2.1.12.5 Synthetic oligonucleotides for patient screening ...................................26 
2.1.12.6 Synthetic oligonucleotides for RT-PCR experiments .............................27 
2.1.12.7 Synthetic oligonucleotides for sequencing ............................................29 
2.1.12.8 Synthetic oligonucleotides for qRT-PCR experiments ...........................29 
2.1.13 Molecular weight standards ..................................................................30 
2.1.14 Animals/ethic statement ........................................................................30 
2.1.15 Patient samples ....................................................................................31 
2.1.16 Databases / Online tools / Programs ....................................................31 
2.1.17 Statistical analysis ................................................................................32 
2.2 Methods ...............................................................................................33 
2.2.1 Molecular biology methods ...................................................................33 
2.2.1.1 Isolation of nucleic acids .......................................................................33 
2.2.1.1.1 Isolation of genomic DNA for mouse genotyping ..................................33 
2.2.1.1.2 Minipreparation of plasmid DNA ...........................................................33 
2.2.1.1.3 Endotoxin-free midipreparation of plasmid DNA ...................................34 
2.2.1.1.4 Isolation of total RNA from cultured cells ..............................................34 
2.2.1.1.5 Isolation of RNA from mouse tissues ....................................................35 
2.2.1.1.6 Determination of nucleic acid concentration ..........................................35 
2.2.1.2 Polymerase Chain Reactions ................................................................35 
2.2.1.2.1 Amplification of DNA .............................................................................35 
2.2.1.2.1.1 Standard PCR ......................................................................................36 
Table of contents  III 
2.2.1.2.1.2 Touchdown PCR ..................................................................................37 
2.2.1.2.1.3 Genotyping PCR ...................................................................................38 
2.2.1.2.1.4 Mutagenesis PCR .................................................................................39 
2.2.1.2.1.5 Mycoplasma contamination PCR ..........................................................41 
2.2.1.2.2 Reverse transcription ............................................................................42 
2.2.1.2.3 Quantitative Real-Time PCR .................................................................42 
2.2.1.2.4 Sequencing analysis .............................................................................43 
2.2.1.3 Agarose gel electrophoresis of DNA .....................................................44 
2.2.1.3.1 Purification of DNA fragments from agarose gels .................................45 
2.2.1.4 Cloning techniques ...............................................................................45 
2.2.1.4.1 Restriction digestion of plasmid DNA ....................................................45 
2.2.1.4.2 Cloning of DNA fragments using In-Fusion® HD Cloning Kit .................46 
2.2.1.4.3 Transformation of competent cells ........................................................46 
2.2.1.4.4 Mutagenesis .........................................................................................47 
2.2.1.5 Yeast two-hybrid assay .........................................................................47 
2.2.2 Protein manipulation methods ..............................................................48 
2.2.2.1 Protein isolation from eukaryotic cells ...................................................48 
2.2.2.2 Protein isolation from yeast cells...........................................................48 
2.2.2.3 Protein concentration from cell culture medium ....................................49 
2.2.2.4 Determination of protein concentration .................................................49 
2.2.2.5 Co-immunoprecipitation ........................................................................49 
2.2.2.6 SDS polyacrylamide gel electrophoresis ...............................................50 
2.2.2.7 Transfer of proteins from a polyacrylamide gel to a membrane .............51 
2.2.2.8 Protein detection on membranes using antibodies ................................51 
2.2.3 Histological methods.............................................................................52 
2.2.3.1 Dissection of mouse tissues and embryos ............................................52 
2.2.3.2 Fixation of cells on slides ......................................................................53 
2.2.3.3 Immunofluorescence staining ...............................................................53 
2.2.4 Cell culture methods .............................................................................53 
2.2.4.1 Coating of cell culture vessels ..............................................................53 
2.2.4.1.1 Preparation of fibronectin coated cell culture vessels............................53 
2.2.4.1.2 Preparation of matrigel coated cell culture vessels ...............................54 
2.2.4.2 Culture of eukaryotic cells .....................................................................54 
2.2.4.2.1 Culture and passaging of murine JoMa1 and JoMa1.3 cells .................54 
2.2.4.2.2 Culture and passaging of murine O9-1 cells .........................................55 
Table of contents  IV 
2.2.4.2.3 Culture and passaging of human HEK293 cells ....................................55 
2.2.4.2.4 Cryopreservation and thawing of eukaryotic cells .................................56 
2.2.4.3 Transfection of eukaryotic cells .............................................................56 
2.2.4.3.1 Transfection of plasmids into eukaryotic cells .......................................56 
2.2.4.3.2 Transfection of short interfering RNAs ..................................................57 
 
3 Results ................................................................................................ 59 
 
3.1 Characterization of murine NCC lines ...............................................59 
3.1.1 Molecular marker expression in murine JoMa cells ...............................59 
3.1.2 Molecular marker expression in murine O9-1 cells ...............................61 
3.1.3 Chd7 expression in murine JoMa cells and O9-1 cells ..........................63 
3.2 O9-1 cells express semaphorin receptors and  
class 3 semaphorins ..........................................................................66 
3.3 Sema3a is expressed, processed and secreted by O9-1 cells  
and exists in monomeric and dimeric isoforms ...............................69 
3.4 Downregulation of Chd7 has influence on the expression level  
of Sema3a in O9-1 cells ......................................................................73 
3.5 Chd7 co-immunoprecipitates with Sema3a in O9-1 cells ................74 
3.6 Detection of the non-synonymous SEMA3A variant c.2002A>G 
(p.I668V) in a CHD7-positive CHARGE syndrome patient ................76 
3.7 Generation of SEMA3A plasmids ......................................................77 
3.8 SEMA3A variants have no effect on the expression, processing  
and secretion as well as dimerization of SEMA3A ...........................78 
3.9 CHD7 co-immunoprecipitates with SEMA3A WT and  
SEMA3A variants ................................................................................83 
3.10 CHD7 shows no direct interaction with SEMA3A WT or  
SEMA3A variants ................................................................................85 
 
4 Discussion .......................................................................................... 89 
 
4.1 Summary of the results ......................................................................89 
Table of contents  V 
4.2 NCCs – which in vitro model to choose? ..........................................90 
4.3 NCCs express class 3 semaphorins and secrete Sema3a ...............92 
4.4 Chd7 regulates Sema3a expression and is associated with  
Sema3a in NCCs .................................................................................94 
4.5 SEMA3A might act as modifier in CHARGE syndrome ....................95 
4.6 Future perspectives............................................................................97 
 
5 Summary ............................................................................................. 99 
 
6 References ........................................................................................ 101 
 
7 Acknowledgements .......................................................................... 113 
 
8 Curriculum vitae ............................................................................... 114 
 
 
 
List of figures  VI 
List of figures 
Figure 1:  Schematic representation of the CHD7 structure ...........................................1 
Figure 2:  Delamination and differentiation of NCCs ......................................................4 
Figure 3:  Schematic representation of the protein structure of semaphorins 
 and their main receptors ................................................................................7 
Figure 4:  Expression analysis of NCC, neuronal, glia, smooth muscle, 
melanocyte and chondrocyte marker genes in JoMa1 cells and  
JoMa1.3 cells ..............................................................................................61 
Figure 5:  Expression analysis of NCC, neuronal, glia, smooth muscle,  
melanocyte and chondrocyte marker genes in O9-1 cells ............................63 
Figure 6:  RT-PCR analysis of Chd7 expression in JoMa cells and O9-1 cells ............64 
Figure 7:  Western blot analysis of Chd7 expression in JoMa cells and O9-1 cells ......64 
Figure 8:  Chd7 immunocytochemical staining of O9-1 cells ........................................66 
Figure 9:  Expression analysis of semaphorin receptors in O9-1 cells .........................67 
Figure 10:  Expression analysis of class 3 semaphorins in O9-1 cells ...........................67 
Figure 11:  Sema3a immunocytochemical staining of O9-1 cells ...................................68 
Figure 12:  Schematic representation of full-length Sema3a protein ..............................69 
Figure 13:  Isoforms of Sema3a resulting from proteolytic processing  
and dimerization ..........................................................................................71 
Figure 14:  Schematic representation of proteolytic processed and dimerized  
Sema3a isoforms identified in concentrated medium as well as  
cytoplasmic and nuclear protein extracts of O9-1 cells ................................72 
Figure 15:  Analysis of the Chd7 expression in O9-1 cells after Chd7 downregulation ...73 
Figure 16:  Analysis of the Sema3a expression in O9-1 cells after Chd7  
downregulation ............................................................................................74 
Figure 17:  Co-immunoprecipitation of Chd7 with Sema3a in O9-1 cells .......................75 
Figure 18:  SEMA3A mutation found in a CHD7-positive CHARGE syndrome patient ...77 
Figure 19:  Schematic representation of full length SEMA3A protein with  
identified mutation .......................................................................................77 
Figure 20:  Expression and proteolytic processing of transient overexpressed  
SEMA3A WT and SEMA3A variants in HEK293 cells ..................................80 
Figure 21:  Secretion and dimerization of transient overexpressed SEMA3A WT  
and SEMA3A variants in HEK293 cells .......................................................82 
List of figures  VII 
Figure 22:  Co-immunoprecipitation of CHD7 with SEMA3A WT and  
SEMA3A variants in HEK293 cells ..............................................................84 
Figure 23:  Expression of the full-length SEMA3A isoform in yeast cells .......................86 
Figure 24:  Schematic overview of the used CHD7 yeast two-hybrid assay plasmids ....87 
Figure 25:  Yeast two-hybrid assay ...............................................................................88 
 
 
 
List of tables  VIII 
List of tables 
Table 1:  Sema3a isoforms detected in concentrated medium as well as  
cytoplasmic and nuclear protein extracts of O9-1 cells ................................72 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations  IX 
Abbreviations 
3‟ 3‟ terminus of DNA 
5‟ 5‟ terminus of DNA 
4-OHT 4-hydroxytamoxifen 
% percent 
α alpha 
∆ delta 
+ plus 
− minus 
± plus/minus 
> greater than or replacement to 
< less than 
≤ less than or equal to 
~ tilde (approximately) 
 infinity 
® registered trademark 
TM unregistered trademark 
 
A 
A adenine or alanine 
aa amino acids 
Ab antibody 
Actg2 actin, gamma 2, smooth muscle enteric 
ADA2 adaptor 2 
ADAM a disintegrin and a metalloprotease domain 
ADAMTS1 ADAM with thrombospondin motif 1 
Ade adenine 
ATCC American Type Culture Collection 
ATP adenosine triphosphate 
ATPase adenosine triphosphatase 
 
 
Abbreviations  X 
B 
Baf47 Brahma-associated factor 47 
bp base pairs 
BRG1 Brahma-related gene 1 
BRK brahma and kismet 
BSA bovine serum albumin 
 
C 
°C centigrade 
C carboxyl-terminus or cytoplasmic protein extract or cytosine 
c. cDNA reference sequence 
CaCl2 calcium chloride 
cDNA complementary deoxyribonucleic acid 
CEE chicken embryo extract 
CHD chromodomain helicase DNA-binding 
CHD7 / Chd7 chromodomain helicase DNA-binding protein 7 
ChIP chromatin immunoprecipitation  
Chromo chromodomain 
CIL contact inhibition of locomotion 
cM concentrated cell culture medium 
CMV pCMV vector 
Cnn1 calponin 1 
CO2 carbon dioxide 
Co-IP co-immunoprecipitation 
Col2a1 collagen, type II, alpha 1 
CR1, 2, 3 conserved region 1, 2, 3 
Cre causes recombination 
Ct threshold cycle 
CUB complement C1r/C1s-Uegf-Bmp1 
Cy3 cyanine 3 
 
D 
d day 
Abbreviations  XI 
DAPI 4‟,6-diamidino-2-phenylindole 
dATP deoxyadenosine triphosphate 
dCTP deoxycytidine triphosphate 
ddH2O bi-distilled water 
DEPC diethyl pyrocarbonate 
dGTP deoxyguanosine triphosphate 
DMEM Dulbecco‟s Modified Eagle Medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DNase I deoxyribonuclease I 
dNTP deoxynucleotide triphosphates 
DO dropout 
DPBS Dulbecco‟s Phosphate-Buffered Saline 
DPBST Dulbecco‟s Phosphate-Buffered Saline with Tween 20 
DpnI Diplococcus pneumonia I 
DTT 1,4-dithiothreitol 
dTTP desoxythymidin triphosphate 
 
E 
E EcoRI or embryonic day 
EcoRI Escherichia coli, strain R I 
EDTA ethylenediaminetetraacetic acid disodium salt dihydrate 
EGF epidermal growth factor 
EMT epithelial-to-mesenchymal transition 
Epha3 Ephrin receptor A3 
Epha5 Ephrin receptor A5 
Epha7 Ephrin receptor A7 
ESC embryonic stem cell 
ET endothelin 
et al. et alii (and others) 
 
F 
FB fibroblast 
Abbreviations  XII 
FBS fetal bovine serum 
FGF-2 fibroblast growth factor-2 
FV/VIII coagulation factor V/VIII homology-like 
 
G 
G guanine 
g gram 
g gravitational acceleration (9.81 m/s2) 
GAD pGADT7 vector 
GAP guanosine triphosphatase (GTPase) activating protein 
gDNA genomic deoxyribonucleic acid 
GDNF glial cell line-derived neurotrophic factor 
Gfap glial fibrillary acidic protein 
GFP green fluorescent protein 
GPI glycosylphosphatidylinositol 
 
H 
h hour or human 
H2O water 
HA hemagglutinin 
HCl hydrochloric acid 
HEK human embryonic kidney 
HeLa Henrietta Lacks 
His histidine 
Hprt hypoxanthine-guanine phosphoribosyltransferase 
HRP horseradish peroxidase 
 
I 
I isoleucine 
ICC immunocytochemistry 
Ig immunoglobulin 
IPT Ig-like-plexin-transcription factors 
ISH in situ hybridization 
Abbreviations  XIII 
K 
kb kilo base 
KCl potassium chloride 
kDa kilo Dalton 
KH2PO4 potassium dihydrogen phosphate 
 
L 
l liter 
LB lysogeny broth 
LDS lithium dodecyl sulfate 
Leu leucine 
LiAc lithium acetate 
LIF leukemia inhibitory factor 
−LT without leucine, tryptophan 
−LTHA without leucine, tryptophan, histidine, adenine 
 
M 
µ micro (10-6) 
µg microgram 
µl microliter 
µM micromolar 
µm micrometer 
M molar 
m milli (10-3) or mouse 
MAM meprin-like 
MEM minimum essential medium 
MES 2-(N-morpholino)ethanesulfonic acid 
mg milligram 
MgCl2 magnesium chloride 
MIM Mendelian Inheritance in Man 
min minute 
ml milliliter 
mM millimolar 
Abbreviations  XIV 
mol mole 
MWCO molecular weight cut-off 
Myco mycoplasma 
 
N 
N nuclear protein extract or amino-terminus 
n nano (10-9) 
NaCl sodium chloride 
Na2HPO4 disodium hydrogen phosphate 
NaOH sodium hydroxide 
NC negative control 
NCC neural crest cell 
N-CoR nuclear receptor co-repressor 
NEAA non-essential amino acids 
Nefh neurofilament, heavy polypeptide 
ng nanogramm 
Ngfr nerve growth factor receptor (previously named P75) 
NM NCBI accession number 
nM nanomolar 
NP NCBI reference sequence for proteins 
Nrp1 neuropilin 1 
Nrp2 neuropilin 2 
n.s. not significant 
 
O 
OD optical density 
 
P 
p protein 
p. protein reference sequence 
P75 nerve growth factor receptor 
Pa Pascal, unit of pressure 
Pax3 paired box 3 
Abbreviations  XV 
PBAF polybromo- and BRG1-associated factor containing complex 
PBS phosphate buffered saline 
PC positive control 
pCMV plasmid cytomegalovirus 
PCR polymerase chain reaction 
PDGF platelet derived growth factor 
Pdgfc platelet-derived growth factor C 
PEG polyethylene glycol 
PFA paraformaldehyde 
pH potential of hydrogen 
PLA proximity ligation assay 
Plxna1 Plexin A1 
PNS peripheral nervous system 
PSI plexin-semaphorin-integrin 
PVDF polyvinylidene fluoride 
 
Q 
q long arm of the chromosome 
qRT quantitative real-time PCR 
qRT-PCR quantitative real-time PCR 
 
R 
R arginine 
RbBP5 retinoblastoma-binding protein 5 
RNA ribonucleic acid 
RT room temperature 
RT-PCR real-time PCR 
 
S 
S SfiI 
s second 
SANT switching-defective protein 3 (SWI3), adaptor 2 (ADA2), nuclear 
receptor co-repressor (N-CoR), transcription factor (TF) IIIB 
Abbreviations  XVI 
SDF1 stromal cell-derived factor 1 
SDS sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEMA / Sema Semaphorin 
SEMA3A / Sema3a sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3a 
SEMA3C / Sema3c sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3c 
SEMA3D / Sema3d sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3d 
SEMA3E / Sema3e sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3e 
seq sequencing 
SfiI Streptomyces fimbriatus I 
siRNA short interfering RNA 
Snai1 snail family zinc finger 1 
Snai2 snail family zinc finger 2 
SNF2 sucrose non-fermentable 2 
S.O.C. super optimal broth with catabolite repression 
Sox9  sex determining region Y (SRY)-box 9 
Sox10 sex determining region Y (SRY)-box 10 
SRY sex determining region of chromosome Y 
SWI2 switch 2 
SWI3 switching-defective protein 3 
 
T 
T threonine or thymine 
Taq Thermus aquaticus 
TBE tris-borate-EDTA 
TBP TATA box binding protein 
TBS Tris-buffered saline 
TBST tris-buffered saline with tween 20 
TE Tris-EDTA 
TF IIIB transcription factor IIIB 
Abbreviations  XVII 
TK tyrosine kinase 
Tris tris(hydroxymethyl)aminomethane 
Trp tryptophan 
Twist1 twist basic helix-loop-helix transcription factor 1 
Tyr tyrosinase 
 
U 
U Unit (enzyme activity) 
UV ultraviolet light 
 
V 
V valine or Volt 
VEGF vascular endothelial growth factor 
Vegfc vascular endothelial growth factor C 
 
W 
W tryptophan 
WB western blot 
Whi Whirligig 
Wnt1 Wnt family member 1 
WT wild type 
w/v weight/volume 
 
X 
x g multiple of gravitational acceleration 
 
Y 
Y2H yeast two-hybrid 
YNB yeast nitrogen base 
 
 
Introduction  1 
1 Introduction 
1.1 CHARGE Syndrome 
1.1.1 Chromodomain helicase DNA-binding protein 7 
Chromodomain helicase DNA-binding (CHD) proteins play a role in transcription activation 
and repression by ATP (adenosine triphosphate)-dependent chromatin remodeling  
(Kim et al., 2008). For this function, all members of the CHD protein family share at the  
N-terminus two tandem chromodomains (chromatin organization modifier domains), 
followed by a SWI2/SNF2 (switch 2/sucrose non-fermentable 2)-like ATPase/helicase 
domain (Woodage et al., 1997; Flaus et al., 2006; Flanagan et al., 2007). In humans, the 
CHD protein family consists of nine members who are divided into three subgroups 
according to their amino acid sequence and additional functional protein domains. CHD7 
is one of the nine CHD family members and belongs to subgroup III. Characteristics of this 
subgroup are three conserved regions (CR1–CR3), a SANT (switching-defective protein 3 
(SWI3), adaptor 2 (ADA2), nuclear receptor co-repressor (N-CoR), transcription factor 
(TF) IIIB) domain and two tandem BRK (brahma and kismet) domains (Hall and Georgel, 
2007; Marfella and Imbalzano, 2007) (Figure 1). The human CHD7 gene (MIM 608892) is 
located on chromosome 8 (8q12.2) and encodes 38 exons. It is highly conserved across 
species and orthologs have been identified in mouse, chicken, zebrafish, Xenopus laevis 
and others (Bosman et al., 2005; Aramaki et al., 2007; Bajpai et al., 2010). 
 
 
 
Figure 1: Schematic representation of the CHD7 structure. CHD7 is one of nine members of 
the CHD family that plays a role in controlling gene expression by ATP-dependent chromatin 
remodeling. CHD7 consists of two N-terminal chromodomains, a SWI2/SNF2-like ATPase/helicase 
domain, three conserved regions namely CR1, CR2 and CR3, a SANT domain and two BRK 
domains. Modified from Schulz et al. (2014a). 
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1.1.2 Mutations in CHD7 lead to CHARGE syndrome 
CHARGE syndrome (MIM 214800) is an autosomal dominant congenital malformation 
disorder known for its clinical variability. Reports of patients who were later found  
to have CHARGE were firstly published in 1979 independent by Hall (1979) and  
Hittner et al. (1979). Two years later, in 1981, Pagon et al. suggested for this disorder the 
acronym CHARGE. The acronym describes the main features seen in patients namely 
coloboma, heart defects, atresia of the choanae, retarded growth and development, 
genital hypoplasia and ear anomalies/deafness (Pagon et al., 1981). The phrase 
„CHARGE association‟ was renamed 2004 into „CHARGE syndrome‟ after identification of 
CHD7 mutations as the major disease cause (Vissers et al., 2004; Aramaki et al., 2006; 
Jongmans et al., 2006; Lalani et al., 2006; Sanlaville et al., 2006; Wincent et al., 2008). 
Blake et al. (1998) defined clinical criteria for the diagnosis of CHARGE syndrome. They 
were updated by Verloes (2005) defining coloboma, atresia of the choanae and 
hypoplastic semicircular canals as major signs and rhombencephalic dysfunction, 
hypothalamo-hypophyseal dysfunction, abnormal middle or external ear, malformations of 
mediastinal organs and mental retardation as minor signs. The incidence varies from 
1:8500 to 1:10,000 (Blake et al., 1998; Issekutz et al., 2005). In the majority of patients 
with the suspected diagnosis CHARGE syndrome heterozygous mutations in the CHD7 
gene are found. Most of them are nonsense or frameshift mutations (due to small 
deletions or insertions), but also missense mutations can occur (Janssen et al., 2012). To 
date, over 500 different pathogenic mutations have been identified which are distributed 
throughout the coding sequence as well as in some intronic sequences (Aramaki et al., 
2006; Jongmans et al., 2006; Lalani et al., 2006; Sanlaville et al., 2006; Sanlaville and 
Verloes, 2007; Vuorela et al., 2007; Janssen et al., 2012; Martin, 2015). Most of them are 
de novo mutations, but also somatic and germline mosaicism in a parent were reported in 
families with more than one affected child (Jongmans et al., 2006; Delahaye et al., 2007; 
Jongmans et al., 2008; Pauli et al., 2009). 
 
 
1.2 Neurocristopathies 
Alterations in the complex succession of events required for induction, proliferation, 
migration and final differentiation of neural crest cells resulting in a large group of birth 
defects, which were firstly termed by Bolande (1974) neurocristopathies. The classification 
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of syndromes as a neurocristophathy evolved over the years now including numerous 
congenital malformation syndromes such as CHARGE, Kallmann, DiGeorge, Treacher-
Collins, Waardenburg or Hirschsprung‟s disease (Siebert et al., 1985; Etchevers et al., 
2006, 2007; Jones et al., 2008; Passos-Bueno et al., 2009; Keyte and Hutson, 2012). 
Interestingly, already in 1985, Siebert et al. postulated the belonging of CHARGE 
syndrome to the neurocristopathies (Siebert et al., 1985) because of the affected 
structures. The most common clinical features seen in neurocristopathies include 
craniofacial defects, hearing loss, pigmentation and cardiac defects as well as missing of 
enteric ganglia (Mayor and Theveneau, 2013). 
 
 
1.3 Neural crest cells – the fourth germ layer 
Neural crest cells (NCCs) are a population of multipotent and migratory progenitors found 
in all vertebrate embryos (Knecht and Bronner-Fraser, 2002; Milet and Monsoro-Burq, 
2012). During embryogenesis they arise from the neural plate border which is induced by 
signaling between the neural and the non-neural ectoderm and from the underlying 
paraxial mesoderm (Gammill and Bronner-Fraser, 2003). The neural plate borders elevate 
during neurulation and cause the neural plate to folds over itself to form the neural tube 
(Gammill and Bronner-Fraser, 2003). In the neural plate border as well as in neighboring 
structures neural plate border specifier genes are upregulated (Bronner and LeDouarin, 
2012). A further refinement of the border region results from the activation of neural crest 
specifiers, genes allowing NCCs the delamination from the neural folds or neural tube, the 
migration and differentiation into various derivatives (Bronner and LeDouarin, 2012) 
(Figure 2). NCCs migrate from the closing neural folds or from the dorsal neural tube 
through the embryo, following specific pathways to contribute to the formation of different 
organs and tissues like skin, heart or peripheral nervous system (PNS) (Gammill and 
Bronner-Fraser, 2003; Kuriyama and Mayor, 2008). Because of their ability to differentiate 
into various cell types like melanocytes, craniofacial cartilage and bone, smooth muscle, 
peripheral and enteric neurons and glia (Kuriyama and Mayor, 2008; Dupin and Sommer, 
2012; Prasad et al., 2012) (Figure 2), they were termed the „fourth germ layer‟ (Hall, 
2000). NCCs are divided into the cranial (cephalic), cardiac, trunk and enteric NCCs. The 
cranial NCCs contribute to craniofacial structures like bones and cartilages of the face and 
neck as well as tendons, muscles and connective tissue of the ear, eye, teeth and blood 
vessels (Mayor and Theveneau, 2013). In addition, they form most of the cranial PNS and 
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modulate brain growth and patterning (Mayor and Theveneau, 2013). The cardiac NCCs 
are a subpopulation of the cranial NCCs and essential for the septation of the heart 
outflow tract (Mayor and Theveneau, 2013). The trunk NCCs form pigment cells, the 
dorsal root and sympathetic ganglia of the PNS and endocrine cells of the adrenal gland, 
whereas the enteric NCCs form the enteric PNS of the gut, which controls the digestive 
track (Mayor and Theveneau, 2013). 
 
 
 
 
Figure 2: Delamination and differentiation of NCCs. NCCs delaminate from the closing neural 
folds or from the dorsal neural tube and differentiate into neurons of the peripheral nervous system, 
glial cells, melanocytes, cranial bones and muscles, odontoblasts or other cell types. Modified from 
Acloque et al. (2009). 
 
 
1.3.1 Migration of NCCs 
The migration of NCCs is a complex and multi-step process. Interestingly, Bajpai et al. 
(2010) demonstrated in humans and in the animal model Xenopus laevis an essential role 
for CHD7 in the formation and migration of NCCs by activating neural crest specifier 
genes as the transcription factors SNAI2 (snail family zinc finger 2, previously named 
Slug), TWIST (twist basic helix-loop-helix transcription factor) and SOX9 (SRY(sex 
determining region Y)-box containing gene 9). NCCs originate at the border between the 
neural and the non-neural ectoderm along the anteroposterior length of the developing 
embryo (Gong, 2014). Before NCCs are able to delaminate from the closing neural folds 
or from the dorsal neural tube, they undergo a process called epithelial-to-mesenchymal 
transition (EMT) in which the NCCs lose their cell-cell contacts, reorganize their 
cytoskeleton and acquire a motile phenotype (Kirby and Hutson, 2014). Premigratory 
NCCs form an epithelium with a typical apical-basal polarity which is surrounded by an 
underlying basement membrane (Kerosuo and Bronner-Fraser, 2012). During EMT, the 
polarity gets lost due to a progressive replacement of tight junctions by gap junctions 
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(Kuriyama and Mayor, 2008). Furthermore, a shift from type I to type II cadherins, a group 
of transmembrane proteins, results in a lower adhesiveness of the cells which allows them 
to increase their motility (Mayanil, 2013). Kerosuo and Bronner-Fraser (2012) point out 
that extracellular matrix proteins, such as ADAM proteins (proteins containing a disintegrin 
and a metalloprotease domain) and matrix metalloproteinases induce a breakdown of the 
basement membrane to allow migration. After undergoing EMT, the NCCs initially 
delaminate as a continuous wave which quickly splits into discrete streams ventrally down 
the embryo displaying a range of migratory behaviors (Shellard and Mayor, 2016). Some 
NCCs exhibit an individual migratory behavior. But although the NCCs undergo EMT, 
most of them migrate together, either as chains, groups or even single sheets (Kulesa  
et al., 2010; Theveneau and Mayor, 2012; Shellard and Mayor, 2016). A process called 
contact inhibition of locomotion (CIL) prevent the NCCs during migration from overlapping 
with each other (Mayor and Carmona-Fontaine, 2010). After contact with one another, the 
migrating NCCs momentarily stop and favors dispersion in the opposite direction (Mayor 
and Carmona-Fontaine, 2010). Nevertheless, the chemoattractant mediated phenomenon 
of co-attraction allows collective migration of the NCCs in spite of reduced cell-cell 
adhesion due to EMT and dispersion of the cells induced by CIL (Carmona-Fontaine  
et al., 2011). The split of NCCs into distinct streams and their precise targeting to their 
destinations are controlled by a plethora of positive and negative regulators including 
signaling molecules and mediated via binding of external ligands to receptors on the  
NCC surface (Theveneau and Mayor, 2012). Negative guidance cues are located at the 
borders of the migration pathways whereas the locations of positive guidance cues are 
along the pathways or within the NCC target regions (Theveneau and Mayor, 2012). 
Some of the main signals regulating NCC migration are semaphorins, ephrins/Ephs,  
slits, ETs (endothelins), SDF1 (stromal cell-derived factor 1), VEGFs and PDGFs 
(vascular endothelial and platelet-derived growth factors), FGFs (fibroblast growth factors) 
and GDNF (glial cell line-derived neurotrophic factor) (Theveneau and Mayor, 2012).  
Schulz et al. (2014b) performed a genome-wide microarray expression analysis on whole 
wildtype and Chd7 deficient (Chd7Whi/+ and Chd7Whi/Whi) mouse embryos of the Whirligig 
mouse line at E9.5, a point in time of NCC migration. They identified a misregulation of 
genes involved in the migration and guidance of NCCs such as the semaphorins Sema3a, 
3c and 3d, the ephrin receptors Epha3, Epha5 and Epha7 and the growth factors Vegfc 
and Pdgfc (vascular endothelial and platelet-derived growth factor C) that further 
underlines the important role of CHD7 in NCC development (Schulz et al., 2014b). 
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1.4 Semaphorins 
Semaphorins are a large family of phylogenetically conserved guidance cues and were 
originally identified as molecules that control axon pathfinding during the development of 
the nervous system (Kolodkin et al., 1993). They are involved in many biological 
processes, including the regulation of immune responses (Suzuki et al., 2008; Takamatsu 
and Kumanogoh, 2012), cardiogenesis (Toyofuku et al., 2007; Toyofuku et al., 2008), 
angiogenesis (Serini et al., 2003) and vasculogenesis (Gu et al., 2005) as well as 
oncogenesis (Sekido et al., 1996). Furthermore, Semaphorins act as guidance cues for a 
range of migrating cells like the NCCs (Eickholt et al., 1999). In these processes 
semaphorins can function either as positive or as negative guidance cues (Tamagnone 
and Comoglio, 2004). To date, more than 20 semaphorin types, secreted or membrane-
associated proteins, have been discovered. All semaphorins are characterized by the 
presence of a conserved extracellular amino-terminal Sema (Semaphorin) domain, 
important for dimerization and binding specificity with receptors, followed by a PSI (plexin- 
semaphorin-integrin) domain and a C-terminus domain, which confers class specific 
features, such as basic, Ig (immunoglobulin)-like and thrombospondin domains (Janssen 
et al., 2010; Liu et al., 2010; Nogi et al., 2010). Semaphorins are grouped into eight 
subfamily classes on the basis of structural and amino acid sequence similarity, 
containing invertebrate (classes 1 and 2), vertebrate (classes 3–7) and viral semaphorins 
(class V) (Jongbloets and Pasterkamp, 2014) (Figure 3). Semaphorins of the classes 2, 3 
and V are secreted proteins while the other semaphorins are transmembrane proteins 
(classes 1, 4, 5 and 6) or GPI (glycosylphosphatidylinositol)-linked proteins (class 7) 
(Jongbloets and Pasterkamp, 2014). Nevertheless, membrane-associated semaphorins of 
the classes 4 and 7 can be further processed into soluble proteins by proteolytic 
degradation (Neufeld et al., 2012). Although additional receptors as TK (tyrosine kinase) 
receptors or integrins have been described, the main semaphorin receptors are plexins 
and neuropilins (Winberg et al., 1998; Takahashi et al., 1999; Tamagnone et al., 1999) 
(Figure 3). The nine vertebrate plexins are grouped into four subfamilies (A–D) and serve 
for the most semaphorins as direct binding receptors (Jongbloets and Pasterkamp, 2014). 
However, some secreted semaphorins, like most of class 3 semaphorins, require the 
presence of one of the two in vertebrates identified neuropilins (Nrp1 or Nrp2) as ligand-
binding co-receptor (Jongbloets and Pasterkamp, 2014). 
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Figure 3: Schematic representation of the protein structure of semaphorins and their main 
receptors. Left column: Semaphorins are grouped into eight subfamily classes on the basis of 
structural and amino acid sequence similarity. The classes 1 and 2 contain invertebrate 
semaphorins, the classes 3–7 vertebrate semaphorins and the class V viral semaphorins. 
Semaphorins of the classes 2 and 3 are secreted proteins, the semaphorin classes 1, 4, 5 and 6 
contain transmembrane proteins and the class 7 semaphorins are GPI-linked proteins. The 
membrane-associated semaphorins of the classes 4 and 7 can be processed into soluble proteins 
by proteolytic degradation indicated with scissors. All semaphorins are characterized by a Sema 
domain, a PSI domain and a specific C-terminus domain. Middle column: The main receptors for 
semaphorins are the plexins and neuropilins. The four subfamilies (A–D) of the nine vertebrate 
plexins, the two vertebrate neuropilins (Nrp 1 and Nrp 2) and their structures are shown.  
Right column: The structural conserved domains are drawn in different shapes and colors as 
indicated in the figure. Domains abbreviations: sema, semaphorin; PSI, plexin-semaphorin-integrin; 
Ig-like, immunoglobulin-like; GPI, glycosylphosphatidylinositol; IPT, Ig-like-plexin-transcription 
factors; GAP, guanosine triphosphatase (GTPase) activating protein; CUB, complement C1r/C1s-
Uegf-Bmp1; FV/VIII, coagulation factor V/VIII homology-like; MAM, meprin-like. Modified from 
Messina and Giacobini (2013). 
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1.4.1 Class 3 semaphorins 
The class 3 semaphorins are produced as secreted proteins and consist of seven 
subgroups (3A-3G). Adams et al. (1997) verified that the initially synthesized pro-form 
undergoes proteolytic processing by furin or furin-like endoproteases generating 
functionally different isoforms. They pointed out that the consensus sequences for furin-
dependent processing are highly conserved in all class 3 semaphorin proteins indicating a 
similar mechanism of regulation for all secreted semaphorins (Adams et al., 1997). For 
semaphorin 3C (SEMA3C), the proteolytic processing also induced by the matrix 
metalloprotease ADAMTS1 (ADAM with thrombospondin motif 1), resulting in a promoted 
cell migration in contrast to other class 3 semaphorins, was proved by Esselens et al. 
(2010). Adams et al. (1997) assumed that the activity of all secreted class 3 semaphorins 
depends on the extent of their proteolytic processing. Furthermore, dimerization of class 3 
semaphorins were identified (Klostermann et al., 1998; Koppel and Raper, 1998). The 
existence of monomeric, dimeric and processed isoforms were proved for semaphorin 3E 
(SEMA3E) (Christensen et al., 2005). 
 
 
1.4.2 SEMA3A mutations contribute to the phenotype of Kallmann 
syndrome 
The involvement of semaphorin 3A (SEMA3A) in the navigation of primary olfactory axons 
during embryogenesis contributes to the phenotype of Kallmann syndrome (MIM 147950) 
(Hanchate et al., 2012; Young et al., 2012). This genetically heterogeneous congenital 
disorder is characterized by hypogonadotropic hypogonadism and an impaired sense of 
smell (Dodé and Hardelin, 2009). SEMA3A mutations were identified in Kallmann 
syndrome patients (Hanchate et al., 2012). Nevertheless, it was suggested that one 
heterozygous SEMA3A mutation alone cannot cause the symptoms, while a combination 
of a SEMA3A mutation with other gene mutations (digenic inheritance) can lead to the 
disease phenotype (Hanchate et al., 2012). Mutations in the Chd7 gene can be found in  
a minority of Kallmann syndrome patients (Kim et al., 2008; Bergman et al., 2011) and for 
this reason it was assumed that Kallmann syndrome represents the mild end of the 
phenotypic spectrum of CHARGE syndrome (Jongmans et al., 2009). Interestingly,  
Schulz et al. (2014b) confirmed an regulatory loop between Chd7 and Sema3a in mouse 
and Xenopus laevis. 
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1.5 Aim of the present study 
It was shown that CHD7, the gene mutated in CHARGE syndrome, regulates genes which 
are involved in NCC formation and guidance as well as in interactions between NCCs and 
other tissues (Schulz et al., 2014b). Furthermore, it was assumed that SEMA3A mutations 
contribute to the pathogenesis of CHARGE syndrome (Schulz et al., 2014b). 
The aim of the present study was to elucidate the pathomechanism behind the 
neurocristopathy CHARGE syndrome and especially the role of SEMA3A in the 
pathogenesis of this complex malformation disorder. 
 
Establishment of an NCC model 
 To provide a suitable cell culture model for the analysis of NCCs in vitro, two 
different mouse NCC lines (a truncal and a cranial) should be tested for different 
marker genes using RT-PCR analysis in order to confirm the status of the NCCs. 
 In both the truncal and the cranial NCC line the expression of Chd7 should be 
analyzed by RT-PCR and western blot analysis. 
 The expression of the main class 3 semaphorin receptors, namely plexins and 
neuropilins, should be verified in NCCs using RT-PCR analysis. 
 
Role of SEMA3A in the pathogenesis of CHARGE syndrome 
 CHARGE syndrome patients with a pathogenic CHD7 mutation should be 
screened for additional mutations in the SEMA3A gene by sequencing analysis. 
 The effect of the identified SEMA3A mutations should be investigated in vitro. 
Therefore, plasmids with the wildtype SEMA3A and the identified SEMA3A 
mutations should be generated. By western blot analysis, the wildtype and the 
variants of SEMA3A should be analyzed using a human cell culture system. 
Interactions between CHD7 and the wildtype SEMA3A as well as the SEMA3A 
variants should be identified with co-immunoprecipitation experiments and should 
be further examined using yeast two-hybrid assay. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Technical equipment 
Technical equipment Manufacturer 
6-Tube Magnetic Separation Rack New England Biolabs, Frankfurt/M 
2720 Thermal Cycler Applied Biosystems, Darmstadt 
3500xL Genetic Analyzer Applied Biosystems, Darmstadt 
7900HT Fast Real-Time PCR System Applied Biosystems, Darmstadt 
Accu-jet® Brand, Wertheim 
Arium® 611 Sartorius, Göttingen 
Autoclaves  
DX-150 Systec, Linden 
FVS/2 Fedegari, Bedano (Suisse) 
VX-95 Systec, Linden  
Balance CP3202S Sartorius, Göttingen 
Camera (gel electrophoresis documentation) Vilbert Lourmat, Eberhardzell 
Centrifuges  
4K15 Sigma, Osterode 
Heraeus BiofugeTM Primo Thermo Electron LED, Osterode 
Heraeus FrescoTM 21 Thermo Electron LED, Osterode 
Micro Centrifuge IR Carl Roth, Karlsruhe 
Microfuge 1-15 Sigma, Osterode 
Heraeus Multifuge X3R Thermo Electron LED, Osterode 
Dry cabinet Memmert, Schwabach 
Electrophorese chamber Central workshop, University of Göttingen 
FluorChem® Q Alpha Innotech, Logan (USA) 
Freezers  
−20°C Liebherr, Ochsenhausen 
−80°C Sanyo, Moriguchi (Japan) 
HerasafeTM (biological safety cabinet) Thermo Electron LED, Langenselbold 
Incubators  
for bacteria (37°C) Memmert, Schwabach 
for cell culture (37°C) Sanyo, Munich 
for yeast (30°C) Memmert, Schwabach 
Innova® 40 (incubation shaker) New Brunswick Scientific, Nürtingen 
Laboport®-Membrane-Vacuumpump N86KN.18 KNF Neuberger, Freiburg  
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Magnetic stirrer IKA Labortechnik, Staufen 
Microscopes  
confocal laser scanning microscope IX81 Olympus, Hamburg 
inverted routine microscope Primovert Zeiss, Göttingen 
stereo microscope Stemi SV 11 Zeiss, Göttingen 
Microwave OMW 310-S ok. / Venalisia Import, Ingolstadt 
Mini Protean® II Cell Bio-Rad, Munich 
NanoDrop 2000c Peqlab, Erlangen 
Novex® Mini-Cell Electrophoresis System Invitrogen, Karlsruhe 
pH-Meter PB-11 Sartorius, Göttingen 
Pipettes  
Multipette® M4 Eppendorf, Hamburg 
Pipetman Gilson, Limburg-Offheim 
Research Eppendorf, Hamburg 
Transferpette®-8 Brand, Wertheim 
Power supplies  
Apelex PS 304 minipac II Biostep, Jahnsdorf 
Power PAC 3000 Bio-Rad, Munich 
Printer system (gel electrophoresis documentation)  
Doc printTM VX2 Peqlab, Erlangen 
P95 Mitsubishi Electric, Tokyo (Japan) 
Refrigerators Liebherr, Ochsenhausen 
 Bosch, Stuttgart 
Roll shaker RM5 Assistent 348 Karl Hecht, Sondheim 
Scissors  
HSB 006-10 Hammacher, Solingen 
HSB 530-08 Hammacher, Solingen 
Semi-Automatic Sheet Heat Sealer 4titude, Berlin 
Shaker IKA Labortechnik, Staufen 
Steel bead, stainless (ø 5 mm) Qiagen, Hilden 
Sterilizer Memmert, Schwabach 
Stuart® SB2 rotator Bibby Scientific, Staffordshire (UK) 
SynergyTM Mx plate reader BioTek, Friedrichshall 
Thermomixer 5436 / compact Eppendorf, Hamburg 
TissueLyser LT Qiagen, Hilden 
Tweezer HWC 110-10 Hammacher, Solingen 
UVsolo TS Imaging System Biometra, Göttingen 
UV table ECX-F20.M PeqLab, Erlangen 
Vortex-Genie® 2 Scientific Industries, New York (USA) 
Water bath GFL, Großburgwedel 
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2.1.2 Consumable materials 
Product name Manufacturer 
Blotting Paper Sheets Sartorius, Göttingen 
Cell culture flasks  
25 cm
2
, 75 cm
2 
with filter Sarstedt, Nümbrecht 
75 cm
2
 without filter Greiner Bio-One, Frickenhausen 
300 cm
2
 with filter TPP, Trasadingen (Switzerland) 
Cell culture plates  
96-well Nuclon A/S, Roskilde (Danmark) 
24-well Th. Geyer, Renningen 
12-well Greiner Bio-One, Frickenhausen 
6-well Greiner Bio-One, Frickenhausen 
10 cm ø Nuclon A/S, Roskilde (Danmark) 
Glas bottles Schott, Mainz / Biochrom, Berlin 
Combitips (advanced) Eppendorf, Hamburg 
Counting chamber, bright-lined (Neubauer) Sarstedt, Nümbrecht 
Cover glasses (24 x 60 mm) Menzel Gläser, Braunschweig 
Cryovials Greiner Bio-One, Frickenhausen 
Culture slides (8-well) BD Biosciences, Heidelberg 
Cuvettes, 10 mm Sarstedt, Nümbrecht 
Disposable syringes BD Biosciences, Heidelberg 
Filter (ø 0.20 µm, ø 0.45 µm) Th. Geyer, Renningen 
Gas cartouche (propane/butane) Th. Geyer, Renningen 
Glass pipettes Schütt, Göttingen 
Gloves Lab Logistic Group, Meckenheim 
AmershamTM ProtranTM Supported 0.45 µm NC GE Healthcare, Freiburg 
AmershamTM HybondTM-P PVDF Transfer Membrane 
0.45 µm 
GE Healthcare, Freiburg 
Mr. FrostyTM Freezing Container Kisker, Steinfurt 
MultiScreen® PCR96 Filter Plates  Merck Millipore, Darmstadt 
NuPAGE® 3–8% Tris-Acetate Gels, 1.0 mm, 10-well Invitrogen, Karlsruhe 
NuPAGE® 4–12% Bis-Tris Gels, 1.0 mm, 10-well Invitrogen, Karlsruhe 
NuPAGE® 4–12% Bis-Tris Midi Gels, 1.0 mm, 20-well Invitrogen, Karlsruhe 
Pasteur pipettes Th. Geyer, Renningen 
PCR cups (0.2 ml) Sarstedt, Nümbrecht 
Petri dishes Sarstedt, Nümbrecht 
Pipette tips (without filter) Glasgerätebau Ochs, Bovenden 
Pipette tips (with filter) Kisker, Steinfurt 
qRT-PCR plates (384-well) 4titude, Berlin 
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qRT-PCR Adhesive Clear Seals 4titude, Berlin 
Reaction tubes (1.5 ml, 2 ml) Glasgerätebau Ochs, Bovenden 
Scalpel Pfm medical, Cologne 
Serological pipettes  
2 ml, 5 ml, 10 ml Sarstedt, Nümbrecht 
25 ml Greiner Bio-One, Frickenhausen 
Transfection tubes Sarstedt, Nümbrecht 
Transfer pipettes (3.5 ml) Sarstedt, Nümbrecht 
Tubes  
13 ml Sarstedt, Nümbrecht 
15 ml, 50 ml Greiner Bio-One, Frickenhausen 
Vivaspin® Turbo 15 (30 kDa MWCO) Sartorius, Göttingen 
 
 
2.1.3 Chemicals, biochemicals and reagents 
Chemical / Biochemical / Reagent Manufacturer 
1-Thioglycerol Sigma-Aldrich, Deisenhofen 
1,4-Dithiothreitol (DTT) AppliChem, Darmstadt 
4-Hydroxytamoxifen (4-OHT) Sigma-Aldrich, Deisenhofen 
Acetic acid Merck, Darmstadt 
Adenine hemisulfate salt Sigma-Aldrich, Deisenhofen 
Agar-Agar, Kobe I Carl Roth, Karlsruhe 
Agarose Peqlab, Erlangen 
Ammonium sulfate Carl Roth, Karlsruhe 
Ampicillin sodium salt Carl Roth, Karlsruhe 
Ampuwa® Fresenius, Bad Homburg 
B-27® Supplement (50x) Gibco, Eggenstein 
Barricidal® Interchem Hygiene, Zürich (Switzerland) 
Boric acid ICN Biomedicals, Eschwege 
Bovine serum albumin (BSA) Fraction V PAA Laboratories, Linz (Austria) 
Bovine Serum Albumin Standard Ampules (2 mg/ml) Thermo Scientific, Rockford (USA) 
Bromphenolblue Carl Roth, Karlsruhe 
Calcium chloride (CaCl2) Carl Roth, Karlsruhe 
Chloroform J.T. Baker, Griesheim 
Chicken embryo extract (CEE) Dr. Sven Lindner, Ruhr-University Bochum 
Complete ES Cell Medium with 15% FBS and LIF Merck Millipore, Darmstadt 
cOmpleteTM Protease Inhibitor Cocktail Tablets Roche, Penzberg 
Cryo-SFM PromoCell, Heidelberg 
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D(+)-Glucose Carl Roth, Karlsruhe 
Deoxynucleotide triphosphates (dNTPs) Bio-Budget Technologies, Krefeld 
Diethyl pyrocarbonate (DEPC) Carl Roth, Karlsruhe 
Dimethyl sulfoxide (DMSO) Carl Roth, Karlsruhe 
DirectPCR® Lysis Reagent Tail Peqlab, Erlangen 
Disodium hydrogen phosphate (Na2HPO4) Carl Roth, Karlsruhe 
DO Supplement (−Ade/−His/−Leu/−Trp) Clontech, Heidelberg 
Dulbecco‟s Modified Eagle Medium (DMEM) PAN-Biotech, Aidenbach 
Dulbecco‟s Modified Eagle Medium/Nutrient Mixture 
F-12 (DMEM/F-12) 
Gibco, Eggenstein 
Dulbecco‟s Phosphate-Buffered Saline (DPBS) PAN-Biotech, Aidenbach 
Epidermal growth factor, human (EGF) Sigma-Aldrich, Deisenhofen 
Ethanol J.T. Baker, Griesheim 
Ethidium bromide Inno-Train Diagnostik, Kronberg/Ts. 
Ethylenediaminetetraacetic acid disodium salt 
dihydrate (EDTA) 
MP Biomedicals, Eschwege 
Fetal bovine serum, SeraPlus (FBS) PAN-Biotech, Aidenbach 
Fibroblast growth factor 2, human (FGF-2) Merck Millipore, Darmstadt 
 PeproTech, Hamburg 
Fibronectin, human (FC010) Merck Millipore, Darmstadt 
FluoroshieldTM with Dapi Sigma-Aldrich, Deisenhofen 
Glycerol Carl Roth, Karlsruhe 
Glycine Carl Roth, Karlsruhe 
HaltTM Protease Inhibitor Single Use Cocktail, EDTA-
free (100x) 
Thermo Scientific, Rockford (USA) 
Hydrochloric acid (HCl) J.T. Baker, Griesheim 
ImmersolTM 518F Zeiss, Oberkochen 
Isopropanol J.T. Baker, Griesheim 
Kanamycin sulfate Carl Roth, Karlsruhe 
L-Histidine monohydrochloride monohydrate Sigma-Aldrich, Deisenhofen 
Lipofectamine® 2000 Transfection Reagent Invitrogen, Karlsruhe 
Lithium acetate (LiAc) Carl Roth, Karlsruhe 
Matrigel® Basement Membrane Matrix Corning, Wiesbaden 
Methanol J.T. Baker, Griesheim 
Milk powder Carl Roth, Karlsruhe 
MEM Non-Essential Amino Acids (NEAA) Gibco, Eggenstein 
N-2 Supplement (100x) Gibco, Eggenstein 
NuPAGE® LDS Sample Buffer (4x) Invitrogen, Karlsruhe 
NuPAGE® MES SDS Running Buffer (20x) Invitrogen, Karlsruhe 
NuPAGE® Tris-Acetate SDS Running Buffer (20x) Invitrogen, Karlsruhe 
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Opti-MEM® I Reduced Serum Medium Gibco, Eggenstein 
P1 / P2 / P3 Buffer Qiagen, Hilden 
Paraformaldehyde (PFA) Carl Roth, Karlsruhe 
Penicillin-Streptomycin Gibco, Eggenstein 
Peptone ex casein Carl Roth, Karlsruhe 
Polyethylene glycol 4000 (PEG4000) Carl Roth, Karlsruhe 
Potassium chloride (KCl) Carl Roth, Karlsruhe 
Potassium dihydrogen phosphate (KH2PO4) Carl Roth, Karlsruhe 
Proteinase K Carl Roth, Karlsruhe 
Protein G Magnetic Beads New England Biolabs, Frankfurt/M 
Random Hexamers (50 µM) Invitrogen, Karlsruhe 
Restriction endonucleases Invitrogen, Karlsruhe 
 New England Biolabs, Frankfurt/M  
Roti®-Nanoquant Carl Roth, Karlsruhe 
Roti®-Safe Carl Roth, Karlsruhe 
S.O.C. medium Invitrogen, Karlsruhe 
Sodium acetate Carl Roth, Karlsruhe 
Sodium chloride (NaCl) AppliChem, Darmstadt 
Sodium hydroxide (NaOH) J.T. Baker, Griesheim 
Streptomycin sulfate salt Sigma-Aldrich, Deisenhofen 
TE buffer Invitrogen, Karlsruhe 
Thimerosal Sigma-Aldrich, Deisenhofen 
Tris(hydroxymethyl)aminomethane (Tris) AppliChem, Darmstadt 
Triton X-100 Serva, Heidelberg 
Trizol Reagent Invitrogen, Karlsruhe 
TrypLETM Express Gibco, Eggenstein 
Trypsin-EDTA PAN-Biotech, Aidenbach 
Trypsin Inhibitor, from Glycine max (soy-bean) Sigma-Aldrich, Deisenhofen 
Tunicamycin from Streptomyces sp. Sigma-Aldrich, Deisenhofen 
Tween® 20 Carl Roth, Karlsruhe 
Western Blocking Reagent Sigma-Aldrich, Deisenhofen 
Yeast extract Carl Roth, Karlsruhe 
YeastmakerTM Carrier DNA Clontech, Saint-Germain-en-Laye (France) 
Yeast Nitrogen Base Without Amino Acids and 
Ammonium Sulfate (YNB) 
Sigma-Aldrich, Deisenhofen 
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2.1.4 Ready-to-use reaction systems 
Reaction system Manufacturer 
BigDye® Terminator v1.1 Cycle Sequencing Kit Applied Biosystems, Darmstadt 
DNase I Kit Sigma-Aldrich, Deisenhofen 
HiPure Plasmid Midiprep Kit Invitrogen, Karlsruhe 
HotStarTaq® Plus Master Mix Kit Qiagen, Hilden 
ImmobilonTM Western Chemiluminescent HRP 
Substrate 
Merck Millipore, Darmstadt 
ImmolaseTM DNA Polymerase Bioline, Luckenwalde 
In-Fusion® HD Cloning Kit Clontech, Saint-Germain-en-Laye (France) 
MSB® Spin PCRapace Kit Invitek, Berlin 
NE-PER® Nuclear and Cytoplasmic Extraction 
Reagents Kit 
Thermo Scientific, Rockford (USA) 
PfuUltra® High-Fidelity DNA Polymerase Agilent Technologies, Waldbronn 
Platinum® Taq DNA Polymerase Invitrogen, Karlsruhe 
Q5® High-Fidelity DNA Polymerase New England Biolabs, Frankfurt/M 
QIAquick® Gel Extraction Kit Qiagen, Hilden 
QuantiTect® SYBR® Green PCR Kit Qiagen, Hilden 
QuikChange II XL Site-Directed Mutagenesis Kit Agilent Technologies, Waldbronn 
SuperscriptTM II Reverse Transcriptase Kit Invitrogen, Karlsruhe 
 
 
2.1.5 Sterilization 
If not indicated differently, buffers and solutions were sterilized in a vapor autoclave for  
20 min at 120°C and 105 Pa. Heat sensitive solutions were sterile filtrated using filtration 
units of 0.20–0.45 µm pore size. Laboratory equipment were either autoclaved as 
mentioned above or heat sterilized at 180°C overnight. 
 
 
2.1.6 Buffers and solutions 
Buffer / Solution Composition 
4-OHT solution 5.16 mM 4-OHT in Ethanol 
  
Adenine solution 10 mg/ml Adenine in Ampuwa 
  
Ampicillin solution 50 mg/ml Ampicillin in Ampuwa 
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Antibody diluent solution 1% BSA in DPBST 
(Immunofluorescence staining)  
  
Antibody diluent solution I 1% BSA or 2% milk powder in TBST 
(Western blot analysis)  
  
Antibody diluent solution II 0.1% Casein solution in TBST 
(Western blot analysis)  
  
Blocking solution 300 mM Glycine 
(Immunofluorescence staining) 3% BSA 
 0.1% Tween 20 
 in PBS 
  
Blocking solution I 5% BSA or milk powder in TBST 
(Western blot analysis)  
  
Blocking solution II 0.1% Casein solution in TBST 
(Western blot analysis)  
  
Casein solution (10%) Western Blocking Reagent (with 10% Casein) 
 1% Thimerosal 
  
dNTPs solution 10 mM dATP 
 10 mM dCTP 
 10 mM dGTP 
 10 mM dTTP 
 in Ampuwa 
  
DPBS with 0.1% Tween 20 (DPBST) 0.1% Tween 20 in DPBS 
  
EGF (human) solution  0.25 mg/ml EGF in 0.1% BSA/10 mM Acetic acid 
  
DEPC-H2O 0.1% Diethylpyrocarbonate in ddH2O 
 Incubation for 24 h by stirring 
  
FGF-2 (human) solution 25 µg/ml FGF-2 (Merck Millipore) in 1 mM           
1-Thioglycerol / 0.01 mM Tris, pH 7.0 
  
 0.1 mg/ml FGF-2 (PeproTech) in 0.1% BSA/PBS 
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Fibronectin (human) solution 50 µg/ml Fibronectin in PBS 
  
Glucose solution (40%) 40% Glucose in ddH2O 
 autoclave for 15 min at 121°C 
  
Glycerol solution (50%) 50% Glycerol in ddH2O 
  
Histidine solution 10 mg/ml Histidine in Ampuwa 
  
Kanamycin solution 50 mg/ml Kanamycin in Ampuwa 
  
LiAc solution (10x) 100 mM LiAc in ddH2O 
 adjust to pH 7.5 
 autoclave for 15 min at 121°C 
  
Loading buffer 0.1 M EDTA 
(Agarose gel electrophoresis) 50% Glycerol 
 0.02% Xylene cyanol 
 0.02% Bromphenol blue 
 0.02% SDS 
 in Ampuwa 
  
Lysis buffer 300 mM NaCl 
 50 mM Tris-HCl, pH 7.5 
 5 mM EDTA 
 0.1% Triton X-100 
 Protease inhibitor cocktail tablet 
 in ddH2O 
  
PBS buffer (10x) 1.4 M NaCl 
 90 mM Na2HPO4 
 27 mM KCl 
 15 mM KH2PO4 
 in ddH2O 
 adjust to pH 7.4 
  
PEG 4000 solution (50%) 50% PEG 4000 in ddH2O 
 autoclave for 15 min at 121°C 
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PEG/LiAc solution 1 ml TE buffer (10x) 
 1 ml LiAc solution (10x) 
 8 ml PEG 4000 solution (50%) 
  
PFA solution (4%) 4% PFA in PBS 
 adjust to pH 6–7 
  
Proteinase K solution 10 mg/ml Proteinase K in Ampuwa 
  
TBE buffer (5x) 445 mM Tris 
 445 mM Boric acid 
 0.01 M EDTA 
 in ddH2O 
  
TBS buffer 154 mM NaCl 
 10 mM Tris-HCl, pH 7.5 
 in ddH2O 
  
TBST buffer 154 mM NaCl 
 10 mM Tris-HCl, pH 7.5 
 0.1% Tween 20 
 in ddH2O 
  
TE buffer (10x) 10% 1 M Tris-HCl, pH 7.5 
 2% 0.5 M EDTA, pH 8.0 
 in ddH2O 
 autoclave for 15 min at 121°C 
  
TE/LiAc solution 500 µl TE buffer (10x) 
 500 µl LiAc solution (10x) 
 4 ml Ampuwa 
  
Transfer buffer (10x, without Methanol) 1.92 M Glycine 
(Western blot analysis) 250 mM Tris 
 in ddH2O 
  
Transfer buffer I 
(Western blot analysis) 
8% Transfer buffer (10x, without Methanol) 
20% Methanol 
 in ddH2O 
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Transfer buffer II 192 mM Glycine 
(Western blot analysis) 25 mM Tris 
 10% Methanol 
 0.025% SDS 
 in ddH2O 
 adjust to pH 8.3 
  
Tris/HCl buffer 1 M Tris in ddH2O 
 adjust with HCl to pH 7.5 
  
Triton X-100 solution (0.1%) 0.1% Triton X-100 in DPBS 
 
 
2.1.7 Plasmids and vectors 
Plasmid / Vector  Source 
CHD7-2-pGBKT7 Schulz et al. (2014a)  
CHD7-3-pGBKT7 Schulz et al. (2014a) 
CHD7-4-pGBKT7 Schulz et al. (2014a) 
CHD7-Cr1-3-pGBKT7 Batsukh et al. (2010) 
CHD8-pGADT7-Rec Batsukh et al. (2010) 
RbBP5-pCMV-HA Schulz et al. (2014a) 
SEMA3A WT-pcDNA3.1/myc-His B AG Pauli, Institute of Human Genetics (Göttingen) 
SEMA3A WT-pCMV-HA generated in the present thesis (chapter 3.7) 
SEMA3A c.196C>T/p.R66W-pCMV-HA generated in the present thesis (chapter 3.7) 
SEMA3A c.2002A>G/p.I668V-pCMV-HA generated in the present thesis (chapter 3.7) 
SEMA3A WT-pGADT7 generated in the present thesis (chapter 3.7) 
SEMA3A c.196C>T/p.R66W-pGADT7 generated in the present thesis (chapter 3.7) 
SEMA3A c.2002A>G/p.I668V-pGADT7 generated in the present thesis (chapter 3.7) 
pcDNATM3.1/myc-His B Invitrogen, Karlsruhe 
pCMV-HA Clontech, Saint-Germain-en-Laye (France) 
pGADT7 Clontech, Saint-Germain-en-Laye (France) 
pGBKT7 Clontech, Saint-Germain-en-Laye (France) 
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2.1.8 Bacterial strains 
Bacterial strain Source 
Escherichia coli DH5α competent cells 
(Subcloning EfficiencyTM DH5αTM, 
Chemically Competent Cells) 
Invitrogen, Karlsruhe 
 
 
2.1.8.1 Media and agar plates for bacterial culture 
Medium / Plate Composition 
LB medium 1% Peptone ex casein 
 1% NaCl 
 0.5% Yeast extract 
 in ddH2O 
  
LB/Ampicillin 0.1% mg/ml Ampicillin in LB Medium 
  
LB/Kanamycin 0.1% mg/ml Kanamycin in LB Medium 
  
LB agar plates 1% Peptone ex casein 
 1% NaCl 
 0.5% Yeast extract 
 1.5% Agar-Agar 
 in ddH2O 
 
 
2.1.9 Eukaryotic cell lines 
Cell line Description Source Culture medium 
HEK293 human embryonic kidney 293 
cells 
ATCC® (CRL-1573TM) 
LGC Standards (Wesel) 
FB medium 
JoMa1 murine trunk NCC line Dr. Sven Lindner 
(Ruhr-University Bochum) 
NCC medium 
JoMa1.3 murine trunk NCC line (clonally 
derived subline from JoMa1) 
Dr. Sven Lindner 
(Ruhr-University Bochum) 
NCC medium 
O9-1 murine cranial NCC line Merck Millipore (SCC049) 
(Darmstadt) 
ESC medium 
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2.1.9.1 Media for eukaryotic cell culture 
Medium  Composition 
ESC medium Complete ES Cell Medium with FBS and LIF 
 25 ng/ml FGF-2 (human, PeproTech) 
  
Fibroblast medium DMEM 
(FB medium) 10% FBS 
 1x NEAA 
 100 U/ml / 0.1 mg/ml Penicillin/Streptomycin 
  
NCC medium DMEM/F-12 
 10% CEE 
 1x B-27 Supplement 
 1x N-2 Supplement 
 100 U/ml / 0.1 mg/ml Penicillin/Streptomycin 
 10 ng/ml EGF (human) 
 1 ng/ml FGF-2 (human, Merck Millipore) 
 200 nM 4-OHT 
 
 
2.1.9.2 Freezing media 
Medium Composition 
ESC freezing medium Cryo-SFM (ready to use) 
  
Fibroblast freezing medium 60% DMEM 
(FB freezing medium) 20% FBS 
 20% DMSO 
  
NCC freezing medium 90% Complete ES Cell Medium with FBS and LIF 
 10% DMSO 
 
 
2.1.10 Yeast strains 
Yeast strain Source 
Y2HGold Clontech, Saint-Germain-en-Laye (France) 
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2.1.10.1 Media and agar plates for yeast culture 
Medium / Agar plate Composition 
SD medium 2.5 g Ammonium sulfate / 475 ml ddH2O 
 0.85 g YNB / 475 ml ddH2O 
 0.3 g DO Supplement / 475 ml ddH2O 
 adjust to pH 5.8 
 autoclave for 15 min at 121°C 
 add 25 ml Glucose (40%) 
 add 0.5 ml Kanamycin 
  
SD medium with Adenine and Histidine 2.5 g Ammonium sulfate / 475 ml ddH2O 
 0.85 g YNB / 475 ml ddH2O 
 0.3 g DO Supplement / 475 ml ddH2O 
 adjust to pH 5.8 
 autoclave for 15 min at 121°C 
 add 25 ml Glucose (40%) 
 add 0.5 ml Kanamycin 
 add 1ml Adenine 
 add 1 ml Histidine 
  
YPDA medium 20 g Peptone ex casein / 950 ml ddH2O 
 10 g Yeast extract / 950 ml ddH2O 
 adjust to pH 6.5 
 autoclave for 15 min at 121°C 
 add 50 ml Glucose (40%) 
 add 2 ml Adenine 
 add 1 ml Kanamycin 
  
−LT agar plates 2.5 g Ammonium sulfate / 475 ml ddH2O 
 0.85 g YNB / 475 ml ddH2O 
 0.3 g DO Supplement / 475 ml ddH2O 
 adjust to pH 5.8 
 add 10 g Agar-Agar 
 autoclave for 15 min at 121°C 
 add 25 ml Glucose (40%) 
 add 0.5 ml Kanamycin 
 add 1ml Adenine 
 add 1 ml Histidine 
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−LTHA agar plates 2.5 g Ammonium sulfate / 475 ml ddH2O 
 0.85 g YNB / 475 ml ddH2O 
 0.3 g DO Supplement / 475 ml ddH2O 
 adjust to pH 5.8 
 add 10 g Agar-Agar 
 autoclave for 15 min at 121°C 
 add 25 ml Glucose (40%) 
 add 0.5 ml Kanamycin 
  
YPDA agar plates 20 g Peptone ex casein / 950 ml ddH2O 
 10 g Yeast extract / 950 ml ddH2O 
 adjust to pH 6.5 
 add 20 g Agar-Agar 
 autoclave for 15 min at 121°C 
 add 50 ml Glucose (40%) 
 add 2 ml Adenine 
 add 1 ml Kanamycin 
 
 
2.1.11 Antibodies 
2.1.11.1 Primary antibodies 
Antigen Company Code Species Clonality Dilution 
α-Tubulin Sigma-Aldrich, Deisenhofen T5168 mouse monoclonal ICC 1:10,000 
     WB 1:4000 
Baf47 Abcam, Cambridge (UK) ab126734 rabbit monoclonal WB 1:1000 
Chd7 
Cell Signaling, Danvers (USA) 6505 rabbit monoclonal ICC 1:20 
Abcam, Cambridge, (UK) ab31824 rabbit polyclonal WB 1:1000 
HA Sigma-Aldrich, Deisenhofen 11867431001 rat monoclonal, 
3F10 
WB 1:1000 
Sema3a Abcam, Cambridge (UK) ab23393 rabbit polyclonal ICC 1:20 
     WB 1:1000 
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2.1.11.2 Secondary antibodies 
Antibody Company Code Dilution 
Anti-Rabbit IgG (whole molecule), 
F(ab‟)2 fragment-Cy3 antibody produced 
in sheep 
Sigma-Aldrich, Deisenhofen 
 
C2306 
 
ICC 1:500 
 
F(ab‟)2-Goat anti-Mouse IgG (H+L) 
Cross-Adsorbed Secondary Antibody, 
Alexa Fluor
®
 488 
Invitrogen, Karlsruhe 
 
 
A11017 
 
 
ICC 1:500 
 
 
Goat IgG anti-Mouse IgG (H+L)-HRPO Dianova, Hamburg 115-035-062 WB 1:10,000 
Goat IgG anti-Rabbit IgG (H+L)-HRPO Dianova, Hamburg 111-035-003 WB 1:10,000 
Peroxidase AffiniPure Goat Anti-Rat 
IgG, F(ab‟)2 fragment specific 
Jackson ImmunoResearch, 
West Grove (USA) 
112-035-006 
 
WB 1:10,000 
 
 
 
2.1.12 Synthetic oligonucleotides 
All synthetic DNA oligonucleotides were purchased from Eurofins MWG Operon 
(Ebersberg). Ampuwa dissolved primer stocks with a final concentration of 100 pmol/µl 
were stored at −20°C. Primers were used at a concentration of 10 pmol/µl for PCR 
experiments. 
 
 
2.1.12.1 Synthetic oligonucleotides for genotyping PCR experiments 
Name Direction Primer sequence 5’  3’ Annealing 
(°C) 
Cycles 
Whi-Genotype 
forward CCTGCTGATGACTGGAAGAAAT 
65 35 
reverse CAAAGAAAAGTTCCCAGCAAAC 
 
 
2.1.12.2 Synthetic oligonucleotides for In-Fusion® experiments 
Name Direction Primer sequence 5’  3’ Annealing 
(°C) 
Cycles 
hSEMA3A-CMV-S-1 
forward ACGCTCTTATGGCCATGGAGGCCATG
GGCTGGTTAACTAGGATTG 
60 35 
hSEMA3A-CMV-E-1 
reverse TCGGTCGACCGAATTCCTAGAGGTAAT
GCAGCTCAGACACT 
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hSEMA3A-GAD-S-1 
forward ACGCTCATATGGCCATGGAGGCCATG
GGCTGGTTAACTAGGATTG 
60 35 
hSEMA3A-GAD-E-1 
reverse CACCCGGGTGGAATTCCTAGAGGTAA
TGCAGCTCAGACACT 
 
 
2.1.12.3 Synthetic oligonucleotides for mutagenesis experiments 
Name Direction Primer sequence 5’  3’ Annealing 
(°C) 
Cycles 
SEMA3A_c196t 
forward CTTCCTTTTGGATGAGGAATGGAGTAG
GCTGTATGTT 
60 20 
reverse AACATACAGCCTACTCCATTCCTCATC
CAAAAGGAAG 
SEMA3A_a2002g 
forward AGGTAACCCTGGAAGTCGTTGACACA
GAGCATTTG 
60 20 
reverse CAAATGCTCTGTGTCAACGACTTCCAG
GGTTACCT 
 
 
2.1.12.4 Synthetic oligonucleotides for mycoplasma contamination 
Name Direction Primer sequence 5’  3’ Annealing 
(°C) 
Cycles 
Myco1 
forward ACACCATGGGAGCTGGTAAT 
55 35 
reverse CTTCWTCGACTTYCAGACCCAAGGCAT 
 
 
2.1.12.5 Synthetic oligonucleotides for patient screening 
Name Direction Primer sequence 5’  3’ Annealing 
(°C) 
Cycles 
SEMA3A 1 
forward TCACCTGTTACCTCCAGTTTCC 65 − 1 
60 
5 
35 reverse GGTTTGATGATTTGGGGTTG 
SEMA3A 2 
forward TCAGGTTACCATGTACCAACAGTC 65 − 1 
60 
5 
35 reverse TGCATCCATTGATTCATTACTGTC 
SEMA3A 3 
forward ACTTCAGTTGCCCCAATGT 65 − 1 
60 
5 
35 reverse CACATGACCCACAAGTGGAA 
SEMA3A 4 
forward CAGTCATGCTGATTGCTGAAA 65 − 1 
60 
5 
35 reverse TGAACCACAAGCAAAATAAACTG 
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SEMA3A 5 
forward TCTCTGATTAACTGATGTGTTGAAA 65 − 1 
60 
5 
35 reverse TTATTTCATAATGGAAAATCTTGGT 
SEMA3A 6 
forward CATGGTCATAACATGAAACTTGC 65 − 1 
60 
5 
35 reverse CCATCATGAAGTCACCACCA 
SEMA3A 7 
forward TGGACTGTTCAGAATGGTATTATTT 65 − 1 
60 
5 
35 reverse CCTGTACCTGTATATTTGACTGCG 
SEMA3A 8/9 
forward GGAACGATTCGACCACAAAT 65 − 1 
60 
5 
35 reverse TGCAAATTATGAGTACTTGGATAGC 
SEMA3A 10 
forward GCCATTTTCACCTATGCCTT 65 − 1 
60 
5 
35 reverse TCTGTCTGTAGCTGCATTGTTTT 
SEMA3A 11 
forward GAACCATTGAGGCCATGTGT 65 − 1 
60 
5 
35 reverse CCAACCCCTGAGATGTTCAA 
SEMA3A 12 
forward AAAAGGAAGACCGATATCAAAGG 65 − 1 
60 
5 
35 reverse TGAGAAAACAAAATATGAGCCAAA 
SEMA3A 13 
forward AGCAATAACCCCAACTTGGTC 65 − 1 
60 
5 
35 reverse ATCAAAAACATGAGGGCAATG 
SEMA3A 14 
forward AGAAGGCCTTTAAAGAAATTAGCA 65 − 1 
60 
5 
35 reverse TTGATGCACTTATTTGAAGAAAGC 
SEMA3A 15 
forward TCTGGTAGTGAAAAAGCCATGA 65 − 1 
60 
5 
35 reverse TCTCTTCGGCTGCATTTCTT 
SEMA3A 16 
forward TGGCAATAACTTGTCTCCTGAA 65 − 1 
60 
5 
35 reverse TGAATGAGCGATTGATTGGT 
SEMA3A 17 
forward ACAGACACGGAGTTTCAGAGC 
65 − 1 
60 
5 
35 
reverse AGATTGGGGTGGTTGATGAG 
reverse CCCACCATTGTAAACATCCA 
 
 
2.1.12.6 Synthetic oligonucleotides for RT-PCR experiments 
Name Direction Primer sequence 5’  3’ Annealing 
(°C) 
Cycles 
Actg2 
forward GGCTTTGCAGGAGATGATGC 64 − 1 
59 
5 
25 reverse GGCAGTGCATAGCCCTCATA 
mChd7_qRT-5 
forward GCAGTCAGAGCAGCAGGAAT 65 − 1 
60 
5 
30 reverse GCTCTGGCCCTGTTTTGACT 
Cnn1 
forward TGGCCCAGAAATACGACCAT 64 − 1 
59 
5 
25 reverse CCTTTTGTCTTGGCCATGCT 
Col2a1 
forward GAAGAGCGGAGACTACTGGATT 64 − 1 
59 
5 
25 reverse AGGTAGGCGATGCTGTTCTT 
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Gfap 
forward GCCTCGGTCCTAGTCGAC 64 − 1 
59 
5 
25 reverse TCCTGTCTATACGCAGCCAG 
Nefh 
forward GCAGCCAAAGTGAACACAGA 64 − 1 
59 
5 
25 reverse TGTAAGCGGCAATCTCAATGT 
mNrp1RT 
forward CCACAGAGAAGCCAACCATT 65 − 1 
60 
5 
30 reverse TGAAGTTGCCATCTCCTGTATG 
mNrp2RT 
forward GGGGAAAACTGCAGCTTTGA 65 − 1 
60 
5 
30 reverse GGCCATCACTCTGCAGTTTC 
P75 
forward CTCAGATGAAGCCAACCACG 63 − 1 
58 
5 
30 reverse GGAGCAATAGACAGGAATGAGG 
Pax3_Seaberg 
forward GGAGGCGGATCTAGAAAGGAAGGA 64 − 1 
59 
5 
25 reverse CCCCCGGAATGAGATGGTTGAA 
PlxnA1RT 
forward TTGGAATGTGCCTGACCTCT 65 − 1 
60 
5 
30 reverse TGAGGTAGAGCTTCACCACC 
mSema3a_RT_3 
forward TGCAGTCCGAAGTCACAGAG 65 − 1 
60 
5 
30 reverse TTGCATGAATCCGTGTTCCAC 
mSema3c_RT_3 
forward GGATCGGCAGTGTGTGTGTA 65 − 1 
60 
5 
30 reverse ACAACGTCATCTGGGAAGTCC 
mSema3d_RT_2 
forward AAGGCTCTGCTGTCTGTGTG 68 − 1 
63 
5 
30 reverse CTGGAAAGTCTCGGGTGGAC 
mSema3e_RT_4 
forward GCATGGGGAAGTTAGGCCAT 68 − 1 
63 
5 
30 reverse CTCGGGTGTAGATCGTGTGG 
Slug 
forward TGCCATCGAAGCTGAGAAGT 64 − 1 
59 
5 
25 reverse GCAGAAGCGACATTCTGGAG 
Snail_Seaberg 
forward AAGCCCAACTATAGCGAGCTG 64 − 1 
59 
5 
25 reverse AGTTGAAGATCTTCCGCGACT 
Sox10 
forward CCCTTCATTGAGGAGGCTGA 63 − 1 
58 
5 
30 reverse TTGGTCCAGCTCAGTCACAT 
Twist_26.01.15 
forward GCCAGGTACATCGACTTCCTG 64 − 1 
59 
5 
25 reverse CCACGCCCTGATTCTTGTGA 
Tyr 
forward AGCATGCACAATGCCTTACA 65 − 1 
60 
5 
30 reverse GAGCGGTATGAAAGGAACCA 
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2.1.12.7 Synthetic oligonucleotides for sequencing 
Name Direction Primer sequence 5’  3’ Annealing 
(°C) 
Cycles 
seq_hSEMA3A-1 
forward ATGGGCTGGTTAACTAGGATTG 
60 30 
reverse CACATTGTTCTTCCCATTCTGA 
seq_hSEMA3A-2 
forward AATGGACAACATTCCTCA 
60 30 
reverse GGAATACATCCTGCAGTTCATC 
seq_hSEMA3A-3n 
forward AGACGCACAAGACGACAAGATA 
60 30 
reverse ATTCTCTCTTCAGGGCTGTGG 
seq_hSEMA3A-4 forward GGGAACAGTAACAAATGGAAGC 60 30 
seq_hSEMA3A-5 
forward GACAGAGCAGCATGATTCCA 
60 30 
reverse ATGGCTGGATGACTTCTTGC 
seq_hSEMA3A-6 
forward AGAGGTTCTGCTGGAAGAAATG 
60 30 
reverse ATTGCCTGAATCCTTCTGTTGT 
seq_mSema3A-1 
forward CACTGGGATTGCCTGTCTTT 
60 30 
reverse GGCCAAGCCATTAAAAGTGA 
seq_mSema3A-2 
forward CGGGACTTCGCTATCTTCAG 
60 30 
reverse GATGAGATGGGCACTGATGA 
seq_mSema3A-3 
forward ACATTTGGCGGATTTGACTC 
60 30 
reverse CTGCATCCACTCGGTCTACA 
seq_mSema3A-4 
forward GCGCACAAGACGACAAGATA 
60 30 
reverse TCTGTGACTTCGGACTGCAT 
seq_mSema3A-5 
forward GTGGAAGCACATGCAAGAGA 
60 30 
reverse AACTCGTGGGTCCTCCTGT 
pCMV 
forward CTCAGTGGATGTTGCCTTTACTTCT 
60 30 
reverse AAGCAATAGCATCACAAATTTCACA 
T7cDNA3 forward TAATACGACTCACTATAGG 60 30 
 
 
2.1.12.8 Synthetic oligonucleotides for qRT-PCR experiments 
Name Direction Primer sequence 5’  3’ Annealing 
(°C) 
Cycles 
mChd7_qRT-3 
forward AGAAGAGAAGCTGGAGGACGA 
60 40 
reverse TGATTTCCAGGGCCTTGTCC 
qRT_mHprt 
forward AGCCCCAAAATGGTTAAGGTTGC 
60 40 
reverse TTGCAGATTCAACTTGCGCTCAT 
mSema3a_RT-1 
forward CGGGACTTCGCTATCTTCAGAACACT 
60 40 
reverse TCATCTTCAGGGTTGTCACTCTCTGG 
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qRT_mTbp 
forward CCCACAACTCTTCCATTCTCAAAC 
60 40 
reverse TCAAGTTTACAGCCAAGATTCACG 
 
 
2.1.13 Molecular weight standards 
Application Standard and Manufacturer 
DNA molecular weight standards 100 bp DNA Ladder (Invitrogen, Karlsruhe) 
  
 1 kb DNA Ladder (Invitrogen, Karlsruhe) 
  
 1 kb Plus DNA Ladder (Invitrogen, Karlsruhe) 
  
 DNA molecular weight standards were diluted 
with loading buffer according to manufacturer‟s 
instructions. 
  
Protein molecular weight standards SeeBlue® Plus2 Pre-Stained Protein Standard 
 (Invitrogen, Karlsruhe) 
  
 HiMarkTM Pre-Stained High Molecular Weight 
Protein Standard (Invitrogen, Karlsruhe) 
 
 
2.1.14 Animals/ethic statement 
The used mouse line Whirligig (Bosman et al., 2005) was kindly provided from K. P. Steel 
(Sanger Centre, Cambridge, United Kingdom) and the Helmholtz Zentrum (Munich). The 
mice were housed in the animal facility of the Institute of Human Genetics (Göttingen) 
under conventional conditions (12 h light/dark cycle, 22°C, 55 ± 5% relative humidity and 
free access to food and water). Animal food was purchased from ssniff Spezialdiäten 
(Soest). All experiments were approved by the Institutional Animal Care and Use 
Committee of the University of Göttingen and conducted according to the European and 
German protection of animal act. The number of sacrificed animals and the stress and 
pain the mice were suffering was kept to a minimum. Euthanasia of mice was performed 
by CO2-asphyxation or cervical dislocation. 
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2.1.15 Patient samples 
Genomic DNA of patient samples was provided by the genetic diagnostics laboratory of 
the Institute of Human Genetics (University Medical Center Göttingen) and by 
collaboration with Conny van Ravenswaaij-Arts of the Department of Genetics (University 
Medical Center Groningen, The Netherlands). The ethical approval was obtained from the 
Ethics Committee of the University Göttingen. 
 
 
2.1.16 Databases / Online tools / Programs 
Analysis of / Designing of / Usage for Database / Online tool / Program 
Gene domains SMART 
 http://smart.embl-heidelberg.de 
  
 UniProtKB 
 http://www.uniprot.org/ 
  
Genome variants Exome Aggregation Consortium (ExAC) Browser 
 http://exac.broadinstitute.org/ 
  
Information about human genes and genetic 
disorders 
Online Mendelian Inheritance in Man (OMIM) 
https://www.omim.org/ 
  
In-Fusion® PCR Cloning System http://bioinfo.clontech.com/infusion/ 
  
Mice administration Tierbase Client 4D v15.1 
  
Nucleotide exchanges MutationTaster 
 http://www.mutationtaster.org/ 
  
 PolyPhen-2 
 http://genetics.bwh.harvard.edu/pph2/ 
  
 SIFT 
 http://sift.jcvi.org/ 
  
Nucleotide sequences Ensembl genome browser 87 
 http://www.ensembl.org/ 
  
 National Center for Biotechnology Information 
(NCBI) 
 https://www.ncbi.nlm.nih.gov/ 
Materials and Methods  32 
Plasmid maps Savvy Version 0.1 
 http://www.bioinformatics.org/savvy/ 
  
Primers Primer3 
 http://bioinfo.ut.ee/primer3-0.4.0/ 
  
Protein molecular weights ExPASy 
http://web.expasy.org/compute_pi/ 
  
Repetitive gene sequences RepeatMasker 
 http://www.repeatmasker.org/ 
  
Restriction sites NEBcutter V2.0 
 http://nc2.neb.com/NEBcutter2/ 
  
Searching for publications PubMed 
 https://www.ncbi.nlm.nih.gov/pubmed/ 
  
Sequences Chromas Lite 2.01 (Technelysium Pty Ltd.) 
  
 Sequence Pilot 4.3.1 (JSI medical systems) 
  
Sequence alignments Basic Local Alignment Search Tool (BLAST) 
provided by NCBI 
 https://blast.ncbi.nlm.nih.gov/Blast.cgi 
 
 
2.1.17 Statistical analysis 
An unpaired student‟s t test was performed to test for statistical significance.  
The calculated p-value indicates the probability that the results are not different  
from each other. A p-value smaller than * p ≤ 0.05 means statistically significant,  
** p ≤ 0.01 means very significant, *** p ≤ 0.001 means extremely significant. 
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2.2 Methods 
2.2.1 Molecular biology methods 
2.2.1.1 Isolation of nucleic acids 
2.2.1.1.1 Isolation of genomic DNA for mouse genotyping 
For mouse genotyping, genomic DNA (gDNA) was isolated from tail biopsy taken at the 
age of four weeks. The tail biopsy was mixed with 200 µl of DirectPCR® Lysis Reagent 
Tail (Peqlab) and 8 µl of proteinase K (10 mg/ml) and incubated at 55°C by shaking at  
950 rpm overnight. The tail biopsy from a mouse embryo was mixed with 100 µl of 
DirectPCR Lysis Reagent Tail and 4 µl of proteinase K (10 mg/ml) and incubated as 
previously described. The following day, proteinase K was inactivated by incubation for  
45 min at 85°C. The samples were short centrifuged, transferred on ice and used for 
genotyping PCR (chapter 2.2.1.2.1.3). Isolated gDNA was finally stored at 4°C. 
 
 
2.2.1.1.2 Minipreparation of plasmid DNA 
Small amounts of plasmid DNA from bacteria were isolated with the ready-to-use buffers 
(P1/P2/P3) for minipreparation (Qiagen). 3 ml of LB medium containing the appropriate 
antibiotic was inoculated with a single bacterial colony or a small amount of a glycerol 
stock and incubated at 37°C by shaking at 160 rpm overnight. For preparation of a 
glycerol stock the following day, 500 µl of the bacterial culture was mixed with 320 µl of 
50% sterile glycerol and stored at −80°C. The extant overnight culture was centrifuged at 
4000 x g for 10 min at 4°C. The bacterial cell pellet was resuspended in 200 µl of  
P1 buffer, transferred into a 1.5 ml reaction tube and 200 µl of P2 buffer (modified alkaline 
lysis) was added. The solution was mixed by inverting and incubated for 5 min at RT. After 
addition of 200 µl P3 buffer (neutralization) and repeated mixing by inverting, the solution 
was centrifuged at 16,000 x g for 10 min at RT. The received supernatant was transferred 
into a new 1.5 ml reaction tube. DNA was precipitated with 800 µl of 100% isopropanol 
(chilled at −20°C) and repeated mixed by inverting before centrifuged at 16,000 x g for  
30 min at 4°C. The DNA pellet was washed with 300 µl of 70% ethanol (chilled at −20°C) 
and centrifuged at 16,000 x g for 5 min at 4°C. After discarding the supernatant, the 
plasmid DNA pellet was dried at 56°C and resolved in an appropriate volume of Ampuwa 
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by gently shaking for 10 min at 56°C. Afterwards, isolated plasmid DNA was stored  
at −20°C. 
 
 
2.2.1.1.3 Endotoxin-free midipreparation of plasmid DNA 
Large amounts of plasmid DNA from bacteria were isolated with ready-to-use reaction 
system HiPure Plasmid Midiprep Kit (Invitrogen, Karlsruhe). 50 ml of LB medium, 
containing the appropriate antibiotic, was inoculated with either 50 µl of bacterial overnight 
culture (taken before minipreparation and stored at 4°C) or a small amount of a glycerol 
stock and incubated at 37°C by shaking at 160 rpm overnight. The overnight culture was 
centrifuged at 4000 x g for 10 min at RT. The bacterial cell pellet was resuspended in 4 ml 
of R3 buffer, further mixed with 4 ml of L7 buffer (modified alkaline lysis), inverted five 
times and incubated for 5 min at RT. After addition of 4 ml N3 buffer (neutralization)  
the suspension was mixed by inverting until the suspension was homogenous and 
centrifuged at 12,000 x g for 10 min at RT. The supernatant was loaded onto a with EQ1 
buffer equilibrated column. The column was washed twice with 10 ml of W8 buffer. The 
DNA was eluted with 5 ml of E4 buffer and further precipitated by addition of 2.5 ml  
100% isopropanol (chilled at −20°C). The suspension was mixed by repeated inverting 
and centrifuged at 16,000 x g for 30 min at 4°C. The DNA pellet was washed with 2.5 ml 
of 70% ethanol (chilled at −20°C). After centrifugation at 16,000 x g for 5 min at 4°C, the 
supernatant was discarded and the DNA pellet was dried at 56°C. The plasmid DNA pellet 
was resolved in an appropriate volume of Ampuwa by shaking for 10 min at 56°C and 
finally stored at −20°C. 
 
 
2.2.1.1.4 Isolation of total RNA from cultured cells 
For total RNA isolation from cultured cells either fresh or at −80°C stored cell pellets were 
used. Pellet was thoroughly mixed with 1 ml of Trizol Reagent (Invitrogen), incubated for  
5 min at RT and 200 µl of chloroform was added. The suspension was vigorously mixed 
for 15 s, incubated for 15 min at RT and centrifuged at 18,600 x g for 15 min at 4°C. After 
centrifugation, the upper aqueous phase containing the RNA was transferred into a new 
reaction tube. For precipitation of the RNA 500 µl of 100% isopropanol (chilled at −20°C) 
was added, the suspension was mixed by inverting, incubated for 10 min before 
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centrifuged at 18,600 x g for 8 min at 4°C. The RNA pellet was washed with 1 ml of  
75% ethanol/DEPC-H2O and centrifuged at 18,600 x g for 5 min at 4°C. The supernatant 
was discarded and the RNA pellet was dried at 60°C. For resolving the pellet, an 
appropriate volume of DEPC-H2O was used by shaking for 10 min at 60°C. The isolated 
RNA was stored at −80°C. 
 
 
2.2.1.1.5 Isolation of RNA from mouse tissues 
The mouse tissue was initially homogenized using the TissueLyser LT (Qiagen). Together 
with a stainless steel bead (ø 5 mm, Qiagen) and 1 ml of Trizol Reagent (Invitrogen) a 
small sample of the tissue was transferred into a 2 ml reaction tube. The tissue was 
homogenized in the TissueLyser LT for 5 min at 50 1/s oscillation. Afterwards, the reaction 
tube was kept on ice for 5 min. After centrifugation at 16,000 x g for 10 min at 4°C, the 
lysed cells containing supernatant was transferred into a new 1.5 ml reaction tube. The 
RNA isolation was continued by using the total RNA isolation protocol from cultured cells 
(chapter 2.2.1.1.4) starting with addition of 200 µl chloroform to the supernatant with the 
lysed cells. 
 
 
2.2.1.1.6 Determination of nucleic acid concentration 
Nucleic acid concentrations and purities were determined by measuring the absorption at 
260 nm using the NanoDrop 2000c UV-Vis spectrophotometer (Peqlab) according to 
manufacturer‟s instructions. Contaminations of protein and salt were estimated with the 
absorbance ratios of A260/280 and A260/230, respectively. 
 
 
2.2.1.2 Polymerase Chain Reactions 
2.2.1.2.1 Amplification of DNA 
The polymerase chain reaction (PCR) represents a standard in vitro method to amplify 
specific DNA fragments (Mullis et al., 1986). The double stranded template DNA is 
denatured at high temperatures (denaturation). This allows short oligonucleotides 
(primers) to bind to the now single stranded DNA (annealing). Bound oligonucleotides are 
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extended by a polymerase (elongation). Periodic repetition of denaturation, annealing and 
elongation results in an exponential increase of specific DNA fragments. The result of the 
PCR can be visualized by agarose gel electrophoresis (chapter 2.2.1.3). 
 
 
2.2.1.2.1.1 Standard PCR 
The standard PCR was used to control the efficiency of cDNA synthesis from RNA 
(chapter 2.2.1.2.2). Specific primers for the housekeeping gene mouse Hprt 
(hypoxanthine-guanine phosphoribosyltransferase) (chapter 2.1.12.8) and the Q5® High-
Fidelity DNA Polymerase (New England Biolabs) with the supplied reagents were used. 
 
The following reagents for 25 µl of reaction mixture were pipetted into a PCR reaction 
tube: 
 
Component Volume 
cDNA 1.0 µl 
Q5 Reaction Buffer (5x) 5.0 µl 
Q5 High GC Enhancer (5x) 5.0 µl 
Primer forward (10 pmol/µl)  1.25 µl 
Primer reverse (10 pmol/µl) 1.25 µl 
dNTP mix (10 mM) 0.5 µl 
Q5 High-Fidelity DNA Polymerase (2 U/µl) 0.25 µl 
Ampuwa 10.75 µl 
 
 
The reaction mixture was incubated in a thermocycler using the following standard  
PCR program: 
 
Step Temperature Time Repeats 
Initial denaturation 98°C 30 s 1 
Denaturation 98°C 10 s 
25 Annealing 60°C 30 s 
Elongation  72°C 20 s 
Final elongation 72°C 2 min 1 
Storage 4°C  1 
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After completion of the thermocycler program, loading buffer was added to 5 µl of the 
reaction mixture and loaded on a 1.5% agarose gel together with 100 bp DNA Ladder 
(Invitrogen). 
 
 
2.2.1.2.1.2 Touchdown PCR 
Generally, the components of the reaction mixture were the same as for standard PCR 
(chapter 2.2.1.2.1.1) with the exception of the touchdown PCR using patients DNA. To 
increase specificity, sensitivity and yield of PCR, a touchdown PCR program was applied.  
 
The reaction mixture was incubated in a thermocycler using the following touchdown  
PCR program: 
 
Step Temperature Time Repeats 
Initial denaturation 98°C 30 s 1 
Denaturation 98°C 10 s 
5 Annealing (2.1.12.6) − 1°C 30 s 
Elongation  72°C 20 s 
Denaturation 98°C 10 s 
(2.1.12.6) Annealing (2.1.12.6) 30 s 
Elongation 72°C 20 s 
Final elongation 72°C 2 min 1 
Storage 4°C  1 
 
 
After completion of the thermocycler program, loading buffer was added to 3‒5 µl of the 
reaction mixture and loaded on a 1.5% agarose gel together with 100 bp DNA Ladder 
(Invitrogen). 
 
 
 
Touchdown PCR with patients DNA samples for mutational analysis 
 
For touchdown PCR with patient DNA samples the HotStarTaq® Plus Master Mix Kit 
(Qiagen) and specific primers (chapter 2.1.12.5) were used. 
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The following reagents for 25.5 µl of reaction mixture were pipetted into a 96-well plate: 
 
Component Volume 
gDNA 1.0 µl 
Primer forward (10 pmol/µl)  1.0 µl 
Primer reverse (10 pmol/µl) 1.0 µl 
HotStarTaq Plus Master Mix 12.5 µl 
Ampuwa 10.0 µl 
 
 
The reaction mixture was incubated in a thermocycler using the following touchdown PCR 
program: 
 
Step Temperature Time Repeats 
Initial denaturation 95°C 7 min 1 
Denaturation 95°C 30 s 
5 Annealing (2.1.12.5) − 1°C 1 min 
Elongation  72°C 1 min 
Denaturation 95°C 30 s 
(2.1.12.5) Annealing (2.1.12.5) 1 min 
Elongation 72°C 1 min 
Final elongation 72°C 5 min 1 
Storage 4°C  1 
 
 
After completion of the thermocycler program, loading buffer was added to 3 µl of the 
reaction mixture and loaded on a 1.0% agarose gel together with 1 kb Plus DNA Ladder 
(Invitrogen). 
 
 
2.2.1.2.1.3 Genotyping PCR 
The genotyping PCR was used for mouse genotyping using gDNA isolated from tail 
biopsy (chapter 2.2.1.1.1). Specific primers for the DNA region which contains the 
nonsense mutation c.2918G>A (p.W973X) in case of the heterozygous or homozygous 
genotype (chapter 2.1.12.1) and the ImmolaseTM DNA Polymerase (Bioline) with the 
supplied reagents were used. 
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The following reagents for 50 µl of reaction mixture were pipetted into a PCR reaction 
tube: 
 
Component Volume 
gDNA 2.0 µl 
ImmoBuffer (10x) 5.0 µl 
MgCl2 Solution (50mM) 1.5 µl 
Primer forward (10 pmol/µl)  1.0 µl 
Primer reverse (10 pmol/µl) 1.0 µl 
dNTP mix (10 mM) 1.0 µl 
Immolase DNA Polymerase (5 U/µl) 0.4 µl 
Ampuwa 38.1 µl 
 
 
The reaction mixture was incubated in a thermocycler using the following standard  
PCR program: 
 
Step Temperature Time Repeats 
Initial denaturation 94°C 5 min 1 
Denaturation 94°C 30 s 
35 Annealing 65°C 45 s 
Elongation  72°C 1 min 
Final elongation 72°C 7 min 1 
Storage 4°C  1 
 
 
After completion of the thermocycler program, loading buffer was added to 3 µl of the 
reaction mixture and loaded on a 1.5% agarose gel together with 100 bp DNA Ladder 
(Invitrogen). The purified PCR product was further used for sequencing analysis (chapter 
2.2.1.2.4) to distinguish between the wildtype, heterozygous and homozygous state of 
Whirligig mice. 
 
 
2.2.1.2.1.4 Mutagenesis PCR 
The mutagenesis PCR was used to create specific, targeted changes in double stranded 
plasmid DNA with the QuikChange II XL Site-Directed Mutagenesis Kit according to 
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manufacturer‟s instructions (chapter 2.2.1.4.4). Specific primers for mutagenesis (chapter 
2.1.12.3) and the PfuUltra® High-Fidelity DNA Polymerase (Agilent Technologies) with the 
supplied reagents were used. 
 
The following reagents for 50 µl of reaction mixture were pipetted into a PCR reaction 
tube: 
 
Component Volume 
Double stranded plasmid DNA (75 ng) x µl  
Reaction buffer (10x) 5.0 µl 
QuikSolution 3.0 µl 
Primer forward (125 ng/µl)  1.0 µl 
Primer reverse (125 ng/µl) 1.0 µl 
dNTP mix 2.0 µl 
PfuUltra High-Fidelity DNA Polymerase (2.5 U/µl) 1.0 µl 
Ampuwa x µl 
 
 
The reaction mixture was incubated in a thermocycler using the following PCR program: 
 
Step Temperature Time Repeats 
Initial denaturation 95°C 1 min 1 
Denaturation 95°C 50 s 
20 Annealing 60°C 1 min 
Elongation  68°C 6 min* 
Final elongation 68°C 7 min 1 
Storage 4°C  1 
 
           * 1 min/kb of plasmid length 
 
 
After completion of the thermocycler program, the mutagenesis protocol was continued 
with DpnI digestion of the amplification products (chapter 2.2.1.4.4). 
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2.2.1.2.1.5 Mycoplasma contamination PCR 
To detect a possible contamination of eukaryotic cells by mycoplasma, a PCR with 
mycoplasma specific primers (chapter 2.1.12.4) and the Platinum® Taq DNA Polymerase 
(Invitrogen) with the supplied reagents was performed. Therefore, 200 µl of used cell 
culture medium was incubated for 5 min at 95°C. After mixing and centrifugation at  
1500 x g for 1 min the supernatant was used for reaction mixture. A mycoplasma 
contaminated cell culture medium was used as positive control. 
 
The following reagents for 50 µl of reaction mixture were pipetted into a PCR reaction 
tube: 
 
Component Volume 
Supernatant from cell culture 1.0 µl 
PCR Buffer (10x) 5.0 µl 
MgCl2 (50 mM) 2.0 µl 
Primer forward (10 pmol/µl)  0.5 µl 
Primer reverse (10 pmol/µl) 0.5 µl 
dNTP mix (10 mM) 1.0 µl 
Platinum Taq DNA Polymerase (5 U/µl) 0.2 µl 
Ampuwa 39.8 µl 
 
 
The reaction mixture was incubated in a thermocycler using the following PCR program: 
 
Step Temperature Time Repeats 
Initial denaturation 94°C 1 min 1 
Denaturation 94°C 30 s 
35 Annealing 55°C 2 min 
Elongation 72°C 1 min 
Final elongation 72°C 7 min 1 
Storage 4°C  1 
 
 
After completion of the thermocycler program, loading buffer was added to 10 µl of the 
reaction mixture and loaded on a 1.5% agarose gel together with 100 bp DNA Ladder 
(Invitrogen). 
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2.2.1.2.2 Reverse transcription 
To remove remaining DNA; a DNase digestion (Sigma-Aldrich) prior to transcription of 
mRNA into cDNA using the SuperScript® II Reverse Transcriptase (Invitrogen) was 
performed. 5 µg of RNA was diluted with DEPC-H2O in a total volume of 8 µl and further 
mixed with 1 µl of 10x reaction buffer and 1 µl of DNase I by pipetting. After incubation for 
15 min at RT, the reaction was stopped by addition of 1 µl Stop Solution, following 
incubation for 10 min at 70°C and 1 min on ice. Afterwards, DNase I digested RNA was 
mixed with 1 µl of Random Hexamers (Invitrogen) and 1 µl of 10mM dNTPs and incubated 
for 5 min at 65°C. After incubation for 1 min on ice, 2 µl of 0.1 M DTT and 4 µl of 5x First-
Strand Buffer was added and mixed by pipetting. After incubation for 2 min at 42°C, 1 µl of 
SuperScript II Reverse Transcriptase was added. The solution was mixed by pipetting and 
incubated for 50 min at 42°C. The reaction was stopped by enzyme inactivation at 70°C 
for 15 min. Amplified cDNA was cooled down for 5 min on ice and stored at −20°C. 
The efficiency of cDNA synthesis was controlled by PCR analysis using specific primers 
for the housekeeping gene mouse Hprt (chapter 2.2.1.2.1.1). 
 
 
2.2.1.2.3 Quantitative Real-Time PCR 
To quantify the relative mRNA expression levels of a certain gene of interest a quantitative 
Real-Time PCR (qRT-PCR) analysis was performed by using fluorescent labeled dNTPs 
for PCR reactions. After each PCR cycle the fluorescent intensity of labeled double 
stranded DNA was measured using the 7900HT Fast Real-Time PCR System (Applied 
Biosystems). During the exponential phase a threshold value of PCR cycles was 
determined in a Ct value. This value defines the PCR cycle with the optimal PCR 
conditions and was used for quantification calculations. The generated data were 
evaluated with the SDS 2.2.1 software (Applied Biosystems) and transferred to MS Excel 
(Microsoft) for further calculations using the ∆∆-Ct method. The mRNA expression of two 
housekeeping genes, mouse Hprt and mouse Tbp (TATA box binding protein) were used 
for normalization. 
Prior to the qRT-PCR analysis, the used cDNA was usually diluted 1:10 with Ampuwa. 
The analysis was carried out in 10 µl reactions with 2.5 µl of diluted cDNA, 2.5 µl of primer 
solution with forward and reverse primer (1 pmol/µl each primer) and 5.0 µl of QuantiTect® 
Materials and Methods  43 
SYBR® Green PCR Kit (Qiagen). The reactions were performed in triplicate in a 384-well 
plate on 7900HT Fast Real-Time PCR System using the following PCR program: 
 
Step Temperature Time Repeats 
 50°C 2 min 1 
Initial denaturation 95°C 15 min 1 
Denaturation 94°C 15 s 
40 Annealing 60°C 30 s 
Elongation  72°C 1 min 
Dissociation curve 
95°C 15 s 1 
60°C 15 s 1 
95°C 15 s 1 
 
 
2.2.1.2.4 Sequencing analysis 
The sequencing analysis was performed based on the chain-terminating Sanger 
sequencing in order to determine the nucleotide sequence of a DNA fragment of  
interest (Sanger et al., 1977). During the elongation step of the sequence reaction, 
deoxynucleotides and dideoxynucleotides, which are labeled with different fluorescent 
dyes, were incorporated into the DNA. The elongation of the chain was terminated 
selectively at A, C, G or T when dideoxynucleotides were incorporated at the 3‟ end of the 
growing chain. Further elongation of the chain was prevented, because the chain lacks a 
3‟-hydroxyl group once a dideoxynucleotide was incorporated. The nucleotides were 
determined due to the detected dye and the positions of the nucleotides within the DNA 
strand were determined due to the length of the fragments. 
The generated PCR product or plasmid was purified before sequencing analysis using the 
ready to use reaction system MSB® Spin PCRapace Kit (Invitek) or the MultiScreen® 
PCR96 Filter Plates (Merck Millipore). The purification was done according to 
manufacturer‟s instructions. 
The sequencing analysis was carried out in a 10 µl reaction using the BigDye® Terminator 
v1.1 Cycle Sequencing Kit (Applied Biosystems). 
For sequencing of gDNA isolated from tail biopsy for mouse genotyping, 6 µl of purified 
gDNA, 1 µl of forward or reverse primer (10 pmol/µl), 1 µl of BigDye Terminator Ready 
Reaction Mix and 2 µl of BigDye Terminator 5x Sequencing Buffer were pipetted into a 
PCR reaction tube. 
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For sequencing of a generated plasmid, 0.5 µl of purified plasmid DNA, 1 µl of forward or 
reverse primer (10 pmol/µl), 1 µl of BigDye Terminator Ready Reaction Mix, 2 µl of 
BigDye Terminator 5x Sequencing Buffer and 5.5 µl of Ampuwa were pipetted into a PCR 
reaction tube. 
For sequencing of a patient sample 5 µl of purified DNA, 1 µl of forward or reverse primer 
(10 pmol/µl), 2 µl of BigDye Terminator Ready Reaction Mix and 2 µl of BigDye 
Terminator 5x Sequencing Buffer were pipetted into a 96-well plate. 
 
The reaction mixture was incubated in a thermocycler using the following PCR program: 
 
Step Temperature Time Repeats 
Denaturation 95°C 20 s 
30 
Annealing 60°C 2 min 
Storage 8°C  1 
 
 
After completion of the thermocycler program each sample was mixed with 10 µl of 
Ampuwa. The final sequencing analysis was performed in house sequencing service 
(Institute of Human Genetics, Göttingen) using the 3500xL Genetic Analyzer (Applied 
Biosystems). The generated data were evaluated with the Chromas Lite 2.01 software 
(Technelysium Pty Ltd.) or the Sequence Pilot 4.3.1 software (JSI medical systems). 
 
 
2.2.1.3 Agarose gel electrophoresis of DNA 
The agarose gel electrophoresis is used to separate DNA fragments within an electric field 
according to their length. 
Depending on the expected fragment size of the DNA fragments, gels with an agarose 
concentration of 0.8‒2.0% (w/v) were prepared. The appropriate amount of agarose was 
dissolved in the appropriate amount of 0.5x Tris-Borate EDTA (TBE) buffer by boiling in a 
microwave. Either Roti®-Safe (Carl Roth) or ethidium bromide (Inno-Train Diagnostik) 
were added to visualize the DNA later under UV light before the mixture was poured into a 
horizontal gel chamber. After polymerization of the gel, it was loaded with the samples 
and an appropriate DNA length standard (chapter 2.1.13) in order to be able to determine 
the length of the DNA fragments. The separation of the DNA fragments was performed in 
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0.5x TBE buffer by the application of an electric field (100‒120 V) and afterwards 
visualized using an UV transilluminator. 
 
 
2.2.1.3.1 Purification of DNA fragments from agarose gels 
The purification of DNA fragments from agarose gels was performed using the ready to 
use reaction system QIAquick® Gel Extraction Kit (Qiagen, Hilden). After separation of 
DNA fragments, the DNA fragment of interest was excised from the gel with a sterile 
scalpel on an UV transilluminator and the gel piece was transferred into a reaction tube 
and weighed. The 3-fold volume of QG Buffer was added according to the weight of the 
excised DNA fragment (1 mg is equivalent to 100 µl). The mixture was incubated for  
10 min at 50°C by shaking and mixing every 2–3 min. After dissolving of the gel piece 
further purification was performed according to manufacturer‟s instructions. The DNA was 
eluted with an appropriate volume of Ampuwa and stored at −20°C. 
 
 
2.2.1.4 Cloning techniques 
2.2.1.4.1 Restriction digestion of plasmid DNA 
Enzymatic cleavage of plasmid DNA was performed with restriction endonucleases 
derived from the companies Invitrogen and New England Biolabs. Generally, per 1 µg 
DNA 10 units of the enzyme were incubated in 1x appropriate buffer at the required 
temperature for at least 2 h, preferentially 3 h, in a total volume of 20–50 µl filled up with 
Ampuwa. The complete digestion of the plasmid DNA was checked by agarose gel 
electrophoresis (chapter 2.2.1.3). 
If for the restriction digestion two different enzymes had to be used, either a buffer 
compatible for both enzymes was chosen or a sequential restriction digestion was 
performed. For sequential restriction digestion, the digested DNA had to be precipitated 
after the use of the first restriction enzyme. Therefore, the reaction volume was filled up 
with Ampuwa to a total volume of 100 µl. 10 µl of 3 M sodium acetate (pH 5.2) was added 
and the solution was mixed for 12 s. After addition of 300 µl 100% ethanol (chilled  
at −20°C), the solution was mixed by inverting and incubated either for 5 min at RT or 
overnight at −20°C. The precipitated DNA was centrifuged at 16,000 x g for 10 min at RT 
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and the received DNA pellet was washed with 1 ml of 70% ethanol (chilled at −20°C). 
After centrifugation at 16,000 x g for 5 min at RT, the pellet was dried at 56°C and 
resolved in an appropriate volume of Ampuwa by shaking for 10 min at 56°C. Afterwards, 
restriction digestion with the second restriction enzyme was performed. 
 
 
2.2.1.4.2 Cloning of DNA fragments using In-Fusion® HD Cloning Kit 
For cloning of DNA fragments into vectors the In-Fusion® HD Cloning Kit (Clontech) was 
used according to manufacturer‟s instructions. The gene of interest was amplified by PCR 
using gene-specific In-Fusion primers. For the In-Fusion cloning reaction the linearized 
vector, the purified PCR fragment and 2 µl of 5x In-Fusion HD Enzyme Premix were 
adjusted with Ampuwa to a total reaction volume of 10 µl. The reaction mixture was 
incubated for 15 min at 37°C followed by an additional incubation for 15 min at 50°C. After 
addition of 40 µl TE buffer (Invitrogen), E. coli DH5α competent cells were transformed 
with 2.5 µl of the reaction mixture (chapter 2.2.1.4.3). 
 
 
2.2.1.4.3 Transformation of competent cells 
For transformation of competent cells with the In-Fusion reaction mixture, 50 µl of E. coli 
DH5α competent cells (Invitrogen) was thawed on ice and 2.5 µl of the reaction mixture 
was added. The mixture was incubated for 30 min on ice and after a heat shock for 45 s  
at 42°C placed for 2 min on ice. Afterwards, 450 µl of S.O.C. medium (Invitrogen) was 
added and the bacteria were incubated for 1 h at 37°C by slight shaking. 50 µl and 100 µl 
of the transformed bacteria were separately spread on LB agar plates containing an 
antibiotic appropriate for the cloning vector and incubated at 37°C overnight. 
For transformation of competent cells with DpnI-treated mutagenesis reaction mixture, 
100 µl of E. coli DH5α competent cells was thawed on ice and 5 µl of the reaction mixture 
was added. After incubating the mixture for 30 min on ice, a heat shock was performed for 
45 s at 42°C. The mixture was further placed for 2 min on ice and 700 µl of S.O.C. 
medium was added. By slight shaking, the bacteria were incubated for 1 h at 37°C. On  
LB agar plates containing an antibiotic appropriate for the cloning vector, 250 µl and  
550 µl of the transformed bacteria were spread separately. The agar plates were 
incubated at 37°C overnight. 
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2.2.1.4.4 Mutagenesis 
The QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) was used to 
create specific, targeted changes in double stranded plasmid DNA. PCR reaction using 
PfuUltra High-Fidelity DNA Polymerase and specific primers were performed (chapter 
2.2.1.2.1.4). The amplification products were digested by addition of 1 µl DpnI restriction 
enzyme (10 U/µl) directly to each amplification reaction, following incubation for 1 h at 
37°C and transformation into E. coli DH5α competent cells (chapter 2.2.1.4.3). The next 
day, minipreparation of plasmid DNA (chapter 2.2.1.1.2) was performed followed by test 
restriction digestion of the isolated plasmid DNA (chapter 2.2.1.4.1) using appropriate 
restriction enzymes to identify positive clones. Plasmid DNA was purified with MSB Spin 
PCRapace Kit and the correct nucleotide sequences of the generated plasmids were 
validated by sequencing analysis (chapter 2.2.1.2.4). 
 
 
2.2.1.5 Yeast two-hybrid assay 
The yeast two-hybrid assay represents an in vivo method to identify novel protein 
interactions, confirm putative direct interactions and define interacting domains using 
yeast cells. The Matchmaker® Gold Yeast two-Hybrid System (Clontech) and the yeast 
strain Y2HGold (Clontech) were used. 
50 ml of YPDA medium was inoculated with 3–4 yeast colonies from an YPDA agar plate 
and incubated (16–18 h) at 30°C by shaking at 220 rpm overnight. 4–8 ml of the overnight 
culture (OD600 > 1.5) was transferred into 300 ml of YPDA medium (OD600 ~0.3) and 
incubated for 3–4 h at 30°C by shaking at 220 rpm until an OD600 between 0.4–0.6 was 
reached. The yeast cell suspension was portioned into 50 ml falcons and centrifuged at 
1000 x g for 5 min at RT. Meanwhile, YeastmakerTM Carrier DNA (10 mg/ml) (Clontech) 
was denatured for 10 min at 95°C and placed for 5 min on ice. Each yeast cell pellet was 
resuspended in 30 ml Ampuwa and centrifuged at 1000 x g for 5 min at RT. Thereafter, 
each yeast cell pellet was resuspended in 1.5 ml of freshly prepared TE/LiAc solution.  
10 µl of denatured Carrier DNA was added to 1 µg of each plasmid and mixed by 
pipetting. After addition of 100 µl yeast cell solution and mixing, 600 µl of freshly prepared 
PEG/LiAc solution was added and mixed. The reaction mixture was incubated for 30 min 
at 30°C by shaking at 500 rpm. Afterwards, 70 µl of DMSO solution was added and mixed 
by inverting. Next, heat shock for 15 min at 42°C was performed, followed by incubation 
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for 2 min on ice and centrifugation at 16,000 x g for 1 min. Each yeast cell pellet was 
resuspended in 300 µl of Ampuwa and plated as drops of 10 µl each on −LT and −LTHA 
agar plates, respectively. The agar plates were incubated for 5–7 d at 30°C. 
 
 
2.2.2 Protein manipulation methods 
2.2.2.1 Protein isolation from eukaryotic cells 
For protein isolation, eukaryotic cells were harvested from cell culture vessel using an 
appropriate protocol (chapter 2.2.4.2). Nuclear and cytoplasmic protein extracts were 
isolated using the NE-PER® Nuclear and Cytoplasmic Extraction Reagents Kit (Thermo 
Scientific) according to manufacturer‟s instructions. 
 
 
2.2.2.2 Protein isolation from yeast cells 
For protein isolation from yeast cells, 8 ml of SD medium with addition of adenine and 
histidine (chapter 2.1.10.1) was inoculated with a single yeast colony from a −LT agar 
plate and incubated (16–18 h) at 30°C by shaking at 250 rpm overnight. The overnight 
culture (OD600 ~1.0) was centrifuged at 1000 x g for 5 min at RT. The yeast cell pellet was 
resuspended in 500 µl of 2 M chilled LiAc and incubated for 5 min on ice. After 
centrifugation at 1000 x g for 5 min at RT, the cell pellet was resuspended in 100 µl of  
0.4 M chilled NaOH, incubated for 5 min on ice and centrifuged at 1000 x g for 5 min. The 
cell pellet was resuspended in 100 µl of sample buffer containing 25 µl of NuPAGE® LDS 
Sample Buffer (4x) (Invitrogen), 10 µl of 1 M DTT and 65 µl of Ampuwa. After yeast 
proteins were denatured for 10 min at 70°C, the mixture was placed for 5 min on ice and 
was further centrifuged at 16,000 x g for 1 min to pellet cell debris. The protein containing 
supernatant was transferred into a new reaction tube and 28 µl of the supernatant was 
used for SDS-PAGE (chapter 2.2.2.6). 
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2.2.2.3 Protein concentration from cell culture medium 
Proteins from cell culture medium were concentrated using the Vivaspin® Turbo 15 
centrifugal concentrators (30 kDa MWCO) (Sartorius) according to manufacturer‟s 
instructions. 
 
 
2.2.2.4 Determination of protein concentration 
Protein concentration was determined according to the method of Bradford (1976). The 
used solution Roti®-Nanoquant (5x) (Carl Roth) consists of the Coomassie Brilliant Blue 
dye that has the property to bind unspecifically to proteins in acidic solution, resulting in a 
shift of its absorption maximum from 465 nm to 595 nm. 
A Bovine Serum Albumin Standard Ampule (Thermo Scientific) was diluted to generate 
standard protein concentrations for a calibration curve to determine the protein 
concentration by extrapolating to this curve. 
To determine protein concentration 5x Roti-Nanoquant was diluted with ddH2O to a final 
1x concentration and further stored at 4°C up to 3 month. Protein sample was diluted 
1:100 with Ampuwa and 50 µl of the sample was pipetted into a 96-well plate in triplicate. 
Ampuwa was used as control. Each diluted protein sample was mixed with 200 µl of  
1x Roti-Nanoquant and incubated for 5 min at RT. The absorptions were measured using 
the SynergyTM Mx plate reader (BioTek) and calculated with the provided Gen5TM software. 
 
 
2.2.2.5 Co-immunoprecipitation 
Co-immunoprecipitation (Co-IP) is a technique to identify protein-protein interactions by 
using a target protein antibody for the indirect capture of proteins that are bound to the 
target protein. These protein complexes can be further analyzed for example by western 
blot analysis to identify unknown complex members. 
To pre-clear isolated protein extract of proteins which can bind unspecifically to the beads, 
500–1000 µg of protein extract and 20 µl of Protein G Magnetic Beads (New England 
Biolabs) were gently mixed, filled up with lysis buffer (chapter 2.1.6) to a total volume of 
500 µl and rotated on the Stuart® SB2 rotator (Bibby Scientific) for 1 h at 4°C. Afterwards, 
a magnetic field was applied for 1 min by placing the reaction tube into a 6-Tube Magnetic 
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Separation Rack (New England Biolabs) to pull the beads to the side of the tube. The 
supernatant was pipetted into a new reaction tube, 2 µg of appropriate antibody (chapter 
2.1.11.1) was added and the mixture was incubated on the rotator at 4°C overnight.  
No antibody was added to the negative control. The following day, 20 µl of Protein G 
Magnetic Beads was added and the mixture was incubated on the rotator for 2 h at 4°C. 
After brief centrifugation, a magnetic field was applied for 1 min and the supernatant was 
removed. The beads were washed with 500 µl of lysis buffer and incubated on the rotator 
for 5 min at 4°C. The mixture was briefly centrifuged and the washing step was 
additionally repeated 4 times as previously described. For the final washing step, 500 µl of 
TBS buffer was used. Thereafter, a magnetic field was applied for 1 min, the supernatant 
was removed and the bead pellet was gently mixed with 16.3 µl of lysis buffer, 6.25 µl of 
LDS Sample Buffer (4x) and 2.5 µl of 1 M DTT. Proteins were denatured for 10 min  
at 70°C and separated from the beads meanwhile. The mixture was placed for 5 min on 
ice and after applying a magnetic field for 1 min, the supernatant was completely used for 
SDS-PAGE (chapter 2.2.2.6). 
 
 
2.2.2.6 SDS polyacrylamide gel electrophoresis 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) was used for the separation of 
proteins according to their molecular weight based on the method described by (Laemmli, 
1970). The method bases on the use of gels and buffers with an operating pH of 7.0. This 
neutral pH increases the stability of both proteins and gels and leads to a better result of 
electrophoresis. 
In general, samples consisted of 30 µg protein, 0.25 volume LDS Sample Buffer (4x) and 
10% 1 M DTT (reducing agent), filled up with Ampuwa to a total volume of 20–28 µl, 
depending on the maximum sample loading volume of the gel. Proteins were denatured 
for 10 min at 70°C and placed on ice for 5 min. After brief centrifugation, protein samples 
were loaded onto a gradient gel (NuPAGE® 3–8% Tris-Acetate Gel or NuPAGE® 4–12% 
Bis-Tris Gel, Invitrogen) placed in Novex® Mini-Cell Electrophoresis System (Invitrogen). 
Pre-stained molecular weight standard (10 µl of SeeBlue® Plus2 Pre-Stained Protein 
Standard or 20 µl of HiMarkTM Pre-Stained High Molecular Weight Protein Standard, 
Invitrogen) was additionally loaded on the gel for determination the size of the separated 
proteins. Gel electrophoresis was performed for 10 min at 80 V and further at either 120 V 
(10-well gel) or 160 V (20-well gel) and depending on the composition of the gel, in  
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1x NuPAGE® Tris-Acetate SDS Running Buffer or 1x NuPAGE® MES SDS Running Buffer 
(Invitrogen). 
 
 
2.2.2.7 Transfer of proteins from a polyacrylamide gel to a membrane 
For detection of proteins by western blot analysis, separated proteins from a 
polyacrylamide gel were transferred to a membrane based on the method described by 
(Gershoni and Palade, 1983). Proteins <150 kDa were transferred on a nitrocellulose 
membrane (AmershamTM ProtranTM Supported 0.45 µm NC, GE Healthcare), whereas 
proteins >150 kDa were transferred on a PVDF membrane (AmershamTM HybondTM-P 
PVDF Transfer Membrane 0.45 µm, GE Healthcare). 
One membrane and four Blotting Paper Sheets (Sartorius) were cut to the size of the 
gradient gel. The nitrocellulose membrane was activated in ddH2O and further equilibrated 
in chilled transfer buffer I (chapter 2.1.6), while the PVDF membrane was activated in 
100% methanol for approximately 30 s and then equilibrated in chilled transfer buffer II 
(chapter 2.1.6) for 5 min. Blotting papers and foam pads were soaked in appropriate 
transfer buffer. For transfer, the tank blotting system Mini Protean® II Cell (Bio-Rad) was 
used and the components were placed in a provided cassette on top of each other as 
follows: two sheets of blotting paper, membrane, polyacrylamide gel and two sheets of 
blotting paper. Potential air bubbles were carefully removed. The cassette was inserted 
into the tank in the way that the gel was located near to the cathode of the blotting system. 
The tank further contained appropriate and chilled transfer buffer and a cooling unit. The 
transfer of proteins <150 kDa was performed at 250 mA per gel for 1 h at 4°C. The 
transfer of proteins >150 kDa was performed at 25 V overnight. Additionally, the buffer 
tank was put in an ice box and the buffer was agitated by a magnetic stirrer to avoid the 
formation of an ion gradient and to insure homogeneity of the buffer temperature. 
 
 
2.2.2.8 Protein detection on membranes using antibodies 
After protein transfer to a membrane, unspecific binding sites were blocked by incubating 
the membrane, depending on the used antibody, with blocking solution I or II (chapter 
2.1.6) for at least 1 h at RT. Primary antibody (chapter 2.1.11.1) was diluted, depending 
on the antibody, in antibody diluent solution I or II (chapter 2.1.6) at 4°C overnight. The 
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following day, the membrane was washed with TBST buffer three times for 10 min to 
remove unbound antibody. The membrane was further incubated with appropriate 
secondary antibody (chapter 2.1.11.2) diluted, depending on the antibody, in antibody 
diluent solution I or II for 1.5–2 h at RT. To remove unbound antibody, the membrane was 
washed three times for 10 min with TBST buffer. The ImmobilonTM Western 
Chemiluminescent HRP Substrate (Merck Millipore) was used to visualize membrane 
bound proteins and was prepared according to manufacturer‟s instructions. The 
membrane was covered with the prepared solution, placed between a plastic wrap and 
incubated for 5 min at RT. The chemiluminescent signals were digitally detected using 
FluorChem® Q (Alpha Innotech) and evaluated with the provided AlphaView® Q software 
(Alpha Innotech). 
 
 
2.2.3 Histological methods 
2.2.3.1 Dissection of mouse tissues and embryos 
For dissection of mouse tissues, the mouse was killed by CO2-asphyxation and the 
required tissues were dissected. For RNA isolation (chapter 2.2.1.1.5) the tissues were 
immediately frozen in liquid nitrogen and further stored at −80°C. 
For dissection of mouse embryos, one-to-one matings of wildtype Whirligig (Chd7+/+) 
female and wildtype Whirligig (Chd7+/+) male mice were set up. Female Whirligig mice 
were daily checked for a vaginal plug, to determine the age of the embryos. When a 
vaginal plug was observed, the day was counted as embryonic stage 0.5 (E0.5). At the 
desired embryonic stage, the pregnant Whirligig mouse was killed by cervical dislocation 
and the uterus was removed. The embryos were dissected out of the yolk sacs, a tail 
biopsy was performed for gDNA isolation (chapter 2.2.1.1.1), further genotyping PCR 
(chapter 2.2.1.2.1.3) and sequencing analysis (chapter 2.2.1.2.4) to confirm the genotype. 
The embryos were immediately frozen in liquid nitrogen and further stored at −80°C for 
RNA isolation (chapter 2.2.1.1.5). 
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2.2.3.2 Fixation of cells on slides 
For histological analysis, O9-1 cells were grown on culture slides (BD Biosciences) 
providing eight chambers. Before plating the cells, slides were coated with matrigel 
(chapter 2.2.4.1.2). 
Before further histological analysis, cells were washed two to three times with DPBS and 
fixed with 4% PFA for 10 min at RT. 
 
 
2.2.3.3 Immunofluorescence staining 
Before immunofluorescence staining, O9-1 cells were fixed (chapter 2.2.3.2) and further 
washed two to three times with ice cold DPBS. Cells were permeabilized with 0.1% Triton 
X-100 solution for 10 min. After washing the cells with DBPS three times for 5 min, 
unspecific binding sites were blocked by incubation with blocking solution (chapter 2.1.6) 
for at least 1 h at RT. Cells were incubated with the appropriate primary antibody (chapter 
2.1.11.1) diluted in antibody diluent solution (chapter 2.1.6) in a humidified chamber at 
4°C overnight. The following day, cells were washed with DPBS three times for 10 min 
and incubated with the appropriate secondary antibody (chapter 2.1.11.2) diluted in 
antibody diluent solution (chapter 2.1.6) in a humidified chamber for 1.5–2 h at RT. 
Afterwards, cells were washed with DPBS three times for 10 min and shortly air-dried. 
Cells were mounted with FluoroshieldTM with Dapi (Sigma-Aldrich), sealed with nail polish 
and stored in the dark at 4°C. Immunofluorescence staining was analyzed with the 
confocal laser scanning microscope IX81 (Olympus) using the provided FV10-ASW1.7 
software. 
 
 
2.2.4 Cell culture methods 
2.2.4.1 Coating of cell culture vessels 
2.2.4.1.1 Preparation of fibronectin coated cell culture vessels 
Human fibronectin (Merck Millipore) was used for the preparation of fibronectin coated cell 
culture vessels. The fibronectin was diluted in chilled DPBS to a concentration of  
50 µg/ml. One cell culture plate (ø 10 cm) was coated with 5 ml fibronectin solution and 
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left on the culture vessel for at least 10 min. Then, the solution was aspirated and could 
be reused several times when stored at 4°C. The culture vessel was left open until it got 
dry (approximately 10 min) and afterwards the cells were plated on the coated culture 
vessel. 
 
 
2.2.4.1.2 Preparation of matrigel coated cell culture vessels 
For the preparation of matrigel coated cell culture vessels the Matrigel® Basement 
Membrane Matrix (Corning) was used. During the work with matrigel, chilled pipette tips 
and DPBS were used. After thawing on ice at 4°C, aliquots of 100 µl were prepared on ice 
and further stored at −20°C. Before use, required quantity of aliquots was thawed on ice 
at 4°C either at least for 1 h or overnight. One aliquot was diluted 1:50 in DPBS, 
respectively. To coat one cell culture plate (ø 10 cm), 5 ml of matrigel solution was used 
and left on the culture vessel for at least 1 h at RT before use. In advance coated culture 
vessels were stored up to 5–6 d at 4°C. The matrigel solution was carefully aspirated just 
before plating the cells. 
 
 
2.2.4.2 Culture of eukaryotic cells 
2.2.4.2.1 Culture and passaging of murine JoMa1 and JoMa1.3 cells 
Murine JoMa1 and JoMa1.3 cells (chapter 2.1.9) were cultured for 3–4 d on fibronectin 
coated cell culture vessels (chapter 2.2.4.1.1) until they reached a confluence of 
approximately 80%. The NCC medium (chapter 2.1.9.1) was carefully aspirated and the 
cells were washed with DPBS. The DPBS was removed from the cells and 1–4 ml of 
Trypsin-EDTA (PAN-Biotech), depending on the size of the culture vessel, was applied. 
After incubation for 3–5 min at 37°C and 5% CO2 in a humidified incubator, the 
detachment of the cells from the culture vessel was controlled under the light microscope. 
To inactivate the Trypsin-EDTA treatment, an equal volume of Trypsin Inhibitor (Sigma-
Aldrich) was added and the cell suspension was centrifuged at 150 x g for 5 min. The 
supernatant was discarded and the cell pellet was resuspended in NCC medium. The 
cells were generally split 1:10 and plated on fibronectin coated culture vessels in an 
appropriate volume of NCC medium. The cells were cultivated at 37°C in a 5% CO2 
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humidified incubator. The medium was daily replaced with freshly added 4-OHT to remove 
not adherent cells and in order to keep the cells in their proliferating and undifferentiated 
state. 
 
 
2.2.4.2.2 Culture and passaging of murine O9-1 cells 
Until the murine O9-1 cells (chapter 2.1.9) reached a confluence of approximately 80% 
they were cultured for 3–4 d on matrigel coated cell culture vessels (chapter 2.2.4.1.2). 
After the aspiration of the ESC medium (chapter 2.1.9.1), the cells were washed with 
DPBS that was removed afterwards. Depending on the size of the culture vessel, the cells 
were treated with 1–4 ml Trypsin-EDTA (PAN-Biotech) and incubated in a 37°C and  
5% CO2 humidified incubator for 3–5 min. Under the light microscope the detachment of 
the cells was controlled. By addition of an equal volume of ESC medium, the Trypsin-
EDTA treatment was stopped and the cell suspension was centrifuged at 300 x g for  
3 min. After discarding the supernatant, the cell pellet was resuspended in ESC medium 
and the cells were typically split 1:100. The cells were plated in ESC medium on matrigel 
coated cell culture vessels and cultivated at 37°C in a 5% CO2 humidified incubator. The 
next day, the medium was replaced to remove not adherent cells and changed every  
2–3 d thereafter. 
 
 
2.2.4.2.3 Culture and passaging of human HEK293 cells 
The human HEK293 cells (chapter 2.1.9) were cultured for 3–4 d in cell culture flasks until 
they reached a confluence of approximately 80%. The FB medium (chapter 2.1.9.1) was 
aspirated and the cells were washed with DPBS. After aspiration of the DPBS, the cells 
were detached from the culture vessel using 1–4 ml TrypLETM Express (Gibco), depending 
on the size of the culture vessel. The detachment of the cells was controlled under the 
light microscope after incubation in a 37°C and 5% CO2 humidified incubator. To 
inactivate the TrypLETM Express treatment, an equal volume of FB medium was added. 
The cell suspension was centrifuged at 190 x g for 5 min. The supernatant was discarded 
and the cell pellet resuspended in FB medium. A typically split ratio was 1:4 to 1:6. The 
cells were plated in culture flasks and cultivated at 37°C in a 5% CO2 humidified incubator. 
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To remove not adherent cells, the medium was changed the next day and then replaced 
every 2–3 d. 
 
 
2.2.4.2.4 Cryopreservation and thawing of eukaryotic cells 
Cells were cryopreserved from confluent cell culture vessels. JoMa1 or JoMa1.3 cell pellet 
was resuspended in 1 ml chilled ready-to-use Cryo-SFM (PromoCell) medium. O9-1 cell 
pellet was resuspended in 1 ml NCC medium with 10% DMSO (chapter 2.1.9.2), whereas 
HEK293 cell pellet was resuspended in 500 µl of FB medium (chapter 2.1.9.1) and 
subsequently mixed with 500 µl of FB freezing medium (chapter 2.1.9.2). The appropriate 
mixture was transferred into well labeled cryovials, which were immediately placed in a 
Mr. FrostyTM Freezing Container (Kisker) and then frozen at −80°C. For long term storage 
the cryovials were placed in liquid nitrogen. 
For the procedure of thawing the cryovial was incubated in a 37°C water bath until the 
cells were almost completely thawed. The cells were carefully mixed with a larger volume 
of appropriate culture medium (chapter 2.1.9.1) and then centrifuged using appropriate 
conditions. After removal of the supernatant, the cells were resuspended in culture 
medium, seeded on appropriate cell culture vessel and cultivated at 37°C in a 5% CO2 
humidified incubator. The next day, not adherent cells were removed by changing the 
culture medium. The further cell culture procedure was performed according to the 
appropriate cell line as described above. 
 
 
2.2.4.3 Transfection of eukaryotic cells 
2.2.4.3.1 Transfection of plasmids into eukaryotic cells 
Eukaryotic cells were transfected with plasmids in order to induce a protein 
overexpression. Lipofectamine® 2000 Transfection Reagent (Invitrogen) was used as 
transfection reagent. This transfection reagent contains lipids which form vesicles with a 
bilayer sheet, so called liposomes, in aqueous solution. Liposomes and nucleic acids can 
form nucleic acid lipid complexes which eukaryotic cells can actively take up by 
endocytosis. The nucleic acids are able to enter the nucleus when the nuclear membrane 
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dissolves during mitosis. For efficient transfection, the division rate of the cells must be 
high as possible. 
One day before transfection, cells were plated on cell culture plates or in cell culture 
flasks. In general, 1.2 x 106 O9-1 cells/ml were plated on culture plates (ø 10 cm) and  
5.0 x 106 HEK293 cells/ml were plated in culture flasks (75 cm2). The following day, 30 µg 
of plasmid DNA was gently mixed with Opti-MEM® I Reduced Serum Medium (Gibco)  
in a total volume of 1875 µl and incubated for 5 min at RT. Furthermore, 75 µl of 
Lipofectamine 2000 was also gently mixed with 1800 µl of Opti-MEM and incubated for  
5 min at RT. Afterwards, the plasmid DNA and the Lipofectamine 2000 mixture were 
combined, gently mixed and incubated for 25 min at RT. Before the transfection mixture 
was added to the cells, the culture medium was aspirated and the cells were washed with 
DPBS. 9 ml of ESC medium (chapter 2.1.9.1) was used as culture medium for O9-1 cells. 
As culture medium for HEK293 cells, 9 ml of DMEM (PAN-Biotech) with 1x NEAA (Gibco) 
was used. The transfection mixture was applied dropwise to the cells, gently mixed with 
the culture medium and incubated for 24 h at 37°C in a 5% CO2 humidified incubator. 
After 4–5 h, 9 ml of culture medium composed of DMEM with 20% FBS (PAN-Biotech) 
and 1x NEAA was added to the transfection reagent containing culture medium of 
HEK293 cells. After incubation time, protein was isolated from the transfected cells. 
 
 
2.2.4.3.2 Transfection of short interfering RNAs 
Short interfering RNAs (siRNAs) are used for silencing of a specific gene. Thereby, siRNA 
binds to a specific mRNA and marks it for degradation. This results in a reduced 
expression of the specific gene. Three different mouse siRNAs against Chd7 (s232009, 
s232010, s232011, Silencer® Select Pre-Designed & Validated siRNA, ambion®, Life 
Technologies, Darmstadt) were used. A siRNA with a sequence that do not target any 
gene product was used as control siRNA (Silencer® Select Negative Control No. 1 siRNA, 
ambion®, Life Technologies, Darmstadt). Lipofectamine 2000 was used as transfection 
reagent. Thereby, complexes of lipids and siRNA oligonucleotides can be formed which 
facilitate the uptake of the siRNA molecules into the cells. 
One day before transfection, murine O9-1 cells were plated on matrigel coated 6-well cell 
culture plates. Per well 0.15 x 106 cells were plated in 2.5 ml of ESC medium (chapter 
2.1.9.1). The following day, 6 µl of siRNA (stock concentration: 10 µM) was gently mixed 
with 294 µl of Opti-MEM and incubated for 5 min at RT. Furthermore, 12 µl of 
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Lipofectamine 2000 was also gently mixed with 288 µl of Opti-MEM and incubated for  
5 min at RT. Afterwards, the siRNA and the Lipofectamine 2000 mixture were combined, 
gently mixed and incubated for 25 min at RT. In the meantime, the cells were washed with 
DPBS and 2.0 ml of ESC medium was added to each well. 500 µl of the transfection 
mixture was applied dropwise to the cells and gently mixed with the culture medium. Each 
well contained a final siRNA concentration of 20 nM. The cells were incubated for 48 h  
at 37°C in a 5% CO2 humidified incubator. After incubation time, RNA was isolated from 
the transfected cells. 
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3 Results 
3.1 Characterization of murine NCC lines 
To choose a suitable cell line for in vitro analyses of NCCs, which are the affected cell 
type leading to the phenotype seen in CHARGE syndrome patients, the expression 
pattern of different molecular markers in the two murine cell lines JoMa and O9-1  
were examined. For testing the NCC behavior of the different cell lines, the NCC marker 
genes Sox10 (SRY (sex determining region Y)-box 10), Ngfr (nerve growth factor  
receptor (TNFR superfamily, member 16)), Snai2 (snail family zinc finger 2), Pax3  
(paired box 3), Snai1 (snail family zinc finger 1) and Twist1 (twist basic helix-loop-helix 
transcription factor 1) were used. Furthermore, the expression of the neuronal marker 
Nefh (neurofilament, heavy polypeptide), the glia marker Gfap (glial fibrillary acidic 
protein) and the two smooth muscle markers Cnn1 (calponin 1) and Actg2 (actin,  
gamma 2, smooth muscle enteric) were investigated. The expression of the melanocyte 
marker Tyr (tyrosinase) and the chondrocyte marker Col2a1 (collagen, type II, alpha 1) 
was also analyzed. 
 
 
3.1.1 Molecular marker expression in murine JoMa cells 
The murine cell line JoMa1 and the clonally derived subline JoMa1.3 were established 
and described as immortalized neural crest stem cell lines by Maurer et al. (2007). 
To monitor the initial situation both JoMa cell lines were tested for the expression pattern 
of different molecular marker genes by RT-PCR analysis on cDNA obtained from total 
RNA of JoMa1 and JoMa1.3 cells (Figure 4 A–C). Whole mouse embryo (E10.5) cDNA 
was used as positive control for Sox10, Ngfr, Snai2, Pax3, Snai1, Twist1, Tyr and Col2a1. 
Mouse brain cDNA was used as positive control for Nefh and Gfap, whereas mouse 
uterus cDNA was used as positive control for Cnn1 and Actg2. H2O was used as negative 
control, respectively. All analyzed NCC markers were expressed in both JoMa cell lines in 
exception of Sox10. The neuronal marker Nefh could be detected with a weak signal only 
in JoMa1 cells, whereas the analyzed glia marker Gfap and the smooth muscle marker 
Cnn1 were not detected in JoMa cells. The second tested smooth muscle marker gene 
Actg2 were weakly expressed in both JoMa cell lines. Tyr, the melanocyte marker, was 
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detected with a weak signal only in the JoMa1 cells. An expression of the chondrocyte 
marker Col2a1 was observed in JoMa1 cells as well as in JoMa1.3 cells. Earlier and later 
cell passages were investigated in the same way with similar results (data not shown). 
The data obtained by the RT-PCR analysis demonstrate based on the tested marker 
genes that JoMa1 and JoMa1.3 cells are undifferentiated NCCs. 
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Figure 4: Expression analysis of NCC, neuronal, glia, smooth muscle, melanocyte and 
chondrocyte marker genes in JoMa1 cells and JoMa1.3 cells. RT-PCR analysis performed on 
cDNA obtained from total RNA of JoMa1 cells and JoMa1.3 cells. The results proved the 
expression of the NCC markers Ngfr, Snai2, Pax3, Snai1 and Twist1, the neuronal marker Nefh, 
the smooth muscle marker Actg2, the melanocyte marker Tyr and the chondrocyte marker Col2a1.  
(A) Expression analysis of the NCC markers Sox10 (444 bp), Ngfr (310 bp), Snai2 (407 bp) and 
Pax3 (374 bp). (B) Expression analysis of the NCC markers Snai1 (420 bp) and Twist1 (331 bp), 
the neuronal marker Nefh (301 bp) and the glia marker Gfap (454 bp). (C) Expression analysis  
of the smooth muscle markers Cnn1 (340 bp) and Actg2 (458 bp), the melanocyte marker  
Tyr (216 bp) and the chondrocyte marker Col2a1 (321 bp). M: 100 bp DNA Ladder; PC 1: positive 
control 1 with whole mouse embryo (E10.5) cDNA, PC 2: positive control 2 with mouse brain 
cDNA, PC 3: positive control 3 with mouse uterus cDNA; NC: negative control with H2O. 
 
 
3.1.2 Molecular marker expression in murine O9-1 cells 
The murine cell line O9-1 was established by Ishii et al. (2012). A whole-genome 
expression profiling of O9-1 cells revealed that this cell line has characteristics of both 
neural crest and stem cells (Ishii et al., 2012). 
The O9-1 cell line was characterized by RT-PCR analysis on cDNA obtained from total 
RNA of O9-1 cells using the same marker genes like with the JoMa1 cells and JoMa1.3 
cells to monitor the initial situation also of this cell line (Figure 5 A–C). Whole mouse 
embryo (E10.5) cDNA was used as positive control for Sox10, Ngfr, Snai2, Pax3, Snai1, 
Twist1, Tyr and Col2a1. Mouse brain cDNA was used as positive control for Nefh and 
Gfap, whereas mouse uterus cDNA was used as positive control for Cnn1 and Actg2.  
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H2O was used as negative control, respectively. O9-1 cells express the tested NCC 
markers although the expression of Pax3 was weak. As in both JoMa cell lines no 
expression of Sox10 could be detected. Furthermore, there were no expression of the 
neuronal marker Nefh, the glia marker Gfap and the melanocyte marker Tyr observed. 
The smooth muscle marker Cnn1 was weak expressed, whereas the other tested smooth 
muscle marker Actg2 and the chondrocyte marker Col2a1 were strongly expressed. 
Earlier and later cell passages were investigated in the same way with similar results 
(data not shown). 
The data obtained by the RT-PCR analysis demonstrate based on the tested marker 
genes that O9-1 cells are, like the JoMa cells, undifferentiated NCCs. 
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Figure 5: Expression analysis of NCC, neuronal, glia, smooth muscle, melanocyte and 
chondrocyte marker genes in O9-1 cells. RT-PCR analysis performed on cDNA obtained from 
total RNA of O9-1 cells. The results revealed the expression of the NCC markers Ngfr, Snai2, 
Pax3, Snai1 and Twist1, the smooth muscle markers Cnn and Actg2 as well as the chondrocyte 
marker Col2a1. (A) Expression analysis of the NCC markers Sox10 (444 bp), Ngfr (310 bp),  
Snai2 (407 bp) and Pax3 (374 bp). (B) Expression analysis of the NCC markers Snai1 (420 bp) 
and Twist1 (331 bp), the neuronal marker Nefh (301 bp) and the glia marker Gfap (454 bp).  
(C) Expression analysis of the smooth muscle markers Cnn1 (340 bp) and Actg2 (458 bp), the 
melanocyte marker Tyr (216 bp) and the chondrocyte marker Col2a1 (321 bp). M: 100 bp DNA 
Ladder; PC 1: positive control 1 with whole mouse embryo (E10.5) cDNA, PC 2: positive control 2 
with mouse brain cDNA, PC 3: positive control 3 with mouse uterus cDNA; NC: negative control 
with H2O. 
 
 
3.1.3 Chd7 expression in murine JoMa cells and O9-1 cells 
To determine whether JoMa cells and O9-1 cells also express Chd7, the gene mutated in 
most patients with CHARGE syndrome, RT-PCR analysis on cDNA obtained from total 
RNA of JoMa cells and O9-1 cells was performed. H2O was used as negative control, 
respectively. As illustrated in Figure 6 A and B, JoMa1 and JoMa1.3 cells as well as  
O9-1 cells showed expression of Chd7. 
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Figure 6: RT-PCR analysis of Chd7 expression in JoMa cells and O9-1 cells. The RT-PCR 
analysis performed on cDNA obtained from total RNA of (A) JoMa1 and JoMa1.3 cells as well as  
(B) O9-1 cells proved the expression of Chd7 (238 bp) in both murine NCC lines. M: 100 bp DNA 
Ladder; NC: negative control with H2O. 
 
The Chd7 expression was also investigated on protein level. Therefore, western blot 
analysis with an anti-Chd7 antibody was performed to detect Chd7 using nuclear protein 
extracts of JoMa cells and O9-1 cells. 30 µg of protein was applied per lane. No clear 
band, but rather a smear could be detected in extracts of JoMa1 and JoMa1.3 cells  
(Figure 7 A). In contrast, a strong ~336 kDa protein band corresponding to the estimated 
size of Chd7 was received in O9-1 cell extract (Figure 7 B). 
 
 
 
Figure 7: Western blot analysis of Chd7 expression in JoMa cells and O9-1 cells. Western 
blot analysis using nuclear protein extracts of JoMa1 and JoMa1.3 cells as well as O9-1 cells with 
an anti-Chd7 antibody to detect Chd7. 30 µg of protein was used per lane. (A) A noticeable  
protein band was received in neither JoMa1 nor JoMa1.3 cell extracts. (B) In the protein extract of 
O9-1 cells, a protein band corresponding to the estimated size of Chd7 (~336 kDa) was detected. 
Molecular weights of proteins and marker bands are indicated in kilo Dalton (kDa). 
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The RT-PCR analysis results of the characterized NCC lines revealed that both JoMa cell 
lines in comparison with the O9-1 cell line differ not much between the tested marker 
genes and the expression of Chd7. However, the western blot analysis revealed a definite 
strong Chd7 expression on protein level in O9-1 cells compared to both JoMa cell lines. In 
addition, O9-1 cells derived from murine cranial NCCs (Ishii et al., 2012), whereas the 
JoMa cell lines derived from murine trunk NCCs (Maurer et al., 2007). Most of the 
symptoms seen in CHARGE syndrome patients can be explained by a defect of the 
induction and migration of cranial NCCs. This is consistent with the observed strong Chd7 
expression in the cranial NCC line O9-1. These facts led to the decision to choose the  
O9-1 cells as a suitable cell line for the investigation of NCCs in vitro. 
 
To confirm the data of the RT-PCR and the western blot analysis concerning the 
expression of Chd7 in the NCC line O9-1, immunocytochemical staining was performed. 
Representative images of O9-1 cells are shown in Figure 8. The cell nucleus was stained 
with DAPI, whereas the cytoskeleton was stained for α-Tubulin using an  
anti-α-Tubulin antibody. To detect the target protein Chd7, an anti-Chd7 antibody was 
used (Figure 8 C). With secondary antibodies conjugated with either Alexa488 (α-Tubulin) 
or Cy3 (Chd7), the localization of the proteins were visualized. Cells were incubated 
without first antibody as negative control. The overlay image revealed that Chd7 was 
localized specifically in the nucleus (Figure 8 D). 
In summary, the results obtained by western blot analysis and immunocytochemical 
staining indicate an intense expression of Chd7 in O9-1 cells. 
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Figure 8: Chd7 immunocytochemical staining of O9-1 cells. Representative images of  
O9-1 cells identified the nuclear localization of Chd7. Cell DNA in nucleus was stained with DAPI 
(blue, A and E) and cytoskeleton was stained with an anti-α-Tubulin antibody (green, B). 
Localization of Chd7 was analyzed by an anti-Chd7 antibody (red, C). Incubation without first 
antibody was used as negative control (F and G). Overlay images are shown in the last column  
(D and H). Alexa488 (B and F) and Cy3 (C and G) conjugated secondary antibodies were used for 
visualization. Representative scale bars are indicated in the overlay images. Scale bars: D: 20 µm; 
H: 10 µm. 
 
 
3.2 O9-1 cells express semaphorin receptors and class 3 
semaphorins 
NCCs are known to express semaphorin receptors namely plexins and neuropilins and 
they are guided by semaphorins during embryogenesis. In order to verify the expression 
of semaphorin receptors in the NCC line O9-1, RT-PCR analysis was performed on cDNA 
obtained from total RNA of O9-1 cells. H2O was used as negative control, respectively. 
The results proved the expression of Plxna1 (plexin A1), Nrp1 (neuropilin 1) and Nrp2 
(neuropilin 2) (Figure 9). 
 
 
Results  67 
 
Figure 9: Expression analysis of semaphorin receptors in O9-1 cells. The RT-PCR analysis 
performed on cDNA obtained from total RNA of O9-1 cells confirmed the expression of  
Plxna1 (170 bp), Nrp1 (195 bp) and Nrp2 (202 bp). M: 100 bp DNA Ladder; NC: negative control 
with H2O. 
 
So far, it is not known that NCCs express semaphorins itself. Nevertheless, RT-PCR 
analysis on cDNA obtained from total RNA of O9-1 cells revealed the expression of  
class 3 semaphorins (Sema3a, 3c, 3d and 3e) in NCCs for the first time (Figure 10), 
suggesting an additional function of these group of semaphorins. H2O was used as 
negative control, respectively. 
 
 
Figure 10: Expression analysis of class 3 semaphorins in O9-1 cells. RT-PCR analysis 
performed on cDNA obtained from total RNA of O9-1 cells revealed the expression of  
Sema3a (186 bp), Sema3c (207 bp), Sema3d (186 bp) and Sema3e (183 bp). M: 100 bp DNA 
Ladder; NC: negative control with H2O. 
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To confirm the data of the RT-PCR analysis concerning the expression of Sema3a in  
O9-1 cells, immunocytochemical staining was used. Representative images of O9-1 cells 
are shown in Figure 11. The cell nucleus was stained with DAPI. The cytoskeleton was 
stained for α-Tubulin with an anti-α-Tubulin antibody. The target protein Sema3a was 
detected using an anti-Sema3a antibody (Figure 11 C). With either Alexa488 (α-Tubulin) 
or Cy3 (Sema3a) conjugated secondary antibodies, the localization of the proteins were 
visualized. No staining was detected in negative controls using no primary antibody. The 
overlay image possessed that Sema3a was localized specifically in the nucleus as well as 
in the cytoplasm of O9-1 cells (Figure 11 D). 
 
 
Figure 11: Sema3a immunocytochemical staining of O9-1 cells. Representative images of  
O9-1 cells revealed cytoplasmic and nuclear localization of Sema3a. Cell DNA in nucleus was 
stained with DAPI (blue, A and E) and cytoskeleton was stained with an anti-α-Tubulin antibody 
(green, B). Localization of Sema3a was analyzed by an anti-Sema3a antibody (red, C). Red arrows 
indicate cytoplasm areas, with high accumulation of Sema3a. Incubation without first antibody was 
used as negative control (F and G). Overlay images are shown in the last column (D and H). 
Alexa488 (B and F) and Cy3 (C and G) conjugated secondary antibodies were used for 
visualization. Representative scale bars are indicated in the overlay images. Scale bars: D: 20 µm; 
H: 10 µm. 
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3.3 Sema3a is expressed, processed and secreted by  
O9-1 cells and exists in monomeric and dimeric 
isoforms 
Related class 3 semaphorins are described to exist in monomeric, dimeric and processed 
isoforms (Adams et al., 1997; Christensen et al., 2005). A schematic representation of the 
full-length Sema3a protein composition with the predicted processing sites and the 
potential isoforms, resulting from proteolytic processing, is illustrated in Figure 12. 
 
 
Figure 12: Schematic representation of full-length Sema3a protein. Positions of the signal 
sequence (red), the Sema (Semaphorin) domain (blue), the PSI (plexin-semaphorin-integrin) 
domain (yellow), the Ig (immunoglobulin)-like domain (green), the basic domain (purple) and the 
predicted processing sites 1, 2 and 3 (black arrowheads) are indicated. Sema3a sequences 
containing the processing sites are represented within the figure (top). Processing site after signal 
sequence (open arrowhead) is permanently used. Theoretical molecular weights of cleavage 
products are shown in kilo Dalton (kDa). Ab: binding region of the used anti-Sema3a antibody. 
Adapted from Adams et al. (1997) and Christensen et al. (2005). 
 
After Sema3a expression was identified in O9-1 cells by RT-PCR analysis (chapter 3.2, 
Figure 10), the expression of Sema3a was investigated on protein level using cytoplasmic 
and nuclear O9-1 protein extracts. Secreted Sema3a was analyzed using concentrated 
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cell culture medium of O9-1 cells. The cytoplasmic and nuclear protein extracts were 
separately isolated and the medium was concentrated after 24 h of usage. In order to 
check monomeric and dimeric Sema3a protein isoforms, the different proteins were 
treated with the reducing agent DTT (+DTT) or without reducing agent (−DTT). Medium 
and protein extracts were analyzed by western blot analysis using an anti-Sema3a 
antibody and 30 µg of protein per lane. 
The representative results are shown in Figure 13. The monomeric isoforms of ~87 kDa 
(p87), ~85 kDa (p85), ~82 kDa (p82) and ~61 kDa (p61) were observed in concentrated 
medium with reduction, whereas the dimeric isoforms of ~174 kDa (p87:p87) and  
~170 kDa (p85:p85) as well as the monomeric isoforms of ~82 kDa (p82) and ~61 kDa 
(p61) were detected in concentrated medium without reduction. In cytoplasmic extract with 
reducing agent, the dimeric isoform of ~170 kDa (p85:p85) and the monomeric isoform of 
~85 kDa (p85) were observed. The dimeric isoform p85:p85 possibly indicates an 
incomplete cleavage of the disulfide bond between the dimer although the reducing agent 
DTT was added. In cytoplasmic extract without reducing agent, the dimeric isoform of 
~170 kDa (p85:p85) was received. The monomeric isoform of ~85 kDa (p85) was 
observed in nuclear extract with reduction, whereas the dimeric isoform of ~170 kDa 
(p85:p85) was received without reduction. In nuclear extract, with and without addition of 
reducing agent, potentially unspecific protein bands due to unspecific binding of the used 
antibody were detected. To proof this assumption, O9-1 cells with a full-lengths Sema3a 
plasmid containing a HA-tag between the signal sequence and the semaphorin domain 
should be performed. By detection the tag using an anti-HA antibody, the same protein 
band pattern without the potentially unspecific bands should be received. 
Detection of α-Tubulin (~50 kDa protein band) served as loading control for the 
cytoplasmic extracts. However, the detection of α-Tubulin in the nuclear extracts revealed 
the additional existence of cytoplasmic proteins. This fact can be possibly explained by 
the used protein extraction method. The nuclear protein Baf47 (~47 kDa protein band) 
was solely received in the nuclear extracts. 
Collectively, the investigation of Sema3a in O9-1 cells on protein level revealed that the 
expressed full-length Sema3a protein undergoes proteolytic processing to shorter 
isoforms. Moreover, the existence of monomeric and dimeric isoforms as well as the 
secretion of Sema3a was demonstrated. The obtained results are summarized in Table 1 
and Figure 14. 
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Figure 13: Isoforms of Sema3a resulting from proteolytic processing and dimerization.  
Cell culture medium was concentrated (cM) after 24 h of usage. Cytoplasmic (C) and nuclear (N) 
protein extracts of O9-1 cells were separately isolated. 30 µg of protein treated with the reducing 
agent DTT (+DTT) or without reducing agent (−DTT) was used per lane. The Sema3a isoforms 
were analyzed by western blot analysis using an anti-Sema3a antibody. In concentrated medium 
with reducing agent the monomeric isoforms of ~87 kDa (p87), ~85 kDa (p85), ~82 kDa (p82) and 
~61 kDa (p61) were detected, whereas in concentrated medium without reducing agent the dimeric 
isoforms of ~174 kDa (p87:p87) and ~170 kDa (p85:p85) and the monomeric isoforms of ~82 kDa 
(p82) and ~61 kDa (p61) were observed. In cytoplasmic extract with reduction, the dimeric isoform 
of ~170 kDa (p85:p85) and the monomeric isoform of ~85 kDa (p85) were received. The dimeric 
isoform p85:p85 possibly indicates an incomplete cleavage of the disulfide bond between the two 
p85 monomeric isoforms despite DTT addition. Without reduction, solely the dimeric isoform of  
~170 kDa (p85:p85) was observed. In the nuclear extract with reducing agent, the monomeric 
isoform of ~85 kDa (p85) was received, whereas without reducing agent the dimeric isoform of 
~170 kDa (p85:p85) was observed. The detection of α-Tubulin (~50 kDa protein band) served as 
loading control for the cytoplasmic extracts, revealing the additional existence of cytoplasmic 
proteins also in the nuclear extracts which can be possible traced back to the used protein 
extraction method. The nuclear protein Baf47 (~47 kDa protein band) was exclusively detected in 
the nuclear extracts. Stars () illustrate potentially unspecific protein bands due to unspecific 
binding of the anti-Sema3a antibody. Molecular weights of proteins and marker bands are indicated 
in kilo Dalton (kDa). 
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Table 1: Sema3a isoforms detected in concentrated medium as well as cytoplasmic and 
nuclear protein extracts of O9-1 cells. Medium and protein extracts were treated with the 
reducing agent DTT (+DTT) and without reducing agent (−DTT) and analyzed by western blot 
analysis using an anti-Sema3a antibody. Approximate molecular weights of the isoforms are given 
in kilo Dalton (kDa). 
 
 
concentrated medium cytoplasmic extract nuclear extract 
+DTT −DTT +DTT −DTT +DTT −DTT 
 
87 kDa 
 
174 kDa 
 
170 kDa 
 
170 kDa 
 
85 kDa 
 
170 kDa 
85 kDa 170 kDa 85 kDa    
82 kDa 82 kDa     
61 kDa 61 kDa     
 
 
 
Figure 14: Schematic representation of proteolytic processed and dimerized Sema3a 
isoforms identified in concentrated medium as well as cytoplasmic and nuclear protein 
extracts of O9-1 cells. Isoforms resulting from combined proteolytic processing and dimerization 
of Sema3a full length protein are shown, which were detectable with the used anti-Sema3a 
antibody by western blot analysis. (A) Four monomeric isoforms were observed: ~87 kDa (p87), 
~85 kDa (p85), ~82 kDa (p82) and ~61 kDa (p61). (B) Two dimeric isoforms were detected: the 
dimeric isoform of ~174 kDa (p87:p87) consist of two ~87 kDa (p87) monomeric isoforms, whereas 
the dimeric isoform of ~170 kDa (p85:p85) consist of two ~85 kDa (p85) monomeric isoforms. 
Disulfide bonds between the dimeric isoforms are indicated with −S−S−. Approximate molecular 
weights of the isoforms are displayed in kilo Dalton (kDa) and in short version (p) (bottom). 
Adapted from Adams et al. (1997) and Christensen et al. (2005). 
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3.4 Downregulation of Chd7 has influence on the 
expression level of Sema3a in O9-1 cells 
In order to determine whether the downregulation of Chd7 has an influence on the 
expression level of Sema3a in NCCs, murine O9-1 cells, which have a high basal Chd7 
expression level (chapter 3.1.3), were transfected with one of three different short 
interfering RNAs (siRNA 1, 2, 3) against Chd7. Total RNA lysates were isolated from O9-1 
cells 48 h after siRNA transfection and reverse transcribed into cDNA. Afterwards, the 
efficiency of the siRNAs was tested by qRT-PCR analysis. All three Chd7-specific siRNAs 
proved to be effective as seen by a reduced Chd7 expression compared with control 
siRNA transfected cells (Figure 15). With siRNA 1 or siRNA 3 transfected O9-1 cells had a 
significantly reduced relative Chd7 expression between 65–70%. 
 
 
Figure 15: Analysis of the Chd7 expression in O9-1 cells after Chd7 downregulation.  
O9-1 cells were transfected with one of three different Chd7-specific siRNAs (siRNA 1, 2, 3).  
Total RNA lysates of transfected cells were isolated 48 h after siRNA transfection and reverse 
transcribed into cDNA which was subjected to qRT-PCR analysis. The transfection of Chd7-
specific siRNAs induced a reduction of the Chd7 expression compared with control siRNA 
transfected cells, demonstrating the effectiveness of the siRNAs. With siRNA 1 or siRNA 3 
transfected cells had a significantly decreased relative Chd7 expression between 65–70%.  
Data are presented as mean ± standard of qRT-PCR analysis performed in triplicate. *** p ≤ 0.001, 
n.s.: not significant (student‟s t test). 
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After demonstrating the effectiveness especially of the Chd7-specific siRNA 1 and  
siRNA 3, the influence on the Sema3a expression was investigated. Therefore, total RNA 
lysates of O9-1 cells transfected with siRNA 1 or siRNA 3 were isolated 48 h after 
transfection. Isolated RNA was reverse transcribed into cDNA and used for qRT-PCR 
analysis. With Chd7-specific siRNA 1 or siRNA 3 transfected cells had a significantly 
decreased relative Sema3a expression of the approximately 30% in comparison with 
control siRNA transfected cells (Figure 16). 
 
 
Figure 16: Analysis of the Sema3a expression in O9-1 cells after Chd7 downregulation.  
Total RNA lysates of O9-1 cells transfected with one of two different Chd7-specific siRNAs  
(siRNA 1, 3) were isolated 48 h after transfection. Into cDNA reverse transcribed RNA was 
subjected to qRT-PCR analysis to check the Sema3a expression after Chd7 downregulation. Both 
single transfected Chd7-specific siRNAs induced a significant reduction of the relative Sema3a 
expression of approximately 30% compared with control siRNA transfected cells. Data are 
presented as mean ± standard of qRT-PCR analysis performed in triplicate. * p ≤ 0.05, ** p ≤ 0.01 
(student‟s t test). 
 
 
3.5 Chd7 co-immunoprecipitates with Sema3a in O9-1 cells 
In order to analyze the existence of Chd7 and Sema3a in the same nuclear protein 
complex in NCCs, co-immunoprecipitation (Co-IP) experiments using protein extract of 
O9-1 cells were performed. Nuclear extract was incubated with an anti-Chd7 antibody to 
precipitate Chd7. By western blot analysis using an anti-Sema3a antibody, a ~85 kDa 
protein band corresponding to the estimated size of the monomeric p85-Sema3a isoform 
was detected (Figure 17 A). This band is probable more intense than in the input control 
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due to the high amount of applied protein in immunoprecipitation and a strong binding of 
the anti-Chd7 antibody. To verify the results in a reciprocal experiment, nuclear extract 
was incubated with an anti-Sema3a antibody to precipitate Sema3a. A ~336 kDa protein 
band corresponding to the estimated size of Chd7 was detected by western blot analysis 
using an anti-Chd7 antibody (Figure 17 B). Nuclear extract without antibody incubation 
served as negative control to prove that Sema3a (Figure 17 A) and Chd7 (Figure 17 B) 
are not capable to bind unspecific to the magnetic beads used for the Co-IP experiments. 
30 µg of nuclear protein per lane was used as input control to demonstrate that Sema3a 
(Figure 17 A) and Chd7 (Figure 17 B) are expressed in the nucleus of O9-1 cells. 
In conclusion, the data obtained by the Co-IP experiments demonstrate an interaction of 
Chd7 with Sema3a in O9-1 cells. 
 
 
Figure 17: Co-immunoprecipitation of Chd7 with Sema3a in O9-1 cells. The Co-IP 
experiments were performed with nuclear protein extract of O9-1 cells. (A) Chd7 was precipitated 
with an anti-Chd7 antibody. A ~85 kDa protein band corresponding to the estimated size of the 
monomeric p85-Sema3a isoform was detected by western blot analysis using an anti-Sema3a 
antibody. This band is probable more intense than in the input control due to the high amount  
of applied protein in immunoprecipitation and a strong binding of the anti-Chd7 antibody.  
(B) The reciprocal experiment was performed to verify the results. Sema3a was precipitated with 
an anti-Sema3a antibody. By western blot analysis using an anti-Chd7 antibody, a ~336 kDa 
protein band corresponding to the estimated size of Chd7 was detected. Nuclear extract without 
antibody incubation was used as negative control (NC) to exclude unspecific binding of Sema3a 
(A) or Chd7 (B) to the magnetic beads used for the Co-IP experiments. 30 µg of nuclear protein per 
lane was used as input control to demonstrate the expression of Sema3a (A) and Chd7 (B) in the 
nucleus of O9-1 cells. Star () illustrate potentially unspecific protein band due to unspecific 
binding of the used anti-Sema3a antibody. Molecular weights of proteins and marker bands are 
indicated in kilo Dalton (kDa). 
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3.6 Detection of the non-synonymous SEMA3A variant 
c.2002A>G (p.I668V) in a CHD7-positive CHARGE 
syndrome patient 
CHARGE syndrome is described as a phenotypically heterogeneous disorder. For this 
reason, it might be possible that there are other genes in addition to CHD7 which might 
act as modifiers leading to a mild or a severe phenotype when these genes are mutated. 
One of these candidate genes could be SEMA3A, known to contribute to the phenotype  
of the CHARGE-related disorder Kallmann syndrome. Therefore, 5 CHARGE patients  
with a mild phenotype and 10 CHARGE patients with a severe phenotype, but all  
carrying pathogenic mutations in CHD7, were screened for additional mutations in 
SEMA3A (MIM 603961). All 17 coding exons and flanking intronic sequences of SEMA3A 
(NM_006080.2) were analyzed by amplifying these regions by PCR using genomic DNA 
and screened for mutations by sequencing analysis. In one patient with a severe 
phenotype, the non-synonymous variant c.2002A>G (p.I668V) was found (Figure 18) 
which is located in the Ig-like domain of SEMA3A (Figure 19). While the in silico programs 
PolyPhen-2 and SIFT predicted that this new variant is tolerated, the program 
MutationTaster predicted it as disease causing. Moreover, the alteration is not listed in the 
database of the Exome Aggregation Consortium (ExAC). Hanchate et al. (2012) 
characterized two other SEMA3A mutations: the variant c.196C>T (p.R66W) should lead 
to an impaired SEMA3A secretion, whereas the variant c.2062A>G (p.T688A) should 
reduce the signal activity of SEMA3A. To clarify the new variant p.I668V, functional 
analysis on human embryonic kidney 293 cells (HEK293 cells) were performed. The wild 
type SEMA3A and the SEMA3A variant p.R66W were used as referees. 
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Figure 18: SEMA3A mutation found in a CHD7-positive CHARGE syndrome patient. All  
17 coding exons and flanking intronic sequences of the SEMA3A gene were sequenced in  
5 CHARGE patients with a mild phenotype and 10 CHARGE patients with a severe phenotype, but 
all carrying pathogenic mutations in the CHD7 gene. One non-synonymous variant was identified in 
a patient with a severe phenotype: c.2002A>G (p.I668V). The mutation is indicated by gray 
background in the forward and the reverse sequence, respectively. 
 
 
 
Figure 19: Schematic representation of full length SEMA3A protein with identified mutation. 
The non-synonymous variant c.2002A>G (p.I668V), which was identified in a CHD7-positive 
CHARGE syndrome patient, is located in the Ig-like domain (green) of SEMA3A. 
 
 
3.7 Generation of SEMA3A plasmids 
The plasmid SEMA3A-WT-pcDNA3.1/myc-His B (NP_006071.1, kindly provided by my 
research group), which contains the human SEMA3A wild type (WT) sequence, was used 
to generate pcDNA3.1/myc-His B plasmids carrying the c.196C>T (p.R66W) and the 
c.2002A>G (p.I668V) mutation, respectively. The plasmid with the variant c.196C>T 
(p.R66W) was used as referee, because this mutation was characterized by Hanchate  
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et al. (2012) leading to an impaired SEMA3A secretion. The mutations were generated 
using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies)  
(chapter 2.2.1.4.4). The generated plasmids SEMA3A-R66W-pcDNA3.1/myc-His B and 
SEMA3A-I668V-pcDNA3.1/myc-His B were validated for the correct nucleotide sequence 
and reading frame by sequencing analysis. 
Afterwards, the SEMA3A WT sequence and the two SEMA3A mutation sequences were 
separately cloned into the pCMV-HA vector (Invitrogen), containing a hemagglutinin (HA) 
epitope tag, as well as into the pGADT7 vector (Clontech) using the In-Fusion®  
HD Cloning Kit (Clontech) (chapter 2.2.1.4.2). Sequencing analysis was used to validate 
the correct nucleotide sequence and reading frame of the generated plasmids. The 
analysis revealed the existence of the HA-tag in front of the SEMA3A signal sequence  
in the generated plasmids. 
 
 
3.8 SEMA3A variants have no effect on the expression, 
processing and secretion as well as dimerization of 
SEMA3A 
The effect of the SEMA3A variant p.I668V, which was detected in a CHD7-positive 
CHARGE syndrome patient (chapter 3.6), was analyzed concerning expression, 
processing and dimerization as well as secretion of SEMA3A. As referees, SEMA3A WT 
and the SEMA3A variant p.R66W were used. 
Therefore, transient overexpression of SEMA3A WT and SEMA3A variants was 
performed with the generated SEMA3A-pCMV-HA plasmids (chapter 3.7) using  
HEK293 cells. This cell line was chosen to test the plasmids in a human cell system  
by western blot analysis. 
HEK293 cells were single transfected with SEMA3A-pCMV-HA plasmids containing the 
human sequence of SEMA3A WT or of the SEMA3A variants c.196C>T (p.R66W) and 
c.2002A>G (p.I668V) to initially analyze the expression of the overexpressed plasmids 
and if the overexpressed SEMA3A undergoes proteolytic processing. HEK293 cells 
without plasmid treatment (untransfected) were used to investigate the SEMA3A 
expression level. Cytoplasmic and nuclear protein extracts were separately isolated 24 h 
after transfection. Western blot analysis was performed using 30 µg of protein per lane. 
Endogenous and overexpressed SEMA3A was detected with an anti-SEMA3A antibody 
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(Figure 20 A), while an anti-HA antibody was used for the detection of the plasmid 
containing HA-tag (Figure 20 B). In cytoplasmic and nuclear protein extracts of 
untransfected HEK293 cells only two potentially unspecific protein bands due to unspecific 
binding of the used anti-SEMA3A antibody were detected, demonstrating that HEK293 
cells express almost undetectable levels of SEMA3A (Figure 20 A). In cytoplasmic and 
nuclear protein extracts of transfected HEK293 cells the monomeric SEMA3A isoforms of 
~87 kDa (p87) and ~85 kDa (p85) were detected (Figure 20 A), suggesting proteolytic 
processing of the overexpressed SEMA3A. Moreover, the results demonstrate that the 
overexpressed SEMA3A WT plasmid in comparison with the overexpressed SEMA3A 
variant plasmids show the same expression pattern in the nucleus and cytoplasm of 
HEK293 cells. 
Using an anti-HA antibody, no protein bands were detected neither in the cytoplasmic nor 
in the nuclear protein extracts except from the positive control, indicating the HA-tag gets 
lost in HEK293 cells after transfection of the SEMA3A plasmids due to proteolytic 
cleavage (Figure 20 B). For this reason the HA-tag could not be detected with the anti-HA 
antibody. Nevertheless, due to an almost undetectable SEMA3A expression level in 
HEK293 cells, the overexpressed SEMA3A was detected in further experiments using an 
anti-SEMA3A antibody. To proof the assumption concerning the unspecific protein bands, 
HEK293 cells should be transfected with SEMA3A WT and SEMA3A variant plasmids 
containing a HA-tag between the signal sequence and the semaphorin domain. 
Consequently, the potentially unspecific protein bands should not be detected using an 
anti-HA antibody. 
Detection of α-Tubulin (~50 kDa protein band) served as loading control (Figure 20 B). 
Although α-Tubulin is expressed in the cytoplasm it was also detected in the nuclear 
protein extracts which can possibly be traced back on the used protein extraction method. 
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Figure 20: Expression and proteolytic processing of transient overexpressed SEMA3A WT 
and SEMA3A variants in HEK293 cells. HEK293 cells were single transfected with SEMA3A-
pCMV-HA plasmids containing the human sequence of SEMA3A WT or of the SEMA3A  
variants c.196C>T (p.R66W) and c.2002A>G (p.I668V). Cytoplasmic (C) and nuclear (N) protein 
extracts were separately isolated 24 h after transfection. 30 µg of protein was used per lane.  
(A) Endogenous and overexpressed SEMA3A was detected by western blot analysis using an anti-
SEMA3A antibody. In untransfected cytoplasmic and nuclear extracts no specific SEMA3A protein 
bands were detected, demonstrating that HEK293 cells express almost undetectable levels of 
SEMA3A. In transfected cytoplasmic and nuclear extracts the monomeric SEMA3A isoforms of  
~87 kDa (p87) and ~85 kDa (p85) were observed, suggesting proteolytic processing of the 
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overexpressed SEMA3A. Nevertheless, no differences in the cytoplasmic and nuclear expression 
pattern of the overexpressed SEMA3A WT plasmid in comparison with the overexpressed 
SEMA3A variant plasmids were observed. Stars () illustrate potentially unspecific protein bands 
due to unspecific binding of the used anti-SEMA3A antibody. (B) In the transfected cytoplasmic 
and nuclear extracts no SEMA3A protein bands were detected with an anti-HA antibody, 
suggesting the HA-tag loss of the generated SEMA3A plasmids due to proteolytic cleavage. 
Nuclear protein extract of HEK293 cells transfected with RbBP5-pCMV-HA plasmid  
(~59 kDa protein band) was used as positive control. The detection of α-Tubulin (~50 kDa protein 
band) served as loading control. Due to the protein extraction method, α-Tubulin was detected in 
the cytoplasmic and the nuclear protein extracts. Molecular weights of proteins and marker bands 
are indicated in kilo Dalton (kDa). 
 
In addition, the dimerization and secretion of overexpressed SEMA3A were analyzed. 
Unspecific binding of the used anti-SEMA3A antibody in unused, concentrated cell culture 
medium and concentrated cell culture medium of untransfected HEK293 cells was 
excluded by western blot analysis (data not shown). Single transfections of HEK293 cells 
with SEMA3A-pCMV-HA plasmids containing the human sequence of SEMA3A WT or of 
the SEMA3A variants c.196C>T (p.R66W) and c.2002A>G (p.I668V) were performed.  
24 h after transfection, the cell culture medium was concentrated and the cytoplasmic and 
nuclear protein extracts were separately isolated. Western blot analysis was performed 
using 30 µg of protein per lane treated with the reducing agent DTT (+DTT) or without 
reducing agent (−DTT). The overexpressed SEMA3A was detected with an anti-SEMA3A 
antibody. The representative results are shown in Figure 21. In concentrated medium  
with reducing agent, the secreted monomeric isoforms of ~87 kDa (p87) and ~61 kDa 
(p61) were detected. In concentrated medium without reducing agent, the secreted 
dimeric isoforms of ~174 kDa (p87:87) and ~112 kDa (p87:p25) as well as the secreted 
monomeric isoforms of ~87 kDa (p87) and ~61 kDa (p61) were received. The secreted 
monomeric p87-SEMA3A isoform without reducing agent is displayed by a lower protein 
band possibly due to the missing of DTT. In cytoplasmic and nuclear extracts with 
reduction, the monomeric isoforms of ~87 kDa (p87) and ~85 kDa (p85) were observed, 
whereas without reduction a ~170 kDa protein band was identified, potentially 
representing the dimeric p85:p85-SEMA3A isoform. 
Based on these findings, no consequences on the secretion and dimerization of SEMA3A 
could be identified by comparing HEK293 cells transfected with the SEMA3A WT plasmid 
and HEK293 cells transfected with the two SEMA3A plasmids with mutation. Thus, the 
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impaired SEMA3A secretion due to the p.R66W mutation described by Hanchate et al. 
(2012) could not be validated. 
 
 
Figure 21: Secretion and dimerization of transient overexpressed SEMA3A WT and SEMA3A 
variants in HEK293 cells. HEK293 cells were single transfected with SEMA3A-pCMV-HA 
plasmids containing the human sequence of SEMA3A WT or of the SEMA3A variants c.196C>T 
(p.R66W) and c.2002A>G (p.I668V). 24 h after transfection, the cell culture medium was 
concentrated (cM) and the cytoplasmic (C) and nuclear (N) protein extracts were separately 
isolated. Western blot analysis was performed with an anti-SEMA3A antibody for the detection of 
overexpressed SEMA3A proteins. 30 µg of protein treated with the reducing agent DTT (+DTT) or 
without reducing agent (−DTT) was used per lane. In concentrated medium with reduction, the 
secreted monomeric isoforms of ~87 kDa (p87) and ~61 kDa (p61) were detected. In concentrated 
medium without reduction, the secreted dimeric isoforms of ~174 kDa (p87:p87) and ~112 kDa 
(p87:p25) as well as the secreted monomeric isoforms of ~87 kDa (p87) and ~61 kDa (p61) were 
received. The secreted monomeric p87-SEMA3A isoform without reducing agent is displayed by a 
lower protein band possibly due to the missing of DTT. In cytoplasmic and nuclear extracts with 
reducing agent, the monomeric isoforms of ~87 kDa (p87) and ~85 kDa (p85) were detected, 
whereas without reducing agent a ~170 kDa protein band was identified, potentially representing 
the dimeric p85:p85-SEMA3A isoform. Consequently, the SEMA3A variants had no effect on the 
secretion and dimerization of SEMA3A by comparing HEK293 cells transfected with the SEMA3A 
WT plasmid and HEK293 cells transfected with the two SEMA3A plasmids with mutation. Stars () 
illustrate potentially unspecific protein bands due to unspecific binding of the used antibody. 
Molecular weights of proteins and marker bands are indicated in kilo Dalton (kDa). 
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3.9 CHD7 co-immunoprecipitates with SEMA3A WT and 
SEMA3A variants 
Chd7 and Sema3a interact in the nucleus of the murine NCC line O9-1 (chapter 3.5). To 
investigate this interaction in HEK293 cells and in order to check whether the interaction 
holds up in presence of SEMA3A mutations, Co-IP experiments were performed. 
Therefore, HEK293 cells were single transfected with SEMA3A-pCMV-HA plasmids 
containing the human sequence of SEMA3A WT or of the SEMA3A variants c.196C>T 
(p.R66W) and c.2002A>G (p.I668V). Nuclear extracts were isolated 24 h after 
transfection. The immunoprecipitation of endogenous CHD7 was performed using an  
anti-CHD7 antibody. Endogenous and overexpressed SEMA3A was detected by western 
blot analysis using an anti-SEMA3A antibody (Figure 22). A ~87 kDa protein band 
corresponding to the estimated size of the monomeric p87-SEMA3A isoform was 
detected. Because of the high amount of applied protein in the immunoprecipitation,  
an interaction of endogenous CHD7 and endogenous SEMA3A was also identified  
in untransfected HEK293 cells. Nuclear extract of HEK293 cells transfected with  
SEMA3A WT plasmid without incubation of an anti-CHD7 antibody served as negative 
control to prove that SEMA3A is not capable to bind unspecific to the magnetic beads 
used for the Co-IP experiments. 30 µg nuclear protein of untransfected and transfected 
HEK293 cells per lane was used as input and transfection control, validating the SEMA3A 
overexpression due to the detection of the monomeric isoforms of ~87 kDa (p87) and ~85 
kDa (p85) in nuclear extracts of transfected HEK293 cells. 
In summary, the data obtained by the Co-IP experiments reveal an interaction of CHD7 
with the overexpressed SEMA3A WT and the overexpressed SEMA3A variants in 
HEK293 cells. 
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Figure 22: Co-immunoprecipitation of CHD7 with SEMA3A WT and SEMA3A variants in 
HEK293 cells. HEK 293 cells were single transfected with SEMA3A-pCMV-HA plasmids 
containing the human sequence of SEMA3A WT or of the SEMA3A variants c.196C>T (p.R66W) 
and c.2002A>G (p.I668V). 24 h after transfection, nuclear protein extracts were isolated. The 
immunoprecipitation of endogenous CHD7 was performed using an anti-CHD7 antibody. By 
western blot analysis using an anti-SEMA3A antibody, endogenous and overexpressed SEMA3A 
was detected. A ~87 kDa (p87) protein band corresponding to the estimated size of the monomeric 
p87-SEMA3A isoform was observed. An interaction of endogenous CHD7 and endogenous 
SEMA3A was also identified in untransfected HEK293 cells, because of the high amount of applied 
protein in the immunoprecipitation. To verify that SEMA3A does not bind unspecific to the magnetic 
beads used for the Co-IP experiments, nuclear extract of HEK293 cells transfected with SEMA3A 
WT plasmid without incubation of an anti-CHD7 antibody was used as negative control (NC). 30 µg 
nuclear protein of untransfected and transfected HEK293 cells per lane served as input and 
transfection control, validating the SEMA3A overexpression due to the detection of the monomeric 
isoforms of ~87 kDa (p87) and ~85 kDa (p85) in nuclear extracts of transfected HEK293 cells. The 
Co-IP experiments demonstrate an interaction of CHD7 with the overexpressed SEMA3A WT and 
the overexpressed SEMA3A variants in HEK293 cells. Stars () illustrate potentially unspecific 
protein bands due to unspecific binding of the used anti-SEMA3A antibody. Molecular weights of 
proteins and marker bands are indicated in kilo Dalton (kDa). 
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3.10 CHD7 shows no direct interaction with SEMA3A WT or 
SEMA3A variants 
To demonstrate the correct expression of the generated full-length SEMA3A plasmids 
(chapter 3.7) for yeast two-hybrid assay, yeast cells were single transformed with the HA-
tag containing plasmids SEMA3A-WT-pGADT7, SEMA3A-R66W-pGADT7 and SEMA3A-
I668V-pGADT7. Whole yeast cell protein lysates were isolated and analyzed with 
antibodies against the HA-tag and SEMA3A by western blot analysis. The representative 
results are shown in Figure 23. The detection of a ~97 kDa protein band corresponding  
to the estimated size of the generated SEMA3A plasmids indicated no proteolytic 
cleavage and thus the usability of the plasmids for yeast two-hybrid assay. Whole protein 
lysate of yeast cells double transformed with CHD7-Cr1-3-pGBKT7 (NP_060250.2) and  
CHD8-pGADT7-Rec (NP_065971.2) were used as positive control for HA-tag expression 
(~70 kDa protein band) as well as negative control for SEMA3A expression (no detectable 
protein band). The detection of α-Tubulin (~50 kDa protein band) ensured equal protein 
loading. 
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Figure 23: Expression of the full-length SEMA3A isoform in yeast cells. To validate that the 
SEMA3A yeast-two hybrid plasmids do not undergo proteolytic cleavage, yeast cells were single 
transformed with the HA-tag containing plasmids SEMA3A-WT-pGADT7, SEMA3A-R66W-pGADT7 
and SEMA3A-I668V-pGADT7. Whole yeast cell protein lysates were incubated with an anti-HA 
antibody (upper, left panel) or an anti-SEMA3A antibody (upper, right panel). By western blot 
analysis, a ~97 kDa protein band corresponding to the estimated size of the generated SEMA3A 
plasmids was detected, indicating no proteolytic cleavage and thus the usability of the  
plasmids for yeast two-hybrid assay. Whole protein lysate of yeast cells double transformed with 
CHD7-Cr1-3-pGBKT7 (NP_060250.2) and CHD8-pGADT7-Rec (NP_065971.2) were used as 
positive control for HA-tag expression (~70 kDa protein band) as well as negative control for 
SEMA3A expression (no detectable protein band). Lower panel: Detection of α-Tubulin (~50 kDa 
protein band) ensured equal protein loading. Molecular weights of proteins and marker bands are 
indicated in kilo Dalton (kDa). 
 
To determine a direct interaction of CHD7 with SEMA3A, yeast two-hybrid assay  
was performed. Four CHD7 plasmids were available as bait plasmids namely  
CHD7-1-pGBKT7 (amino acids 1–799), CHD7-2-pGBKT7 (amino acids 732–1567), 
CHD7-3-pGBKT7 (amino acids 1533–2380) and CHD7-4-pGBKT7 (amino acids  
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2325–2997) (Schulz et al., 2014a). These plasmids divide the human full length CHD7 
protein into four overlapping fragments without disruption of a known functional domain 
(Figure 24). Owing to autoactivation of the CHD7-1-pGBKT7 plasmid in the yeast system, 
no yeast two-hybrid assay could be performed with this plasmid (Schulz et al., 2014a). In 
addition, the CHD7-Cr1-3-pGBKT7 plasmid was used as bait, spanning the amino acids 
1591-2181 (Figure 24) (Batsukh et al., 2010). All appropriate bait plasmids were used with 
the prey plasmids SEMA3A-WT-pGADT7, SEMA3A-R66W-pGADT7 and SEMA3A-I668V-
pGADT7 for yeast two-hybrid assay, respectively. The plasmid SEMA3A-R66W-pGADT7 
contain the already known SEMA3A missense mutation p.R66W (Hanchate et al., 2012), 
whereas the plasmid SEMA3A-I668V-pGADT7 include the missense mutation identified in 
a CHD7-positive CHARGE syndrome patient (chapter 3.6). Yeast colonies on −LT agar 
plates indicated a successful transformation (Figure 25 A, C and E). No autoactivation  
of the yeast reporter gens could be observed on –LTHA agar plates using an empty 
pGBKT7 bait vector together with the prey plasmids in an autoactivation test, respectively 
(Figure 25 B, D and F). As positive control, the bait plasmid CHD7-Cr1-3-pGBKT7 and  
the prey plasmid CHD8-pGADT7-Rec (amino acids 1789–2091) were used (Batsukh  
et al., 2010) (Figure 25 B, D and F). The yeast two-hybrid assay with the SEMA3A 
plasmids SEMA3A-WT-pGADT7, SEMA3A-R66W-pGADT7 and SEMA3A-I668V-pGADT7 
revealed no direct interactions with the plasmids CHD7-2-pGBKT7, CHD7-3-pGBKT7, 
CHD7-4-pGBKT7 and CHD7-Cr1-3-pGBKT7 (Figure 25 B, D and F), demonstrating that 
these parts of CHD7 do not directly bind to SEMA3A WT or SEMA3A variants. 
 
 
 
Figure 24: Schematic overview of the used CHD7 yeast two-hybrid assay plasmids. The 
plasmids CHD7-1-pGBKT7 to CHD7-4-pGBKT7 divide the full-length CHD7 protein into four 
overlapping parts. A known functional domain is thereby not disrupted. The plasmid CHD7-Cr1-3-
pGBKT7 achieves this requirement as well. Schulz et al. (2014a). 
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Figure 25: Yeast two-hybrid assay. Yeast two-hybrid assay was performed with the plasmids 
CHD7-2-pGBKT7, CHD7-3-pGBKT7, CHD7-4-pGBKT7 and CHD7-Cr 1-3-pGBKT7 as baits, which 
are parts of the human full-length CHD7 protein. The plasmids SEMA3A-WT-pGADT7, SEMA3A-
R66W-pGADT7 and SEMA3A-I668V-pGADT7 were used as preys. Yeast colonies on −LT agar 
plates indicated a successful transformation (A, C and E). All prey plasmids were tested on −LTHA 
agar plates for autoactivation of the Y2HGold yeast strain reporter gens with the empty pGBKT7 
bait vector (B, D and F). As positive control, the bait plasmid CHD7-Cr1-3-pGBKT7 and the prey 
plasmid CHD8-pGADT7-Rec were used (B, D and F). The yeast two-hybrid assay revealed no 
direct interaction of the CHD7 parts with the SEMA3A WT or the SEMA3A variants (B, D and F). 
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4 Discussion 
4.1 Summary of the results 
Using RT-PCR analysis, the two different murine NCC lines JoMa and O9-1 were 
characterized for the expression of different marker genes and Chd7. The nuclear 
expression of Chd7 was validated in both NCC lines by western blot analysis and in the 
O9-1 cells also with immunocytochemical staining. The results of the western blot analysis 
revealed a strong Chd7 expression in O9-1 cells in comparison with JoMa cells. Based on 
these findings, further experiments were performed with O9-1 cells. With RT-PCR 
analysis it was further shown that O9-1 cells express beside the receptors of class 3 
semaphorins also class 3 semaphorins itself. The nuclear and cytoplasmic Sema3a 
expression was confirmed by immunocytochemical staining and western blot analysis. 
Moreover, proteolytic processing, dimerization and secretion of Sema3a were identified 
using western blot analysis. A downregulation of Chd7 with specific siRNAs revealed a 
reduced Sema3a expression in O9-1 cells. Using Co-IP experiments, the nuclear 
interaction of Chd7 with Sema3a was shown in two ways: by precipitation of Chd7 and 
detection of Sema3a as well as by precipitation of Sema3a and detection of Chd7. 
A mutational screen of the coding sequence of SEMA3A in 5 CHARGE patients with a 
mild phenotype and 10 CHARGE patients with a severe phenotype, but all carrying 
pathogenic mutations in the CHD7 gene, was performed. In one patient, the non-
synonymous variant c.2002A>G (p.I668V) was identified in a heterozygous state. This 
new identified variant, as well as the already published variant p.R66W, were 
characterized in the human HEK293 cell line using overexpressing SEMA3A plasmids 
containing one of the mutations, respectively. Western blot analyses demonstrated that 
expression, proteolytic processing and dimerization as well as secretion of SEMA3A were 
not affected by both mutations. The performed Co-IP experiments revealed that CHD7 
interacts with SEMA3A WT and the two SEMA3A variants, p.R66W and p.I668V. 
However, yeast two-hybrid assay identified no direct interaction of the used CHD7 
fragments with full-length constructs of wildtype or mutated SEMA3A. 
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4.2 NCCs – which in vitro model to choose? 
The symptoms seen in CHARGE syndrome patients likely predominantly result from 
defects of the cranial NCCs and their subpopulation, the cardiac NCCs, cell populations 
largely responsible for forming the vertebrate head, heart and the peripheral nervous 
system (Kulesa et al., 2010). The assumption that the malformations and defects seen in 
CHARGE syndrome patients result from abnormalities during NCC development were 
already published in 1985 (Siebert et al., 1985). Furthermore, defects in the interaction 
between mesoderm and NCCs (Van Meter and Weaver, 1996) or disturbances in 
mesenchymal-epithelial interactions (Williams, 2005) were also supposed as pathogenic 
mechanisms causing CHARGE. In 2004, Vissers et al. identified mutations in the CHD7 
gene as the underlying cause leading to the complex developmental disorder CHARGE 
syndrome (Vissers et al., 2004). In several other studies, further heterozygous mutations 
or deletions of CHD7 were described in CHARGE syndrome patients (Aramaki et al., 
2006; Jongmans et al., 2006; Lalani et al., 2006; Sanlaville et al., 2006; Wincent et al., 
2008). CHD7 was also identified as a member of complexes which regulate time and 
tissue specific gene expression (Layman et al., 2010). The initial presumption that 
CHARGE belongs to the neurocristopathies was confirmed by Bajpai et al. (2010) for  
the first time. Performing Chd7 knockdown experiments in Xenopus laevis embryos, 
Bajpai et al. (2010) demonstrated that Chd7 is essential for the formation of NCCs by 
activating transcriptions factors such as Snai2 (previously named Slug), Sox9 and Twist 
and observed abnormal NCC migration into the pharyngeal arches. Bajpai et al. (2010) 
also identified the association of Chd7 with the PBAF complex and supposed that this 
cooperation regulates the gene expression during NCC formation in Xenopus laevis. 
A suitable NCC model for in vitro studies was essential to investigate the functions of 
Chd7 in NCC. To examine that these cell line truly represents NCC and express Chd7, the 
two murine NCC lines, the trunk JoMa cells and the cranial O9-1 cells, were characterized 
by RT-PCR and western blot analysis as well as immunocytochemical staining. Both cell 
lines grow as monolayers and display a stellate like morphology, typical for NCCs  
(Rao and Anderson, 1997). Furthermore, they can be cultured in a suitable culture 
medium without loss of their self-renewal capacity and multipotency. Maurer et al. (2007) 
generated the immortalized cell line JoMa1 and a clonally derived cell line termed 
JoMa1.3 using transgenic mice (Jager et al., 2004) at E8.75, expressing a conditional  
4-Hydroxytamoxifen (4-OHT) inducible allele of c-Myc (c-MycER
T
; Pelengaris et al., 1999; 
Rudolph et al., 2000). JoMa cells proliferate robustly as long as c-MycER
T
 is active in a  
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4-OHT dependent manner (Maurer et al., 2007). They were described to express amongst 
others the two NCC markers Sox10 and Ngfr (previously named P75), indicating that 
these cells have the potential to differentiate into various cell types in vivo (Maurer et al., 
2007). A detailed look at the RT-PCR primers used by Maurer et al. (2007) for the 
expression analysis of marker genes in JoMa cells revealed that several primers were not 
useful for RT-PCR analysis due to recognition sites in intronic sequences. For this reason, 
the Sox10 expression in JoMa cells described by Maurer et al. (2007) is questionable.  
Maurer et al. (2007) successfully differentiated both JoMa cell lines into neurons, glia, 
melanocytes, smooth muscle cells and chondrocytes in vitro. The second murine NCC 
line, the O9-1 cells, was generated by Ishii et al. (2012). This cell line was obtained from 
mass culture of Wnt1-Cre;R26R-GFP reporter-expressing NCCs from mouse embryos  
at E8.5 (Ishii et al., 2012). Whole-genome expression profiling suggested that this cell line 
stably expresses both NCC and stem cell markers and was successfully differentiated into 
osteoblasts, chondrocytes, smooth muscle cells and glia (Ishii et al., 2012). 
By RT-PCR analysis on cDNA obtained from total RNA of JoMa and O9-1 cells the initial 
situation of both NCC lines was monitored concerning the expression of different marker 
genes and Chd7. In contrast to the tested NCC markers Ngfr, Snai2, Pax3, Snai1 and 
Twist1, the NCC marker Sox10 was not detected in both cell lines, indicating JoMa and 
O9-1 cells are no pre-migratory cell lines. The further tested marker genes for neurons, 
glial cells, smooth muscle cells, melanocytes and chondrocytes displayed in both NCC 
lines a similar expression pattern. The additionally analyzed Chd7 gene was found to be 
expressed in both NCC lines. To verify the results of the Chd7 expression on protein level, 
nuclear protein extracts of JoMa cells and O9-1 cells were tested by western blot analysis. 
The expression of Chd7 could be confirmed in O9-1 cells, but not in JoMa cells because 
no clear protein band of Chd7 was detected. By immunocytochemical staining it was 
shown that Chd7 is specifically and intensely expressed in the nucleus of O9-1 cells. The 
strong Chd7 expression strengthens the hypothesis that the symptoms seen in CHARGE 
syndrome can be explained by a dysfunction of the cranial NCCs and not of the trunk 
NCCs. For this reason, further experiments were performed with the cranial O9-1 cell line, 
representing multipotent mesenchymal cranial NCCs. 
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4.3 NCCs express class 3 semaphorins and secrete Sema3a 
Randall et al. (2009) demonstrated that the phenotype of pharyngeal arch artery defects in 
Chd7 heterozygous mice could not be rescued by expression of Chd7 in the murine NCCs 
alone, whereas Chd7 expression in both NCCs and the pharyngeal ectoderm led to a full 
rescue of the pharyngeal arch artery alterations. As candidate genes for the interaction 
between the ectoderm and the NCCs, semaphorins, ephrins, slits, Pdgfs and Vegfs were 
suggested (Randall et al., 2009). To identify Chd7 target genes in different tissues with 
functions in NCC development and possible other pathways which might also contribute to 
the phenotype of CHARGE syndrome, Schulz et al. (2014b) performed a genome-wide 
microarray expression analysis on whole wild type and Chd7 deficient (Chd7Whi/+ and 
Chd7Whi/Whi) embryos of the Whirligig mouse line at E9.5 and identified 98 differentially 
expressed genes. Many of the misregulated genes are known to play a role in NCC 
migration and axon guidance like class 3 semaphorins and ephrins as well as transcription 
factors, overall genes belonging to the candidate molecules for the interaction between 
the ectoderm and the NCCs assumed by Randall et al. (2009). 
During development, NCCs are guided to their appropriate target regions through the 
embryo by many attractive and repulsive cues. A group of guidance cues that is well 
investigated are the semaphorins which exert their effects through the binding to 
multimeric receptor complexes at the cell membrane and initiating of unique intracellular 
signal transduction cascades (Jongbloets and Pasterkamp, 2014). 
To test whether the NCC line O9-1 expresses semaphorin receptors, RT-PCR analysis on 
cDNA obtained from total RNA of O9-1 cells was performed, representing expression  
of neuropilin and plexin receptors. Plein et al. (2015) performed Sema3c in situ 
hybridization (ISH) on outflow tracts of mouse embryos and identified Sema3c expression 
in myocardial cuff cells and in the area where cardiac NCCs were located. In contrast  
to prior studies, who interpreted this result as an indication that Sema3c guide cardiac 
NCCs into this area, Plein et al. (2015) suggested that cardiac NCCs express Sema3c 
itself. By performing a Sema3c ISH on Wnt1-Cre Rosa
Yfp
 outflow tracts, they found  
that Sema3c was expressed in a subpopulation of cardiac NCCs. Therefore, they 
supposed that semaphorins might act not only as guidance cues, but also have additional 
functions (Plein et al., 2015). After the validation of the semaphorin receptor expression  
in O9-1 cells, which are essential for the guidance of the semaphorins, a possible 
semaphorin expression in NCC itself was investigated. RT-PCR analysis on cDNA of  
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O9-1 cells identified the expression of class 3 semaphorins, in particular Sema3a, 
Sema3c, Sema3d and Sema3e, in NCCs for the first time. 
 
These results raised several questions: 
 
1. In which cell compartments of NCCs are class 3 semaphorins localized? 
2. Exist class 3 semaphorins as monomeric and dimeric isoforms in NCCs? 
3. Undergo class 3 semaphorins proteolytic processing in NCCs? 
4. Are class 3 semaphorins secreted by NCCs? 
 
For SEMA3A, a secreted class 3 semaphorin with repulsive effects on primary olfactory 
axons, a contribution to the phenotype of Kallmann syndrome was demonstrated 
(Hanchate et al., 2012; Young et al., 2012). Phenotypic features of the heterogeneous 
congenital disorder Kallmann syndrome, like a hypogonadotropic hypogonadism and  
an absent or impaired sense of smell (anosmia) (Dodé and Hardelin, 2009), are also 
frequently observed in patients with CHARGE syndrome (Chalouhi et al., 2005; Pinto  
et al., 2005; Ogata et al., 2006). In addition, mutations in the CHD7 gene can be found in 
patients with CHARGE and in a minority of patients with Kallmann syndrome (Kim et al., 
2008; Bergman et al., 2011). For this reason, the Kallmann syndrome was suggested to 
represent the mild end of the phenotypic spectrum of CHARGE syndrome (Jongmans  
et al., 2009). Consequently, if CHD7 and SEMA3A play a role in the pathogenesis of 
Kallmann syndrome, it might be possible that beside CHD7 additional SEMA3A 
contributes to the pathogenesis of CHARGE syndrome. Therefore, Sema3a was further 
investigated in the NCC line O9-1 by immunocytochemical staining and western blot 
analysis. Sema3a localization was not only identified in concentrated culture medium, 
exposing secretion of Sema3a by O9-1 cells, but also in the cytoplasm and nucleus of  
O9-1 cells. The localization of Sema3a in the nucleus is not due to a nuclear localization 
signal which is not present in Sema3a. It could be explained by glycosylation of  
the Sema3a isoforms (Rondanino et al., 2003). The isoforms detectable with the  
used anti-Sema3a antibody displayed full-size and partially processed monomers and  
dimers, indicating proteolytic cleavage of the full-length Sema3a by furin and furin-like 
endoproteases or matrix metalloproteases and dimerization as described for related  
class 3 semaphorins (Adams et al., 1997; Klostermann et al., 1998; Koppel and Raper, 
1998; Christensen et al., 2005; Esselens et al., 2010). Processing of the inactive full-
length Sema3a isoform is described to result in activation of its repulsive properties and 
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generation of functionally different isoforms (Adams et al., 1997). Adams et al. (1997) 
further assumed that specific proteases and protease inhibitors might locally activate or 
modulate repulsive signals and consequently contribute to class 3 semaphorin specificity. 
Nevertheless, further experiments are needed to clarify these aspects. 
In conclusion, the experiments demonstrate that NCCs express, process and secrete 
Sema3a, providing Sema3a itself. These results lead to the suggestion that Sema3a has 
in addition to its NCC guidance aspect other diverse functions. 
 
 
4.4 Chd7 regulates Sema3a expression and is associated 
with Sema3a in NCCs 
Chd7 is highly conserved across species and orthologs have been identified in mouse, 
chicken, zebrafish, Xenopus laevis and others (Bosman et al., 2005; Aramaki et al., 2007; 
Bajpai et al., 2010). A downregulation of Chd7 in Xenopus laevis embryos displayed major 
features seen in CHARGE syndrome patients (Bajpai et al., 2010) and led to induction 
and migration defects of NCCs (Bajpai et al., 2010; Schulz et al., 2014b), while 
downregulation of Sema3a in Xenopus laevis embryos only affected NCC migration 
(Schulz et al., 2014b). Sema3a expression analysis in heterozygous (Chd7Whi/+) as well as 
homozygous (Chd7Whi/Whi) Whirligig mice and after downregulation of Chd7 in Xenopus 
laevis embryos revealed a decreased or complete depletion of Sema3a expression 
exposing the evolutionary conservation of the Chd7-Sema3a regulatory loop (Schulz  
et al., 2014b). 
To analyze whether this regulatory mechanism is also found in NCCs, knockdown 
experiments were performed by transfecting O9-1 cells with Chd7-specific siRNAs. 
Analysis of Sema3a expression after downregulation of Chd7 revealed a decreased 
expression of Sema3a, demonstrating that the regulatory loop is also present in NCCs. 
Co-IP experiments performed with O9-1 cells further demonstrated an interaction of Chd7 
with Sema3a in nuclear extract of NCCs suggesting an association of Chd7 and Sema3a 
in the same protein complex. Chd7 rescue experiment performed by co-injection of a 
Chd7 morpholino and Sema3a RNA demonstrated a partially rescue of the Chd7 
knockdown phenotype seen in Xenopus laevis embryos (Borchers, unpublished data), 
indicating a possible role of Sema3a in the pathogenesis of CHARGE syndrome. 
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4.5 SEMA3A might act as modifier in CHARGE syndrome 
High clinical inter- and intra-familial variability is observed in the malformation disorder 
CHARGE syndrome (Aramaki et al., 2006; Jongmans et al., 2006; Lalani et al., 2006). 
Genetic modifiers make an important contribution to different kinds of disease like 
neurological (Kearney, 2011) or arrhythmogenic disorders (Crotti et al., 2005). Modifier 
can enhance or suppress the phenotype of a disorder. To analyze whether SEMA3A 
mutations contribute to the pathogenesis of CHARGE syndrome and maybe negatively 
modulate the phenotypic outcome of the affected patients, 5 patients with a mild and  
10 patients with a severe phenotype, but all carrying a pathogenic mutation in the CHD7 
gene, were sequenced for the presence of additional mutations in the coding sequence of 
the SEMA3A gene. 
One non-synonymous mutation in a heterozygous state, namely c.2002A>G (p.I668V) 
was identified in a patient with a severe phenotype. This variant is not listed in the 
database of the Exome Aggregation Consortium (ExAC). While two in silico programs 
predicted this variant to be tolerated (PolyPhen-2 and SIFT), the in silico program 
MutationTaster predicted the variant as disease causing. Interestingly, Schulz et al. 
(2014b) screened 45 patients diagnosed with CHARGE, but lacking a mutation in the 
CHD7 gene for mutations in SEMA3A and identified also the non-synonymous variant 
c.2002A>G (p.I668V) in one patient and two other non-synonymous variations namely 
c.196C>T (p.R66W) and c.2062A>G (p.T688A) in a heterozygous state in two other 
patients. Two of the later found mutations were already described in patients with 
Kallmann syndrome leading to an impaired SEMA3A secretion (p.R66W) or a reduced 
signal activity of SEMA3A (p.T688A) (Hanchate et al., 2012). Based on these findings, a 
pathogenic effect of SEMA3A in Kallmann syndrome was assumed (Hanchate et al., 
2012). Nevertheless, Hanchate et al. (2012) supposed that heterozygous SEMA3A 
mutations are not sufficient to induce the phenotype of Kallmann syndrome alone, but 
might contribute to it by a combination with other mutated Kallmann syndrome causing 
gene mutations due to digenetic inheritance. This hypothesis was fleshed out by 
identification that the non-synonymous mutation p.R66W was inherited from the healthy 
father of a CHARGE syndrome patient (Schulz et al., 2014b) and can be further 
strengthen because of two independently described patients with bi-allelic mutations in 
SEMA3A causing an autosomal recessive type of syndromic short stature (Hofmann et al., 
2013; Baumann et al., 2017). 
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Functional analyses on transfected HEK293 cells were performed to analyze the effect of 
the new identified SEMA3A mutation p.I668V in a CHD7-positive CHARGE syndrome 
patient. Therefore, the mutation was induced by side-directed mutagenesis into a plasmid 
containing the human SEMA3A WT sequence to generate an overexpression plasmid with 
the defect and to study the effect of the new SEMA3A mutation. As referees, 
overexpression plasmids containing either the already described SEMA3A mutation 
p.R66W or the SEMA3A WT sequence were used. With the performed western blot 
analyses, no alterations concerning the expression, processing or dimerization as well as 
secretion of SEMA3A were detected by the mutations p.R66W and p.I668V. These results 
indicate that the p.R66W mutation might has no effect on the secretion of SEMA3A as 
assumed by Hanchate et al. (2012). However, the results obtained by Hanchate et al. 
(2012) were limited by the analysis of only conditioned medium without transfection 
control. During writing this thesis, my research group studied the effect of tunicamycin, a 
glycosylation inhibitor, on the glycosylation of overexpressed SEMA3A in HEK293 cells 
using overexpressing plasmids containing either the SEMA3A WT or the SEMA3A 
mutations p.R66W and p.I668V. The results of the western blot analysis revealed that 
after tunicamycin treatment of transfected HEK293 cells, in nuclear and cytoplasmic 
extracts, which contained the overexpressed SEMA3A WT and the overexpressed 
SEMA3A with the mutation p.I668V, only unglycosylated SEMA3A was detected. Indeed, 
in nuclear and cytoplasmic extracts containing the overexpressed SEMA3A with the 
mutation p.R66W, unglycosylated as well as glycosylated SEMA3A was received. These 
results might be explained due to structural modifications of SEMA3A caused by the 
p.R66W mutation. Sema3a rescue experiments in Xenopus laevis embryos performed by 
co-injection of a Chd7 morpholino with Sema3a-WT, Sema3a-p.R66W or Sema3a-
p.I668V RNA supposed that only the Sema3a-p.R66W RNA cannot compensate the 
defects produced by the Chd7 morpholino (Borchers, unpublished data). These data 
strengthen the hypothesis that the p.R66W mutation is pathogenic, whereas the 
pathogenicity of the p.I668V mutation could not be clarified. Nevertheless, as presumed  
in previous studies, heterozygous SEMA3A mutations alone are not sufficient to cause  
a pathogenic phenotype, but might act as modifier or contribute to it through their 
interactions with other mutated genes due to digenetic inheritance. In addition, Sema3a 
was identified in this thesis to be expressed and secreted by the NCC line O9-1 
suggesting a new function of SEMA3A. Although Co-IP experiments on transfected 
HEK293 cells indicated a co-existence of CHD7 and SEMA3A in the same protein 
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complex, yeast two-hybrid assay revealed no direct interaction for CHD7 and SEMA3A. 
The association of CHD7 and SEMA3A in a nuclear protein complex might indicate a 
function for SEMA3A as transcription factor beside the guidance function as described by 
Kuriyama and Mayor (2008). Moreover, another effectiveness of Sema3a might be 
possible, because it is secreted by NCCs itself and not only by the surrounding tissue. 
 
 
4.6 Future perspectives 
The Sema3a expression analysis in the NCC line O9-1 revealed the existence of Sema3a 
not only in the secreted medium, but also in the cytoplasm and in the nucleus of the cells 
although Sema3a is predicted not to have a nuclear localization signal. To test the 
accuracy of the detected endogenous Sema3a in O9-1 cells and furthermore of the 
overexpressed SEMA3A in HEK293 cells, plasmids containing a detectable HA-tag with 
and without mutation should be used for transfection and western blot analysis. My 
research group already started with these experiments during writing my thesis. 
In order to identify the precise localization of Sema3a in the cytoplasm as well as in the 
nucleus, a co-immunostaining using different cell organelle markers could be performed. 
To elucidate Sema3a target genes in NCCs, the expression profiles of O9-1 cells treated 
with and without siRNA against Sema3a should be compared by whole-genome 
microarray analysis. The identified genes could be validated by qRT-PCR analysis and 
chromatin immunoprecipitation (ChIP) assay. 
To confirm the identified association of Chd7 and Sema3a in the same nuclear protein 
complex in O9-1 cells, Duolink proximity ligation assay (PLA) should be performed. 
Further, the composition of the whole protein complex should be analyzed. Therefore, a 
chemical crosslinking in combination with mass spectrometry could be used to examine 
the structure and composition of the likely heterogenic complex. 
To identify Sema3a target genes in NCCs, the expression profiles of O9-1 cells treated 
with and without siRNA against Sema3a should be compared by whole-genome 
microarray analysis. 
NCCs are guided by semaphorins, but also express semaphorins themselves as 
demonstrated in the present thesis. Using a migration assay, the influence of 
downregulated or mutated Sema3a as well as Chd7 on the migration of NCCs could be 
examined. 
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In this thesis it is supposed that mutated SEMA3A might act as modifier in the phenotypic 
variable malformation syndrome CHARGE contributing to a more severe phenotype of  
the affected patients. To strengthen this hypothesis further mild and severe affected 
CHARGE syndrome patients carrying a pathogenic CHD7 mutation should be screened 
for additional mutations in the SEMA3A gene. Possible identified new SEMA3A mutations 
as well as already known SEMA3A mutations either assumed to contribute to the 
phenotype of Kallmann syndrome (Hanchate et al., 2012; Young et al., 2012) or causing 
an autosomal recessive type of syndromic short stature (Hofmann et al., 2013; Baumann  
et al., 2017) should be investigated by functional analysis as performed in this thesis. 
Moreover, the Xenopus laevis model could be used for further functional analyses 
regarding selected mutations. After a Sema3a knockdown using Sema3a morpholinos, 
other selected mutations could be used for rescue experiments to analyze the effect of the 
mutations. 
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5 Summary 
CHARGE syndrome is a complex congenital malformation disorder, caused in more about 
two-thirds of the cases by heterozygous loss of function mutations in the chromodomain 
helicase DNA-binding protein 7 (CHD7). The acronym CHARGE reflects the main clinical 
features seen in the most CHARGE syndrome patients namely coloboma, heart defects, 
atresia of the choanae, retarded growth and development, genital hypoplasia and ear 
anomalies/deafness. Because of the phenotypic spectrum, it was supposed that the 
CHARGE syndrome belongs to the neurocristopathies. In addition, the essential role of 
CHD7 for the formation and migration of neural crest cells (NCCs), which give rise to 
many tissues of the embryo including craniofacial and heart structures, was recently 
demonstrated. 
Two murine NCC lines, the trunk JoMa cells and the cranial O9-1 cells, were 
characterized for the expression of NCC and other molecular marker genes as well as 
Chd7 by RT-PCR analysis. The results revealed that the two cell lines do not differ  
much in the expression of the tested marker genes for NCCs, neurons, glial cells,  
smooth muscle cells, melanocytes and chondrocytes as well as Chd7. The nuclear 
expression of Chd7 was validated by western blot analysis and for O9-1 cells also by 
immunocytochemical staining. The results of the western blot analysis demonstrated a 
strong Chd7 expression in O9-1 cells in comparison with JoMa cells. This strengthens the 
assumption that the symptoms seen in CHARGE syndrome are caused by a dysfunction 
of the cranial NCCs and not of the trunk NCCs. 
Proper NCC guidance through the embryo depends on guidance cues and the large 
family of the semaphorins thereby plays an important role. Subsequent experiments were 
performed with the NCC line O9-1. Using RT-PCR analysis, the expression of semaphorin 
receptors and for the first time of class 3 semaphorins was identified in NCCs. Sema3a 
expression was proven by immunocytochemical staining and western blot analysis. 
Further experiments were carried out to check the localization of Sema3a in the different 
cell compartments and a possible Sema3a secretion into the cell culture medium. Western 
blot analysis revealed both the expression in the nucleus and the cytoplasm and the 
secretion into the medium. Moreover, the proteolytic cleavage and dimerization of 
Sema3a could be identified as described for class 3 semaphorins. Recently, the described 
regulatory effect of Chd7 on Sema3a in Xenopus laevis embryos and mouse embryos 
could be confirmed in O9-1 cells through the Sema3a downregulation by siRNA-mediated 
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depletion of Chd7. Further experiments revealed a co-immunoprecipitation of Chd7 with 
Sema3a, indicating the association of these two proteins in the same protein complex. 
A further part of the present thesis focused on the identification of possible mutations in 
the SEMA3A gene of CHD7-positive CHARGE syndrome patients. SEMA3A mutations 
are hypothesized to negatively modulate the phenotype of CHARGE patients and are 
known to be involved in the pathogenesis of the allelic disorder Kallmann syndrome, 
which is suggested to represent the mild end of the phenotypic abnormalities seen in 
CHARGE syndrome. The non-synonymous SEMA3A mutation c.2002A>G (p.I668V) was 
identified in a severe affected CHARGE syndrome patient. This finding might strengthens 
the hypothesis that SEMA3A act as modifier in CHARGE patients with a pathogenic 
mutation in the CHD7 gene contributing to a more severe phenotype in these patients due 
to digenetic inheritance. It would also explain the high clinical inter- and intra-familial 
variability of CHARGE syndrome. The new identified mutation and the already published 
variant p.R66W were characterized with overexpressing plasmids in the human  
HEK293 cell line on protein level. The obtained results showed no effect of the  
mutations on expression, proteolytic processing, dimerization or secretion of SEMA3A.  
By co-immunoprecipitation experiments it was demonstrated that CHD7 interacts with 
SEMA3A WT and the two SEMA3A variants, p.R66W and p.I668V. Yeast-two hybrid 
assay indeed revealed no direct interaction between CHD7 and SEMA3A with or without 
mutation. 
In summary, the results of the present thesis are another step towards understanding the 
pathomechanism behind the neurocristopathy CHARGE syndrome. 
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